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The	   ATM	   protein	   senses	   DNA	   double-­‐stranded	   breaks	   (DSBs)	   and	   facilitates	   proper	  
repair.	  B	  and	  T	   lymphocytes	  of	  ATM-­‐deficient	  patients	  have	   increased	  antigen	   receptor	   locus	  
translocations	   associated	  with	   aberrant	   V(D)J	   recombination.	   Correspondingly,	   ATM-­‐deficient	  
humans	  are	  predisposed	  to	  both	  T	  and	  B	  cell	  malignancies.	  However,	  ATM-­‐deficiency	   in	  mice	  
only	  leads	  to	  T	  cell	  lymphomas,	  all	  of	  which	  harbor	  T	  cell	  receptor	  locus	  translocations	  resulting	  
from	  aberrant	  V(D)J	  recombination.	  
The	  first	  goal	  of	  this	  study	  was	  to	  assess	  whether	  ATM-­‐deficient	  B	  cell	  lymphomas	  occur	  
in	   mice	   in	   which	   V(D)J	   recombination	   is	   targeted	   to	   the	   c-­‐myc	   oncogene	   or	   in	   which	   B	   cell	  
survival	  is	  increased	  via	  enforced	  expression	  of	  the	  anti-­‐apoptotic	  Bcl2	  protein.	  We	  found	  that,	  
in	   the	   absence	   of	   ATM,	   either	   inserting	   the	   V(D)J	   substrate	   into	   c-­‐myc	   or	   enhancing	   B	   cell	  
survival	   led	   to	   the	  development	  of	  mature	  B	   cell	   lymphomas	   in	   a	   subset	   of	  mice.	  Moreover,	  
combining	  both	  genetic	  alterations	  led	  to	  complete	  penetrance	  of	  mature	  B	  cell	  lymphomas	  in	  
the	  ATM-­‐deficient	  background.	  	  
The	   second	   goal	   was	   to	   elucidate	   the	   mechanisms	   that	   led	   to	   ATM-­‐deficient	   B	   cell	  
lymphoma	   development	   in	   our	  models.	  We	   found	   that	   nearly	   all	   tumors	   harbored	   recurrent	  
chromosomal	  translocations	  that	  fused	  V(D)J-­‐associated	  IgH	  locus	  DSBs	  to	  regions	  downstream	  
	  iv 
of	   c-­‐myc,	   resulting	   in	   dicentric	   chromosomes	   and	   c-­‐myc	   amplification	   by	   a	   breakage-­‐fusion-­‐
bridge	  (BFB)	  mechanism.	  Then,	  we	  employed	  genome-­‐wide	  translocation	  cloning	  to	  study	  the	  
fate	   of	   introduced	   c-­‐myc	   DSBs	   in	   activated	   wild-­‐type	   and	   ATM-­‐deficient	   B	   cells.	   In	   ATM-­‐
deficient,	  but	  not	  wild-­‐type,	  B	  cells,	  a	  30	  megabase	  region	  downstream	  of	  IgH	  is	  a	  hotspot	  for	  c-­‐
myc	   translocations.	   We	   found	   that	   these	   translocation	   breakpoints	   originated	   from	   newly	  
generated	  DSBs	  downstream	  of	  IgH	  in	  activated	  mature	  B	  cells	  and	  that	  many	  did	  not	  originate	  
from	  the	  IgH	  class-­‐switching	  process	  that	  introduces	  DSBs	  into	  IgH	  in	  mature	  B	  cells.	  	  
Based	  on	  our	  overall	  studies,	  we	  propose	  that	  ATM	  prevents	  conversion	  of	  unrepaired	  
V(D)J-­‐associated	  IgH	  chromosomal	  breaks	  in	  developing	  B	  cells	  into	  dicentric	  chromosomes	  that	  
can	   persist	   through	   development.	  We	   further	   propose	   that,	   through	   a	   BFB	  mechanism,	   such	  
dicentrics	   in	   mature	   B	   cells	   can	   give	   rise	   to	   new	   chromosome	   12	   DSBs	   that	   contribute	   to	  
oncogenic	  translocations.	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CHAPTER	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  BACKGROUND	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1.1.	  Study	  Overview	  
	  
B	  and	  T	   lymphocytes	  express	   specialized	  antigen	   receptors,	   respectively	   termed	   the	  B	  
cell	   receptor	   (BCR)	  and	   the	  T	  cell	   receptor	   (TCR).	  The	  membrane-­‐bound	  BCR	  and	   its	   secreted	  
form,	  called	  antibodies,	  are	  comprised	  of	  a	  pair	  of	   identical	   immunoglobulin	  (Ig)	  heavy	  chains	  
(IgH),	  encoded	  by	  the	   IgH	   locus,	  and	  a	  pair	  of	   identical	   Ig	   light	  chains	  (IgL),	  encoded	  by	  either	  
the	   Igκ	  or	   Igλ	   light	  chain	   loci	   (Jackson	  et	  al.,	  2013).	  The	  N-­‐terminal	  portion	  of	   the	  heavy	  and	  
light	  chains	  contains	   the	  variable	   (V)	   region,	  and	   is	   involved	   in	   specific	  antigen	  binding,	  while	  
the	  C-­‐terminal	  portion	   is	  termed	  the	  constant	  (C)	  region	  (Cobb	  et	  al.,	  2006).	  The	  IgH	  C	  region	  
(CH)	  can	  be	  encoded	  by	  several	  different	  sets	  of	  CH	  exons	  which	  determine	  Ig	  class	  and	  effector	  
functions	   (Cobb	  et	  al.,	  2006).	  TCRs	  are	  made	  up	  of	  either	  αβ	  or	  γδ	  heterodimers	  encoded	  by	  
TCR	  α/δ,	  β,	  and	  γ	  loci;	  the	  N-­‐terminal	  region	  of	  TCR	  chains	  is	  also	  a	  variable	  region	  involved	  in	  
antigen	  recognition	  (Cobb	  et	  al.,	  2006).	  Each	  individual	  B	  or	  T	  cell	  expresses	  a	  receptor	  with	  a	  
unique	   specificity,	   with	  most	   foreign	   antigens	   being	   recognized	   by	   a	   subset	   B	   and/or	   T	   cells	  
within	  the	  extremely	   large	  populations	  of	  unique	  B	  and	  T	  cell	  clones	  within	  a	  given	   individual	  
(Vettermann	  and	  Schlissel,	  2010).	  	  	  	  
Most	  of	  this	  great	  antibody	  and	  TCR	  diversity	  is	  not	  directly	  encoded	  in	  the	  genome,	  but	  
is	   generated	   through	   a	   process	   in	   which	   the	   exons	   encoding	   Ig	   or	   TCR	   variable	   regions	   are	  
assembled	   from	   component	   V,	   D,	   and	   J	   segments	   in	   developing	   B	   and	   T	   lymphocytes	   by	   a	  
process	  termed	  V(D)J	  recombination	  (Jackson	  et	  al.,	  2013).	  The	  V(D)J	  recombination	  process	  is	  
initiated	  in	  progenitor	  B	  cells	  in	  the	  bone	  marrow	  (BM)	  or	  progenitor	  T	  cells	  in	  the	  thymus	  by	  a	  
lymphocyte-­‐specific	   endonuclease	   comprised	   of	   the	   recombination	   activating	   gene	   1	   and	   2	  
proteins,	  which	  form	  a	  complex	  referred	  to	  as	  RAG	  (Nishana	  and	  Raghavan,	  2012).	  RAG	  initiates	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the	  cleavage	  phase	  of	  V(D)J	  recombination	  by	  introducing	  DNA	  double-­‐strand	  breaks	  (DSBs)	  at	  
the	   borders	   of	   a	   pair	   of	   V,	   D,	   or	   J	   segments	   (termed	   coding	   segments)	   and	   short	   conserved	  
flanking	  sequences	  referred	  to	  as	  recombination	  signal	  sequences	  (RSSs)	   (Schatz	  et	  al.,	  2008).	  	  
These	  RAG-­‐initiated	  DSBs	  at	  the	  two	  participating	  coding	  segments	  and	  their	  flanking	  RSSs	  are	  
joined	   exclusively	   by	   the	   classical	   non-­‐homologous	   DNA	   end-­‐joining	   (C-­‐NHEJ)	   pathways,	  
resulting	   in	   V(D)J	   coding	   joins	   and	   RSS	   joins,	   respectively	   (Boboila	   et	   al.,	   2012).	   V(D)J	  
recombination	  is	  initiated	  by	  RAG	  and	  completed	  by	  C-­‐NHEJ	  strictly	  in	  the	  G1	  phase	  of	  the	  cell	  
cycle	  (Helmink	  and	  Sleckman,	  2012).	  
During	   B	   cell	   development,	   complete	   V(D)J	   exons	   are	   assembled	   upstream	   of	   the	   Cµ	  
constant	  region	  exons,	  the	  first	  set	  of	  CH	  exons	  expressed	  during	  development.	  Transcription	  is	  
initiated	   upstream	   of	   the	   V(D)J	   and	   terminated	   downstream	   of	   the	   Cµ	   exons	   to	   produce	   a	  
transcript	   that	  after	   splicing	  generates	  a	  messenger	  RNA	  encoding	   the	  µ	   heavy	   chain	  protein	  
(Perlot	   and	   Alt,	   2008).	   Subsequent	   assembly	   and	   expression	   of	   a	   functional	   IgL	   chain	   gene,	  
which	  associates	  with	  the	  µ heavy	  chain,	  leads	  to	  the	  formation	  of	  IgM,	  which	  is	  expressed	  on	  
the	   surface	   of	   the	   resulting	   IgM+	   B	   cell	   (Vettermann	   and	   Schlissel,	   2010).	   Surface	   IgM-­‐
expressing	  B	  cells	  migrate	   from	  the	  BM	  to	  peripheral	   lymphoid	  organs,	   such	  as	   the	  spleen	  or	  
lymph	  nodes,	  where	   upon	   stimulation	  with	   a	   cognate	   antigen	  or	   through	   certain	   of	   types	   of	  
activation,	   they	   can	   be	   stimulated	   to	   undergo	   two	   additional	   Ig	   diversification	   processes,	  
namely	  IgH	  class	  switch	  recombination	  (CSR)	  and	  IgH	  and	  IgL	  somatic	  hypermutation	  (SHM)	  (Di	  
Noia	  and	  Neuberger,	  2007).	  CSR	  changes	  antibody	  effector	  functions	  by	  replacing	  the	  Cµ	  exons	  
with	  a	  different	  set	  of	  CH	  exons	  from	  sets	  of	  CH	  exons	  that	  lie	  100-­‐200kb	  downstream	  in	  the	  IgH	  
locus	  (Keim	  et	  al.,	  2013).	  SHM,	  which	  occurs	  in	  specialized	  lymphoid	  structures	  termed	  germinal	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centers	   (GCs),	   introduces	   point	  mutations	   into	   IgH	   and	   IgL	   variable	   region	   exons,	   generating	  
further	  BCR	  variable	  region	  diversity	  in	  a	  given	  B	  cell	  clone	  and	  allowing	  for	  selection	  of	  B	  cells	  
that	  express	  BCRs	  with	  higher	  antigen-­‐binding	  affinity,	  a	  process	  termed	  affinity	  maturation	  (Di	  
Noia	  and	  Neuberger,	  2007).	  	  
CSR	   and	   SHM	   are	   initiated	   by	   activation-­‐induced	   cytidine	   deaminase	   (AID),	   a	   protein	  
that	  deaminates	  cytidine	  residues	  on	  single-­‐stranded	  DNA	  (ssDNA)	  (Chaudhuri	  et	  al.,	  2007).	  This	  
deamination	   process	   initiates	   a	   cascade	   of	   reactions	   that	   involve	   activities	   of	   normal	   base	  
excision	   (BER)	   and	  mis-­‐match	   repair	   (MMR)	   pathways	   that,	   instead	  of	   normal	   repair,	   are	   co-­‐
opted	  to	  introduce	  mutations	  or	  DSBs	  (Di	  Noia	  and	  Neuberger,	  2007).	  For	  CSR,	  the	  AID-­‐initiated	  
DSBs	  occur	  in	  large	  repetitive	  sequences,	  known	  as	  switch	  (S)	  regions,	  which	  precede	  each	  set	  
of	  CH	  exons.	  The	  DSBs	   in	  the	  donor	  Sµ	   region	  are	   joined	  to	  the	  DSBs	   in	  one	  of	  the	  acceptor	  S	  
regions	  preceding	  downstream	  set	  of	  CH	  exons	  (Chaudhuri	  et	  al.,	  2004).	  To	  complete	  CSR,	  these	  
AID-­‐initiated	  S	  region	  DSBs	  also	  are	  usually	  joined	  by	  C-­‐NHEJ	  (Boboila	  et	  al.,	  2012).	  However,	  in	  
the	  absence	  of	  C-­‐NHEJ	  factors,	  S	  region	  DSBs	  can	  still	  be	  fused	  to	  yield	  CSR	  by	  alternative	  end-­‐
joining	   (A-­‐EJ)	   pathways,	   although	   to	   a	   lessor	   extent	   than	  with	  normal	   C-­‐NHEJ	   (Boboila	   et	   al.,	  
2012).	  During	  SHM,	  AID-­‐initiated	  lesions	  in	  variable	  region	  exons	  are	  predominantly	  processed	  
into	  mutations	  as	  opposed	  to	  DSBs,	  with	  this	  mutation	  activity	  also	  involving	  co-­‐opted	  BER	  and	  
MMR	  pathway	  activity	   (Di	  Noia	  and	  Neuberger,	  2007).	  CSR	  also	   is	   initiated	  during	  the	  G1	  cell	  
cycle	   phase	   and	   completed	   predominantly	   by	   C-­‐NHEJ	   of	   two	   region	   DSBs	   (Nussenzweig	   and	  
Nussenzweig,	  2010)	  
Chromosomal	  translocations	  appear	  to	  result	  predominantly	  from	  joining	  two	  separate	  
DSBs	   together.	   Translocations	   can	   be	   inter-­‐chromosomal	   if	   the	   join	   DSBs	   that	   occur	   on	   two	  
	   5 
different	   chromosomes.	   Depending	   on	   how	   the	   DSBs	   are	   joined,	   inter-­‐chromosomal	  
translocations	   can	   result	   in	   the	   joining	   of	   the	   telomeric	   end	   of	   one	   chromosome	   to	   the	  
centromeric	   end	   of	   another	   or	   they	   can	   result	   in	   dicentric	   chromosomes	   and/or	   acentric	  
chromosome	  fragments	  (Bunting	  and	  Nussenzweig,	  2013).	  Translocations	  can	  also	  occur	  intra-­‐
chromosomally	   if	   they	   join	   two	   separate	   DSBs	   on	   the	   same	   chromosome;	   such	  
intrachromosomal	  translocations	  might	  result	  in	  deletions	  or	  inversions	  depending	  which	  ends	  
of	  the	  DSBs	  are	  joined	  (Zhang	  et	  al.,	  2010).	  Joining	  of	  a	  single	  DSBs	  that	  has	  been	  resected	  can	  
also	  result	  in	  deletions.	  The	  high	  frequency	  of	  DSBs	  generated	  during	  B	  and	  T	  cell	  development	  
and	  activation	  pose	  a	  great	  threat	  for	  the	  generation	  of	  translocations	  and	  other	  chromosomal	  
aberrations	  (Gostissa	  et	  al.,	  2011).	  Indeed,	  spontaneous	  B	  or	  T	  cell	  lymphomas	  in	  humans	  and	  
certain	   mouse	   models	   often	   harbor	   recurrent	   translocations	   that	   fuse	   Ig	   or	   TCR	   loci	   to	  
oncogenes	   and/or	   lead	   to	  deletion	  of	   tumor	   suppressor	   genes	   (Seifert	   et	   al.,	   2013).	  A	   classic	  
example	   is	   the,	   T(8;14)	   translocation	   in	   Burkitt’s	   B	   cell	   lymphoma	   (BL)	   that	   joins	   the	   c-­‐MYC	  
oncogene	   on	   chromosome	   8	   to	   the	   IGH	   locus	   on	   chromosome	   14,	   thereby	   bringing	   c-­‐MYC	  
under	   the	   control	   of	   the	  3’	   regulatory	  elements	  of	   IGH	   leading	   to	   the	  deregulation	  of	  c-­‐MYC	  
(Robbiani	  and	  Nussenzweig,	  2013;	  Gostissa	  et	  al.,	  2011).	  	  
C-­‐NHEJ	   maintains	   genomic	   integrity	   by	   promoting	   re-­‐joining	   of	   DSBs	   and,	   thereby,	  
suppressing	   chromosome	   breaks	   and	   the	   joining	   separate	   DSBs	   to	   form	   chromosomal	  
translocations	   (Gostissa	   et	   al.,	   2011).	   C-­‐NHEJ	   works	   throughout	   the	   cell	   cycle	   but	   is	   most	  
important	   in	   G1	   when	   homologous	   recombination,	   the	   other	   major	   mammalian	   DSB	   repair	  
pathway,	  is	  not	  available	  (Boboila	  et	  al.,	  2012).	  Ku70,	  Ku80,	  XRCC4,	  and	  Ligase	  4	  are	  	  “core”	  C-­‐
NHEJ	  factors	  and	  are	  absolutely	  required	  for	  V(D)J	  recombination	  (Boboila	  et	  al.,	  2012).	  Ku70-­‐	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or	  Ku80-­‐deficient	  mice	  exhibit	  growth	  defects,	   increased	  sensitivity	   to	  DNA	  damaging	  agents,	  
chromosomal	   instability,	  and	  severe	  combined	  immunodeficiency	  (SCID)	  due	  to	  an	   inability	  to	  
carry	   out	   end-­‐joining	   to	   complete	   V(D)J	   recombination	   (Gostissa	   et	   al.,	   2011).	   XRCC4	   or	   Lig4	  
deficiency	  results	  in	  late	  embryonic	  lethality	  due	  to	  neuronal	  lethality;	  but	  developing	  embryos	  
exhibit	  similar	  defects	   to	  those	  associated	  with	  Ku-­‐deficiency	   including	  a	  block	   in	  B	  and	  T	  cell	  
development	  due	  to	  a	  V(D)J	  recombination	  defect	  (Gao	  et	  al.,	  2000;	  Frank	  et	  al.,	  1998).	  Most	  C-­‐
NHEJ	  deficient	  mice	  do	  not	  recurrently	  develop	  lymphoid	  or	  other	  cancers,	  at	  least	  in	  part	  due	  
to	   cells	   containing	  unrepaired	  G1	  DSBs	  being	  eliminated	  at	   the	  G1/S	  phase	   transition	  via	   cell	  
cycle	  checkpoints	  (Puebla-­‐Osorio	  and	  Zhu,	  2008).	  In	  this	  regard,	  combined	  deficiency	  in	  mice	  for	  
a	  C-­‐NHEJ	  component	  and	  p53,	  a	  tumor	  suppressor	  which	  activates	  the	  G1	  cell	  cycle	  checkpoint	  
in	   response	   to	   unrepaired	  DSBs,	   leads	   to	   recurrent	   development	   of	   pro-­‐B	   cell	   lymphomas	   in	  
mice	  (Gostissa	  et	  al.,	  2011).	  A	  hallmark	  of	  pro-­‐B	  cell	  lymphomas	  in	  C-­‐NHEJ/p53-­‐double	  deficient	  
background	   is	   the	  presence	  of	   complex	   translocations	  with	  gene	  amplification,	   referred	   to	  as	  
complicons.	  The	  complicon	  derives	   from	  the	   fusion	  of	  RAG-­‐initiated	  DSBs	   in	   the	   IgH	   locus	  on	  
chromosome	   12	   to	   a	   large	   region	   downstream	   of	   the	   c-­‐myc	   gene	   on	   chromosome	   15	  
generating	  dicentric	  chromosomes	  that	  ultimately	  lead	  to	  oncogenic	  amplification	  of	  the	  c-­‐myc	  
genes	   via	   breakage-­‐fusion-­‐bridge	   (BFB)	   mechanism	   (Gostissa	   et	   al.,	   2011;	   Zhu	   et	   al.,	   2002).	  
Mechanistically,	  these	  complicons	  are	  thought	  to	  be	  result	  from	  unrepaired	  RAG-­‐initiated	  DSBs	  
due	  to	  C-­‐NHEJ	  deficiency	  persisting	  through	  the	  G1	  checkpoint	  in	  the	  absence	  of	  p53	  and	  then	  
being	  replicated	  to	  generate	  dicentrics	  (Difilippantonio	  et	  al.,	  2002;	  Zhu	  et	  al.,	  2002).	  	  
The	   Ataxia	   Telangiectasia-­‐mutated	   (ATM)	   DNA	   damage	   response	   (DDR)	   pathway	   is	  
activated	   in	   response	   to	   DSBs	   in	   G1,	   including	   those	   initiated	   by	   RAG	   and	   AID,	   to	   further	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promote	  efficient	  C-­‐NHEJ	  DSB	  repair	  and	  also	  to	  effect	  protective	  G1	  checkpoints.	  In	  response	  
to	  DSBs,	  the	  ATM	  kinase	  is	  activated	  and	  then,	  in	  turn,	  activates	  both	  downstream	  components	  
involved	   in	  promoting	   repair	  of	  DSBs	  by	  C-­‐NHEJ	  and	   in	  mediating	  checkpoints	   (Bednarski	  and	  
Sleckman,	  2012).	   In	  this	  context,	   in	  developing	   lymphocytes,	  the	  ATM	  DSB	  response	  stabilizes	  
RAG-­‐initiated	  V(D)J	  recombination	  DSBs	  and,	  more	  generally,	  appears	  to	  tether	  DSBs	  to	  prevent	  
premature	   separation,	   thereby,	   contributing	   is	   required	   for	   their	   proper	   repair	   by	   C-­‐NHEJ	  
(Huang	   et	   al.,	   2007;	   	   Vacchio	   et	   al.,	   2007;	   Bredemeyer	   et	   al.,	   2006,	   Matei	   et	   al.,	   2006).	   In	  
response	  to	  DSBs	  in	  G1,	  ATM	  also	  activates	  p53	  to	  enforce	  the	  G1	  cell	  cycle	  checkpoint	  to	  arrest	  
cells	   to	  allow	  for	  proper	  DSB	  repair	  and/or	   to	  eliminate	  cells	  with	  persistent	  unrepaired	  DSBs	  
before	  progression	  into	  S	  phase	  (Helmink	  and	  Sleckman,	  2012).	  As	  mentioned	  above,	  the	  p53-­‐
dependent	  G1	  checkpoint	  prevents	  cells	  from	  replicating	  unrepaired	  DSBs	  which	  could	  lead	  to	  
chromosomal	  aberrations	  and	  further	  genome	  instability	  (Gostissa	  et	  al.,	  2011).	  
ATM-­‐deficiency	  in	  humans	  leads	  to	  Ataxia	  Telangiectasia	  (AT),	  a	  condition	  characterized	  
by	   neurodegeneration,	   immunodeficiency,	   increased	   sensitivity	   to	   ionizing	   radiation,	   and	  
increased	  predisposition	  to	  T	  and	  B	  cell	  malignancy	  (Perlman	  et	  al.,	  2012).	  ATM	  inactivation	  in	  
mice	   recapitulates	   several	   aspects	   of	   AT,	   including	   the	   predisposition	   to	   thymic	   lymphoma	  
(Ambrose	   and	   Gatti,	   2013).	   Notably,	   murine	   ATM-­‐deficient	   thymic	   lymphomas	   all	   harbor	  
recurrent	  chromosomal	  translocations	  that	  all	   involve	  RAG-­‐initiated	  DSBs	   in	  the	  Tcrd	   locus	  on	  
chr	   14	   (Zha	   et	   al.,	   2010).	   These	   recurrent	   Tcrd	   translocations	   include	   the	   generation	   of	  
complicons	   from	  chr	  14	  dicentrics	   that	  are	   initiated	  by	  RAG-­‐generated	  DSBs	   in	   the	  Tcrd	   locus	  
and	  which	   are	   accompanied	   by	   joining	   of	  Tcrd	   chr	   14	  DSBs	   to	  DSBs	   on	   other	   chromosomes,	  
most	   notably	   chr	   12	   downstream	   of	   the	   IgH	   locus	   (Zha	   et	   al.,	   2010).	   This	   picture	   of	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chromosomal	  aberrations	   in	  ATM-­‐deficient	   thymic	   lymphomas	   is	   strikingly	   reminiscent	  of	   the	  
chromosomal	  aberrations	  found	  in	  the	  C-­‐NHEJ/p53-­‐deficient	  pro-­‐B	  cell	  lymphomas	  (see	  above).	  
Mechanistically,	   such	   similarities	  may	   be	   explained	   by	   the	   fact	   that	   ATM	  deficiency	   provides	  
both	  the	  V(D)J	   joining	  defect	  and	  the	  G1-­‐checkpoint	  defect	   (Helmink	  and	  Sleckman,	  2012).	   In	  
this	   regard,	   it	   is	   also	   notable	   that	   this	   "double	   whammy"	   of	   ATM-­‐deficiency	   allows	   V(D)J	  
recombination-­‐associated	   DSBs	   within	   the	   IgH	   locus	   in	   developing	   pro-­‐B	   cells	   to	   somehow	  
persist	   through	  development	   into	  mature	  B	  cells	  where	   they	  can	  contribute	   to	   translocations	  
(Callen	  et	  al.,	  2007).	  	  
Despite	   the	   genomic	   instability	   and	   predisposition	   to	   T	   cell	   lymphoma,	   ATM-­‐deficient	  
mice	  do	  not	  develop	  B	   lineage	   lymphomas	  as	   are	  often	  observed	   in	  human	  AT	  patients.	   The	  
initial	  goal	  of	  the	  studies	  described	  in	  this	  thesis	  was	  to	  create	  a	  mouse	  model	  of	  mature	  B	  cell	  
lymphoma	   in	   the	   ATM-­‐deficient	   background.	   We	   hypothesized	   that	   the	   frequency	   of	   DSBs	  
within	   oncogenes	   such	   as	   c-­‐myc	   and/or	   the	   survival	   of	   ATM-­‐deficient	   B	   cells	   may	   be	   rate-­‐
limiting	   factors	   that	   prevent	   the	   accumulation	   of	   oncogenic	   translocations	   and	   the	  
development	  of	  B	  cell	  lymphoma.	  To	  test	  the	  role	  of	  DSBs,	  we	  asked	  whether	  the	  targeting	  of	  
RAG-­‐initiated	   DSBs	   to	   c-­‐myc	   locus	   in	   developing	   mouse	   B	   cells	   could	   lead	   to	   increased	  
predisposition	   to	   B	   cell	   malignancies	   with	   c-­‐myc	   translocations.	   To	   test	   the	   role	   of	   B	   cell	  
survival,	   we	   asked	   whether	   enforced	   expression	   of	   the	   bcl-­‐2	   anti-­‐apoptotic	   factor	   in	   ATM-­‐
deficient	  B	  cells	  in	  vivo	  leads	  to	  B	  cell	  lymphoma	  development.	  We	  found	  that,	  in	  the	  absence	  
of	  ATM,	  either	  inserting	  RAG	  target	  sequences	  into	  the	  c-­‐myc	  locus	  or	  enhancing	  B	  cell	  survival	  
via	  enforced	  Bcl2	  expression	  led	  to	  the	  development	  of	  peripheral,	  predominantly	  IgM+,	  B	  cell	  
lymphomas	  in	  a	  significant	  fraction	  of	  the	  mice.	  Strikingly,	  combining	  both	  RAG	  targets	  in	  c-­‐myc	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and	   deregulated	   Bcl2	   expression	   led	   to	   complete	   penetrance	   of	   such	   peripheral	   B	   cell	  
lymphomas.	  	  
The	  second	  goal	  of	  our	  studies,	  was	  to	  determine	  whether	  the	  ATM-­‐deficient	  mature	  B	  
cell	   lymphomas	   that	  arose	   in	  our	  model	  were	  associated	  with	   recurrent	  genomic	  aberrations	  
and,	  if	  so,	  to	  determine	  the	  underlying	  mechanisms.	  In	  this	  regard,	  we	  found	  that	  nearly	  all	  of	  
the	  ATM-­‐deficient	  mature	  B	  cell	  lymphomas	  that	  arose	  in	  each	  of	  three	  ATM	  deficient	  models	  
harbored	   translocations	   that	   appeared	   to	   fuse	   RAG-­‐initiated	   DSBs	   during	   attempted	   V(D)J	  
joining	   on	   chromosome	   12	   within	   the	   IgH	   locus	   to	   DSBs	   on	   chromosome	   15	   that	   occurred	  
within	  a	  region	  5kb	  to	  several	  hundred	  kb	  downstream	  of	  c-­‐myc.	  Such	  joins,	  as	  observed	  in	  C-­‐
NHEJ	   and	   p53	   deficient	   pro-­‐B	   lymphomas,	   result	   in	   the	   formation	   of	   dicentric	   chromosomes	  
and	  c-­‐myc	  amplification	  by	  the	  breakage-­‐fusion-­‐bridge	  mechanism.	  To	  elucidate	  mechanisms	  of	  
how	   RAG-­‐generated	   DSBs	   might	   lead	   to	   dicentric	   chromosome	   formation	   and	   oncogenic	  
translocations	   in	   peripheral	   (mature)	   B	   cells,	   we	   employed	   high	   throughput	   genome-­‐wide	  
translocation	  sequencing	  technology	  (HTGTS)	  to	  study	  the	  fate	  of	  DSBs	   introduced	   into	  c-­‐myc	  
gene	  in	  wild-­‐type	  and	  ATM-­‐deficient	  splenic	  B	  cells	  activated	  for	  CSR.	  Mapping	  of	  genome-­‐wide	  
translocation	   junctions	   revealed	   that	   in	   both	   WT	   and	   ATM-­‐deficient	   B	   cells	   DSBs	   in	   c-­‐myc	  
frequently	  translocate	  to	  AID-­‐initiated	  DSBs	  in	  donor	  and	  acceptor	  IgH	  S	  regions	  as	  previously	  
observed	  (Chiarle	  et	  al.,	  2011).	  However,	   in	  ATM-­‐deficient	  B	  cells	  but	  not	  wild	  type	  B	  cells,	  c-­‐
myc	  translocation	  junctions	  also	  occurred	  at	  high	  levels	  in	  a	  30	  megabase	  region	  downstream	  of	  
the	  IgH	  locus.	  Further	  analysis	  demonstrated	  that	  many	  translocations	  downstream	  of	  the	  IgH	  
locus	  in	  ATM-­‐deficient	  cells	  were	  generated	  de	  novo	  and	  in	  an	  AID-­‐independent	  manner.	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Based	   on	   the	   results	   of	   our	   overall	   studies	   and	   those	   of	   others	   (Bunting	   and	  
Nussenzweig,	  2013),	  we	  propose	  that	  the	  IgH	  DSBs	  in	  ATM-­‐deficient	  peripheral	  B	  cells	  resulted	  
from	  BFB	   cycles	   involving	  dicentrics	   of	   chromosomes	  12	   and	   that	   such	  dicentrics	   are	   formed	  
both	  during	  aberrant	  repair	  of	  AID-­‐initiated	  and	  RAG-­‐initiated	  DSBs.	  We	  further	  propose	  that,	  in	  
the	   absence	   of	   normal	   G1	   checkpoints	   due	   to	   ATM-­‐deficiency,	   dicentrics	   arising	   from	   RAG-­‐
initiated	  DSBs	  generated	  in	  pro-­‐B	  cells	  are	  propagated	  through	  development	  to	  mature	  B	  cells	  
where	   they	   can	   form	   new	   DSBs	   via	   BFB	  mechanism	   that	   can	   contribute	   to	   translocations	   in	  
peripheral	   B	   cells.	   Together,	   findings	   from	  our	   tumor	  models	   and	   our	  HTGTS	   studies	   show	   a	  
novel	   role	   for	   ATM	   in	   suppressing	   unrepaired	   RAG-­‐initiated	   DSBs	   from	   propagating	   during	  
development	  and	  serving	  as	  substrates	  for	  the	  formation	  of	  dicentric	  chromosomes	  and	  further	  
DSBs	  in	  peripheral	  B	  cells	  that	  can	  contribute	  to	  oncogenic	  translocation.	  These	  findings	  may	  be	  
relevant	  to	  human	  peripheral	  B	  cell	  lymphomas	  with	  apparent	  V(D)J	  recombination	  associated	  
translocations.	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1.2.	  Antigen	  Receptor	  Gene	  Assembly	  In	  Developing	  Lymphocytes	  
1.2.1.	  Structure	  Of	  Antibody	  Molecule	  And	  Immunoglobulin	  Loci	  Organization	  
The	   IgH	   and	   IgL	   chains	   are	   comprised	   of	   variable	   and	   constant	   regions	   (Cobb	   et	   al.,	  
2006).	   These	   regions	   are	   composed	   of	   three-­‐dimensionally	   folded	   segments	   called	   domains.	  
The	   Ig	  heavy	  chain	  consists	  of	  one	  variable	   (VH)	  and	  three	  constant	   (CH)	  domains.	  The	   Ig	   light	  
chain	  consists	  of	  one	  variable	  (VL)	  and	  one	  constant	  (CL)	  domain	  (Jackson	  et	  al.,	  2013).	  Each	  light	  
chain	   is	   bound	   to	   the	   heavy	   chain	   by	   a	   disulfide	   bond	   and	   by	   a	   combination	   of	   noncovalent	  
interactions	   such	   as	   salt	   bridges,	   hydrogen	   bonds,	   and	   hydrophobic	   bonds	   (Nishana	   and	  
Raghavan,	  2012).	  The	  two	  heavy	  chains	  are	  held	  together	  by	  similar	  noncovalent	  and	  disulfide	  
bonds,	  resulting	  in	  the	  four-­‐chain	  immunoglobulin	  structure	  (Figure	  1).	  
Figure	   1.	   Schematic	   representation	   of	   an	   immunoglobulin.	   The	   IgH	   chains	   are	  
depicted	   in	   orange	  with	   the	   variable	   region	   in	   dark	   orange.	   The	   IgL	   chains	   are	  
depicted	   in	   blue	  with	   variable	   region	   in	   dark	   blue.	   Each	  domain	   is	   depicted	   as	  
rectangles.	  Assembled	  V(D)J	  exons	  are	  indicated.	  Disulfide	  bonds	  are	  depicted	  as	  
purple	  lines.	  	  
	  
The	  IgH	  chain	  is	  encoded	  by	  variable	  (V),	  diversity	  (D),	  and	  joining	  (J)	  gene	  segments.	  In	  
mouse,	  the	  IgH	  locus	  spans	  approximately	  3	  Mb	  near	  the	  telomeric	  portion	  of	  chromosome	  12	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followed	  by	  8	  CH	  genes	  (Cµ,	  Cδ,	  Cγ3,	  Cγ1,	  Cγ2b,	  Cγ2a,	  Cε,	  and	  Cα,	  from	  5’	  to	  the	  3’	  of	  the	  locus)	  
(Shih	  and	  Krangel,	  2013).	  VH	  segments	   that	   lie	   closer	   to	   the	  D	  region	  are	   termed	  “proximal,”	  
whereas	  VH	  segments	  that	  lie	  further	  upstream	  are	  termed	  “distal”	  (Jung	  et	  al.,	  2006).	  A	  strong	  
enhancer	  element	   termed	   the	   intronic	   enhancer	   (iEµ)	   lies	  between	   JH	  4	   and	  Cµ,	   the	   first	  CH	  
gene,	   and	   function	   to	   promote	   V(D)J	   recombination	   (Gostissa	   et	   al.,	   2011).	   A	   series	   of	  
enhancers	  termed	  the	  IgH	  3’	  regulatory	  region	  (IgH	  3’RR)	  lies	  downstream	  of	  Cα,	  the	  most	  3’	  CH	  
gene,	  and	  regulates	  CSR	   in	  mature	  B	  cells	  by	  modulating	   IgH	   locus	  conformation	  and	   looping	  
(see	  below)	  (Gostissa	  et	  al.,	  2011).	  Transcriptional	  promoters	  are	  located	  upstream	  of	  each	  VH	  
segment,	  upstream	  of	  DH	  segments,	  and	  in	  iEµ	  (Cobb	  et	  al.,	  2006).	  	  
The	  murine	  Igκ	  locus	  on	  chromosome	  6	  comprises	  more	  than	  100	  Vκ	  and	  4	  functional	  Jκ	  
gene	  segments,	  with	  a	  single	  Cκ	  gene.	  The	  κ	  intronic	  enhancer	  (iEκ)	  lies	  between	  the	  Jκ	  cluster	  
and	   the	   Cκ	   gene	   and	   the	   3’	   κ	   enhancer	   (3’Eκ)	   lies	   downstream	   of	   the	   Cκ	   gene	   (Shih	   and	  
Krangel,	   2013).	   The	   murine	   Igλ	   locus	   is	   arranged	   in	   two	   duplicated	   units	   and	   spans	  
approximately	  200	  kb	  on	  chromosome	  16	   (Cobb	  et	  al.,	   2006).	  The	  λ	   locus	   contains	  a	   total	  of	  
three	   functional	  Vλ	  and	   Jλ	  gene	  segments,	  and	   three	  Cλ	  genes	  with	  each	   Jλ	   segment	  directly	  
upstream	  of	  the	  respective	  Cλ	  gene,	  and	  a	  λ	  enhancer	  (Eλ)	  located	  downstream	  of	  each	  λ	  locus	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Figure	  2.	  Schematic	  representation	  of	  the	  murine	  B	  cell	  receptor	   loci.	  The	  V,	  D,	  
and	   J	   gene	   segments	   are	   depicted	   as	   rectangles.	   The	   estimated	   number	   of	  
antigen	  receptor	  gene	  segments	   for	   the	  VH	  and	  Vκ	   loci	   is	   indicated	  above	  each	  
locus.	  The	  12-­‐RSSs	  are	  depicted	  as	  open	  triangles.	  The	  23-­‐RSSs	  are	  depicted	  as	  
solid	   triangles.	   Enhancers	   and	   promoters	   are	   depicted	   as	   gray	   circles	   and	  
rectangles,	   respectively.	   Constant	   regions	   are	   depicted	   as	   single	   rectangles	  
without	  showing	   individual	  exons.	  Distances	  between	  the	  various	  elements	  are	  
not	  drawn	  to	  scale.	  From	  Hesslein	  and	  Schatz,	  2001.	  	  
	  
1.2.2.	  Structure	  Of	  T	  Cell	  Receptor	  Molecules	  And	  T	  Cell	  Receptor	  Loci	  Organization	  
	   The	   TCR	   shares	   common	   characteristics	   with	   the	   immunoglobulin	   molecule.	   It	   is	  
comprised	  of	  two	  different	  polypepetide	  chains,	  αβ	  or	  γδ.	  Each	  chain	  consists	  of	  an	  N-­‐terminal	  
variable	   (V)	   domain,	   followed	   by	   a	   constant	   (C)	   domain,	   and	   then	   a	   membrane-­‐anchoring	  
domain	   (Zoete	   et	   al.,	   2013).	   The	   V	   domains	   from	   the	   two	   chains	   organize	   into	   one	   antigen-­‐
binding	   site.	   Unlike	   B	   cells,	   after	   T	   cells	   are	   stimulated	   with	   antigen,	   there	   is	   no	   further	  
mutation	   in	   the	   antigen-­‐binding	   site	   or	   switching	   of	   constant-­‐region	   class	   as	   occurs	   for	  
immunoglobulins.	  	  
TCRs	  are	  encoded	  by	  β,	  δ,	  α,	  and	  γ	  gene	  families,	  organized	  in	  three	  genomic	  loci:	  α/δ,	  β,	  
and	   γ	   (Cobb	   et	   al.,	   2006).	   Similar	   to	   IgH,	   the	   TCRβ	   and	   TCRδ	   variable	   region	   exons	   are	  
assembled	   from	  V,	  D,	   and	   J	   gene	   segments.	  On	   the	  other	   hand,	   the	   TCRα	  and	  TCRγ	   variable	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region	   exons	   are	   assembled	   from	  only	  V	   and	   J	   gene	   segments	   (Cobb	  et	   al.,	   2006).	   The	   TCRβ	  
locus	  spans	  approximately	  700	  kb	  region	  on	  mouse	  chromosome	  6	  and	  contains	  two	  Cβ	  genes,	  
each	   associated	   with	   one	   Dβ	   and	   six	   Jβ	   gene	   segments,	   and	   34	   Vβ	   gene	   segments	   located	  
upstream	  of	  the	  DJβ	  clusters	  (Cobb	  et	  al.,	  2006).	  
The	  TCRα	  and	  δ	  loci	  are	  embedded	  in	  the	  same	  genomic	  region	  on	  chromosome	  14.	  In	  
these	  loci,	  there	  are	  12	  Vδ,	  two	  Dδ	  and	  two	  Jδ	  gene	  segments,	  followed	  by	  one	  Cδ	  gene,	  and	  85	  
Vα	  and	  at	   least	  60	  Jα	  gene	  segments	  upstream	  of	  a	  single	  Cα	  gene	  (Cobb	  et	  al.,	  2006).	  The	  δ	  
locus	  is	  located	  between	  the	  α	  V	  and	  J	  regions	  so	  that	  it	  is	  deleted	  in	  cells	  undergoing	  TCRα	  V-­‐
to-­‐J	  recombination	  (Krangel,	  2009).	  	  
The	  TCRγ	  locus,	  spans	  approximately	  200	  kb	  on	  mouse	  chromosome	  13	  and	  consists	  of	  
seven	  Vγ	  and	  three	  functional	  Jγ	  and	  Cγ	  genes	  (Cobb	  et	  al.,	  2006)	  (Figure	  3).	  The	  organization	  of	  
human	  Ig	  and	  TCR	  loci	  is	  similar	  to	  their	  mouse	  counterparts	  (Hesslein	  and	  Schatz,	  2001).	  	  
Figure	  3.	  Schematic	  representation	  of	  the	  murine	  T	  cell	   receptor	   loci.	  The	  V,	  D,	  
and	   J	   gene	   segments	   are	   depicted	   as	   rectangles.	   The	   estimated	   number	   of	  
antigen	   receptor	   gene	   segments	   for	   each	   locus	   is	   indicated	   above	   each	   locus.	  
The	   12-­‐RSSs	   are	   depicted	   as	   open	   triangles.	   The	   23-­‐RSSs	   are	   depicted	   as	   solid	  
triangles.	  Enhancers	  and	  promoters	  are	  depicted	  as	  gray	  circles	  and	  rectangles,	  
respectively.	   Constant	   regions	   are	   depicted	   as	   single	   rectangles.	   Distances	  
between	  the	  various	  elements	  are	  not	  drawn	  to	  scale.	  From	  Hesslein	  and	  Schatz,	  
2001.	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1.2.3.	  Mechanisms	  Of	  V(D)J	  Recombination	  
V(D)J	   recombination	   is	   initiated	   when	   developing	   lymphocytes	   express	   the	   RAG	  
endonuclease	  (Nishana	  and	  Raghavan,	  2012).	  RAG	  initiates	  V(D)J	  recombination	  by	  introducing	  
DSBs	  between	  V,	  D,	  and	  J	  segments	  and	  their	  flanking	  RSSs,	  resulting	  in	  a	  pair	  of	  hairpin-­‐sealed	  
coding	  ends	  and	  a	  pair	  of	  blunt	  signal	  ends	  (Schatz	  and	  Swanson,	  2011).	  RAG	  also	  functions	  to	  
hold	  these	  DSBs	  in	  a	  postcleavage	  synaptic	  complex	  until	  they	  can	  be	  joined	  by	  C-­‐NHEJ	  (Helmink	  
and	  Sleckman,	  2012).	  RSSs	  contain	  highly	  conserved	  palindromic	  7-­‐bp	  sequence	  (heptamer)	  and	  
9-­‐bp	  sequence	  (nonamer)	  motifs,	  separated	  by	  a	  relatively	  nonconserved	  spacer	  of	  either	  12	  or	  
23	  bp,	  referred	  to	  as	  “12RSSs”	  and	  “23RSSs”,	  respectively	  (Nishana	  and	  Raghavan,	  2012).	  	  
RAG	   function	   requires	   simultaneous	   binding	   to	   two	   RSSs,	   one	   with	   a	   12RSS	   and	   the	  
other	  with	  a	  23RSS,	  a	  restriction	  referred	  to	  as	  the	  12/23	  rule	   (Brady	  et	  al.,	  2010).	   In	   IgH,	   for	  
example,	  the	  VH	  segments	  are	  flanked	  by	  23RSSs,	  12RSSs	  flank	  both	  sides	  of	  the	  DH	  segments,	  
and	  23RSSs	  flank	  the	  JH	  segments.	  The	  12/13	  rule	  contributes	  to	  the	  ordered	  rearrangement	  of	  
receptor	  loci	  in	  developing	  B	  cells	  such	  that	  the	  assembly	  of	  the	  D-­‐	  JH	  segments	  occurs	  before	  
they	  recombine	  to	  VH	  segments,	  thereby	  preventing	  direct	  V-­‐	  JH	  recombination.	  In	  contrast,	  the	  
configuration	   of	   the	   TCRβ	   locus	   is	   such	   that	   23RSSs	   flank	   Vβs,	   12RSSs	   flank	   Jβs,	   and	   12	   and	  
23RSSs	   flank	   Dβs	   at	   either	   side.	   However,	   V(D)J	   recombination	   still	   progresses	   first	   with	   the	  
assembly	  of	  the	  D-­‐Jβ	  segment	  then	  the	  V-­‐DJβ	  segment.	  This	  restriction,	  which	  is	  still	  mediated	  
by	   RSS	   sequence,	   is	   referred	   to	   as	   “beyond	   12/23	   rule”	   (Brady	   et	   al.,	   2010).	   In	   this	   regards,	  
several	  studies	  have	  shown	  that	  the	  beyond	  12/23	  rule	  is	  enforced	  by	  specific	  RSSs	  (Tillman	  et	  
al.,	  2004;	  Jung	  et	  al.,	  2003;	  Wu	  et	  al.,	  2003;	  Bassing	  et	  al.,	  2000).	  Restricting	  RAG	  expression	  to	  
developing	   lymphocytes	   and	   targeting	   RAG-­‐dependent	   cutting	   to	   specific	   RSS	   sequences	   are	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important	  mechanisms	  to	  prevent	  generation	  of	  off-­‐target	  DSBs,	  which	  could	  potentially	  have	  a	  
major	  impact	  on	  genomic	  stability	  (see	  below).	  
	  
1.2.4.	  Developmental	  Regulation	  Of	  V(D)J	  Recombination	  
To	  ensure	  proper	  cleavage	  and	  joining	  of	  the	  coding	  segments,	  the	  recombination	  and	  
assembly	  of	  functional	  V(D)J	  exons	  is	  a	  tightly	  regulated	  phenomenon.	  V(D)J	  recombination	  in	  
developing	  B	  and	  T	  cells	  takes	  place	  in	  a	  lineage-­‐specific	  manner:	  despite	  being	  subjected	  to	  the	  
same	  V(D)J	  recombination	  machinery,	  functional	  rearrangement	  of	  Ig	  loci	  only	  takes	  place	  in	  B	  
cells	  and	  functional	  rearrangement	  of	  Tcr	  loci	  only	  in	  T	  cells	  (Cobb	  et	  al.,	  2006).	  Among	  cells	  of	  
the	   same	   lineage,	   V(D)J	   recombination	   is	   further	   regulated	   in	   a	   developmental	   stage-­‐specific	  
manner	   by	   regulated	   gene	   accessibility,	   which	   confers	   ordered	   rearrangement	   of	   antigen	  
receptor	   genes	   such	   that	   the	   IgH	   locus	   undergoes	   rearrangement	   before	   the	   IgL	   loci	   in	  
developing	   B	   cells	   and	   the	   Tcrb	   locus	   undergoes	   rearrangements	   before	   the	   Tcra	   locus	   in	  
developing	  αβ	  T	  cells	  (Cobb	  et	  al.,	  2006).	  
Early	  B	   lineage	  cells,	   termed	  pro-­‐B	  cells,	  activate	   the	   IgH	   locus	  and	   first	   recombine	  DH	  
and	  JH	  gene	  segments,	  followed	  by	  VH	  to	  DJH	  rearrangement	  to	  generate	  a	  complete	  VH(D)JH	  
exon	   (Vettermann	   and	   Schlissel,	   2010).	   DH-­‐to-­‐JH	   recombination	   occurs	   on	   both	   IgH	   alleles,	  
whereas	  the	  subsequent	  VH	  to	  DJH	  rearrangement	  occurs	  only	  on	  one	  allele,	  a	  process	  called	  
allelic	   exclusion,	   which	   prevents	   the	   assembly	   of	   multiple	   antigen	   receptors	   in	   a	   single	   cell	  
(Luning	  Prak	  et	  al.,	  2011).	  Given	  that	  the	  nature	  of	  coding	  joins	  is	  inherently	  imprecise,	  only	  one	  
in	   three	   rearrangements	   will	   give	   rise	   to	   an	   open	   reading	   frame	   capable	   of	   expressing	   a	  
functional	  protein.	  Therefore,	  B	  cells	  which	  first	  assemble	  a	  non-­‐productive	  or	  non-­‐pairing	  (see	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below)	   VH(D)JH	  exon	   can	   undergo	   rearrangement	   of	   the	   second	   IgH	   allele	   (Vettermann	   and	  
Schlissel,	  2010)	  (Figure	  4).	  
Figure	   4.	   Schematic	   representation	  of	  mouse	  B	   cell	   development.	   The	   stage-­‐specific	  
rearrangement	  of	  IgH	  and	  IgL	  loci	  are	  indicated.	  The	  expression	  of	  RAG	  is	  depicted	  and	  
darker	  shading	  indicates	  a	  higher	  relative	  level	  of	  expression.	  From	  Alt	  et	  al.,	  2013.	  	  
	  
Upon	  productive	   rearrangement	  of	   the	  V(D)J	  exon,	  a	  μ	  heavy	  chain	   (μHC)	  encoded	  by	  
V(D)J	  and	  Cμ	  is	  produced.	  The	  μ	  heavy	  chain	  is	  paired	  with	  the	  surrogate	  light	  chain	  (SLC),	  which	  
is	   comprised	   of	   the	   invariant	   polypeptides	   VpreB	   and	   λ5	   (Vettermann	   and	   Schlissel,	   2010).	  
Successful	   assembly	   of	   μHC	   to	   SLC	   produces	   a	   pre-­‐B-­‐cell	   receptor	   (pre-­‐BCR)	   that	   signals	  
differentiation	  of	   pro-­‐B	   cells	   to	   the	  pre-­‐B	   cell	   stage,	  where	   the	   IgL	   genes	   are	   assembled.	   Igκ	  
rearrangement	   always	   precedes	   Igλ	   rearrangement	   (Luning	   Prak	   et	   al.,	   2011).	   Productive	  
rearrangement	  of	  Vκ	  and	   Jκ	  gene	  segments	  allows	   for	   the	  expression	  of	   Igκ	   light	  chain	   (κLC)	  
that	   can	   be	   paired	   with	   μHC	   to	   form	   a	   functional	   BCR.	   An	   inability	   to	   pair	   κLC	   with	   the	  
preexisting	   μHC	   or	   a	   pairing	   that	   results	   in	   an	   autoreactive	   BCR	   leads	   to	   secondary	  
rearrangements	  of	  the	   IgL	   loci	  via	  a	  process	  called	  receptor	  editing	  (Luning	  Prak	  et	  al.,	  2011).	  
During	  receptor	  editing,	  rearranged	  VκJκ	  exons	  can	  be	  replaced	  by	  rearrangement	  of	  upstream	  
Vκ	  to	  downstream	  Jκ	  gene	  segments	  (Luning	  Prak	  et	  al.,	  2011).	  Alternatively,	  a	  rearrangement	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that	   deletes	   the	   Igκ	   locus	   allows	   the	   cells	   to	   undergo	   rearrangement	   in	   the	   Igλ	   locus.	  
Expression	   of	   a	   functional	   BCR	   on	   the	   cell	   surface	   allows	   pre-­‐B	   cells	   to	   develop	   into	   IgM+	  
immature	  B	  cells,	  which	  migrate	  to	  the	  periphery.	  
Developing	   T	   cells	   follows	   similar	   regulation	   as	   they	   undergo	   rearrangement	   and	  
expression	  of	  various	  Tcr	  genes	  in	  the	  thymus.	  Rearrangement	  of	  TCR	  α/δ,	  β,	  and	  γ	  are	  carried	  
out	   at	   two	   distinct	   stages	   of	   thymocyte	   development.	   Thymocytes	   commit	   to	   the	   αβ	   or	   γδ	  
lineages	  upon	  the	  outcome	  of	  these	  TCR	  gene	  recombination	  events.	  In	  the	  case	  of	  αβ	  T	  cells,	  
the	   Tcrb	   locus	   rearranges	   first	   in	   the	   CD4-­‐CD8-­‐	   double-­‐negative	   (DN)	   2	   and	   3	   stages	   of	  
thymocyte	  development	   (Krangel,	   2009).	  Developmental	   stage-­‐specific	   recombination	  of	  Tcrb	  
dictates	  that	  Dβ-­‐to-­‐Jβ	  rearrangement	  precedes	  Vβ-­‐to-­‐DJβ	  recombination	  and	  the	  expression	  of	  a	  
productive	   rearrangement	   of	   the	   Tcrb	   gene	   allows	   for	   differentiation	   into	   CD4+CD8+	   double-­‐
positive	   (DP)	   cells,	   in	   which	   Tcra	   recombination	   occurs	   (Spicuglia	   et	   al.,	   2010).	   Afterwards,	  
TCRαβ-­‐expressing	  cells	  can	  be	  further	  selected	  into	  mature	  CD4+	  or	  CD8+	  single-­‐positive	  (SP)	  T-­‐
cells	  (Figure	  5).	  Similarly	  to	  IgH,	  the	  TCRβ	  locus	  is	  allelically	  excluded,	  so	  that	  only	  one	  allele	  is	  
functionally	  rearranged	  and	  expressed	   in	  mature	  αβ	  T	  cells	   (Luning	  Prak	  et	  al.,	  2011;	  Krangel,	  
2009).	  	  
	  
1.2.5.	  Higher-­‐Order	  Regulation	  of	  V(D)J	  Recombination	  
The	   correct	   execution	   of	   V(D)J	   recombination	   is	   tightly	   controlled	   by	   several	   higher-­‐
order	   mechanisms	   that	   include	   transcription,	   chromatin	   modifications,	   and	   chromosome	  
conformational	  changes,	  which	  ultimately	  act	  by	  modulating	   locus	  accessibility.	  A	   first	  clue	  to	  
this	  regulatory	  mechanism	  begins	  with	  the	  discovery	  of	  germline	  transcripts.	  It	  is	  observed	  that	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transcription	   of	   germline	   gene	   segments	   coincided	   with	   B	   cell	   developmental	   stages	   where	  
these	   gene	   segments	   are	   poised	   for	   recombination	   (Yancopoulos	   and	  Alt,	   1985).	   Since	   these	  
initial	   observations,	   the	   correlation	   between	   germline	   transcription	   and	   V(D)J	   recombination	  
has	  been	  extended	  to	  all	  Ig	  and	  TCR	  gene	  segments	  (Abbey	  and	  O’	  Neill,	  2008).	  	  
Figure	   5.	   Schematic	   representation	   of	   mouse	   α/β	   T	   cell	   development.	   The	  
developmental	   stage-­‐specific	   rearrangements	   of	   TCR	   genes	   and	   surface	  
expression	  of	  the	  pre-­‐TCR	  are	  indicated.	  From	  Cobb	  et	  al.,	  2006.	  	  
	  
Genic	  and	  intergenic	  germline	  antisense	  transcription	  occurs	  extensively	  in	  the	  VH	  region	  
(Matheson	  and	  Corcoran,	  2012).	  This	  transcription	  occurs	  on	  both	  alleles	  and	  was	  detected	  in	  a	  
large	  proportion	  of	  pro-­‐B	  cells	  prior	  to	  VH-­‐to-­‐DJH	  rearrangement,	  suggesting	  that	  this	  antisense	  
transcription	  remodels	  the	  VH	  region	  to	  promote	  accessibility	  to	  the	  VH	  gene	  segments	  (Bolland	  
et	  al.,	  2004).	  Lastly,	  in	  pre-­‐B	  and	  mature	  B	  cells,	  sense	  transcription	  of	  assembled	  V(D)JH	  exons	  is	  
detected	   from	   the	   VH	   promoter	   but	   neither	   sense	   nor	   antisense	   transcription	   occurs	   in	   the	  
distal	  VH	  segments	  (Giallourakis	  et	  al.,	  2004)	  (Figure	  6).	  Taken	  together,	  transcriptional	  status	  of	  
Ig	  genes	  may	  play	  an	  important	  role	  in	  opening	  up	  the	  locus	  to	  recombination	  machinery.	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Figure	   6.	   Schematic	   representation	  of	   the	  mouse	   IgH	   locus	   transcription	   and	   rearrangement.	  
Top	  panel	  depicts	  events	  in	  early	  pro-­‐B	  cell	  stage.	  Middle	  panel	  depicts	  events	  in	  late	  pro-­‐B	  cell	  
stage.	   Bottom	   panel	   depicts	   events	   in	   pre-­‐B	   and	   mature	   B	   cell	   stage.	   Sense	   transcripts	   are	  
depicted	  as	  green	  arrows.	  Rearrangement	  of	  gene	  segments	  is	  depicted	  as	  broken	  blue	  arrows.	  
Antisense	   VH	   germline	   transcripts	   are	   depicted	   as	   red	   arrows.	   Antisense	   DH	   germline	  
transcripts	  are	  depicted	  as	  broken	  red	  arrows.	  From	  Giallourakis	  et	  al.,	  2004.	  
	  
Another	  correlate	  of	  loci	  accessibility	  is	  epigenetic	  regulation	  of	  the	  chromatin.	  Histone	  
acetylation,	  a	  hallmark	  of	  transcriptionally	  and	  recombinationally	  active	  chromatin,	  appears	  to	  
be	  activated	  in	  a	  stepwise	  process	  that	  coincides	  with	  the	  order	  of	  V(D)J	  recombination.	  In	  pro-­‐
B	  cells	  before	  DH-­‐to-­‐JH	   recombination	  occurs,	   the	  genomic	  region	  spanning	  the	  DH,	   JH,	  and	  Cμ	  
exons	   becomes	   accessible	   to	   RAG	   as	   evident	   by	   H3	   and	  H4	   acetylation	   (Subrahmanyam	   and	  
Sen,	  2010).	  On	   the	  contrary,	   the	  VH	   region	   remains	  hypoacetylated	  and	   is	   inaccessible	   to	   the	  
recombination	  machinery	  (Subrahmanyam	  and	  Sen,	  2010).	  	  
Trimethylation	  of	   the	  H3K4	   residue	   (H3K4me3)	  has	  been	  shown	   to	  be	  highly	  enriched	  
around	   active	   promoters	   (Heintzman	   et	   al.,	   2007).	   The	   functional	   consequence	   of	   this	  
enrichment	   links	   histone	  modifications	   to	   the	   function	   of	   the	   RAG	   endonuclease.	   The	   RAG2	  
protein	  consists	  of	   core	  and	  noncore	   regions.	  The	  core	  RAG2	   fragment	   facilitates	   cleavage	  of	  
RSSs	  during	  recombination	  whereas	  the	  noncore	  fragment	  is	  hypothesized	  to	  facilitate	  faithful	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recombinations	   of	   gene	   segments	   (Jones	   and	   Simkus,	   2009).	   The	   RAG2	   noncore	   fragment	  
contains	   a	   non-­‐canonical	   plant	   homeodomain	   (PHD)	   that	   has	   been	   shown	   to	   mediate	  
interactions	  with	  chromatins	  (Matthews	  et	  al.,	  2007).	  In	  the	  context	  of	  V(D)J	  recombination,	  the	  
recognition	  and	  binding	  to	  H3K4me3	  by	  the	  RAG2	  plant	  homeodomain	  (PHD)	  are	  postulated	  to	  
promote	  V(D)J	   recombination	  by	   recruiting	  or	   retaining	   the	  RAG	  complex	  at	  antigen	   receptor	  
loci	  (Matthews	  and	  Oettinger,	  2009).	  	  	  	  	  
In	  addition	  to	  iEµ,	  a	  number	  of	  regulatory	  elements	  have	  been	  identified	  in	  the	  murine	  
IgH	  locus.	  	  Recently,	  a	  4kb	  intergenic	  region	  between	  DFL16.1	  and	  VH81X,	  named	  intergenic	  control	  
region	  1	  (IGCR1),	  has	  been	  shown	  to	  play	  a	  critical	   role	   in	  regulating	   IgH	   locus	  recombination	  
(Guo	  et	  al.,	  2011).	  The	  IGCR1	  contains	  two	  binding	  sites	  for	  CCCTC-­‐binding	  factor	  (CTCF).	  CTCF	  is	  
a	  highly	  conserved,	  ubiquitously	  expressed	  transcription	  factor	  that	  binds	  a	  GC-­‐rich	  consensus	  
sequence	  (Phillips	  and	  Corces,	  2009).	  CTCF	  has	  been	  shown	  to	  exhibit	  transcriptional	  activation	  
as	   well	   as	   transcriptional	   insulation	   activity	   via	   mediation	   of	   chromatin	   looping	   (Shih	   and	  
Krangel,	  2013).	  Mutation	  of	  these	  CTCF-­‐binding	  elements	  (CBEs)	  increase	  transcription	  level	  of	  
proximal	  VH	  genes,	  resulting	  in	  decreased	  utilization	  of	  the	  distal	  VH	  genes	  and	  loss	  of	  ordered	  
VH-­‐to-­‐DJH	  rearrangement	  (Guo	  et	  al.,	  2011).	  Moreover,	  lineage	  specificity	  was	  also	  affected,	  as	  
VH-­‐to-­‐DJH	  recombination	  was	  detected	  in	  CBE-­‐mutant	  thymocytes	  (Guo	  et	  al.,	  2011).	  Therefore,	  
IGCR1	  has	  been	  proposed	   to	   insulate	  proximal	  VH	   segments	   from	  rearranged	  D-­‐JH	   substrates,	  
favoring	  recombination	  to	  more	  distal	  VHs	  (Figure	  7).	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Figure	  7.	  Schematic	  representation	  of	  the	  mouse	   IGCR1	  organization.	  The	  most	  
distal	   VH	   segment	   is	   depicted	   as	   a	   blue	   line.	   The	  most	   proximal	   VH	   segment	   is	  
depicted	   as	   a	   red	   line.	   CBE	   sites	   are	   depicted	   as	   purple	   triangles.	   The	   DH	  
segments	  are	  depicted	  as	  green	  lines	  with	  the	  most	  5’	  and	  3’	  segment	  indicated.	  
The	  JH	  segments	  are	  depicted	  as	  black	  lines.	  Regulatory	  elements	  are	  depicted	  as	  
black	  circles.	  From	  Guo	  et	  al.,	  2011.	  	  
	  
	   Another	   major	   challenge	   during	   V(D)J	   recombination	   is	   how	   to	   bring	   together	   gene	  
segments	   that	   reside	  over	   very	   large	   linear	  distances.	  A	   complex	  and	  dynamic	  modulation	  of	  
antigen	   receptor	   loci	   conformation	   has	   been	   recently	   proposed	   to	   be	   responsible	   for	   such	  
process.	  Several	  studies	  suggest	  a	  model	  where	  the	  IgH	  locus	  in	  pre-­‐pro	  B	  cells	  is	  organized	  in	  
multiple	   large	   “rosette-­‐like”	   compartments	   or	   subdomains,	   each	   composed	   of	  multiple	   DNA	  
loops	   (Subrahmanyam	   and	   Sen,	   2012;	   Bossen	   et	   al.,	   2012).	   Upon	   the	   initiation	   of	   V(D)J	  
recombination,	  these	  subdomains	  undergo	  further	  interactions	  required	  to	  bring	  the	  distal	  VHs	  
segments	  in	  close	  proximity	  to	  the	  DH	  and	  JH	  segments	  for	  synapsis	  and	  cleavage	  by	  RAG.	  	  
	   The	  newly	  identified	  IgH	  regulatory	  elements	  termed	  Pax5-­‐activated	  intergenic	  repeats	  
(PAIRs)	   are	   believed	   to	   modulate	   the	   IgH	   locus	   contraction	   (Ebert	   et	   al.,	   2011).	   PAIRs	   are	  
interspersed	   within	   the	   distal	   VH	   gene	   segments,	   contain	   binding	   sites	   for	   a	   B	   cell-­‐specific	  
transcription	  factor	  E2A,	  and	  also	  interact	  with	  CTCF	  (Ebert	  et	  al.,	  2011).	  PAIRs	  have	  also	  been	  
shown	  to	   induce	  pro-­‐B	  cell-­‐specific	  germline	   transcription	  and	  active	  chromatin	  modifications	  
coinciding	  with	   the	   IgH	   locus	   contraction	   (Ebert	   et	   al.,	   2011).	   Further	   genetic	   studies	  will	   be	  
needed	   to	   better	   elucidate	   the	   exact	   role	   of	   PAIRs	   in	   V(D)J	   recombination.	   Such	   locus	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contraction	  can	  be	  visualized	  by	  three-­‐dimensional	  FISH:	   IgH	  and	   Igκ	   loci	  undergo	  contraction	  
specifically	  in	  rearranging	  cells,	  while	  they	  are	  in	  a	  decontracted	  state	  in	  other	  developmental	  
stages	   and	   cell	   types	   (Hewitt	   et	   al.,	   2010;	   Roldan	   et	   al.,	   2005).	   A	   similar	   stage-­‐specific	  
contraction	  has	  been	  described	  at	  TCRα/δ	  and	  TCRβ	  loci	  (Shih	  and	  Krangel,	  2013).	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1.3.	  Secondary	  Antibody	  Diversification	  
Successful	   rearrangement	   of	   the	   IgH	   and	   IgL	   by	   V(D)J	   recombination	   results	   in	   the	  
expression	  of	  IgM	  and/or	  IgD	  molecules	  on	  the	  surface	  of	  B	  lymphocytes.	  The	  expression	  of	  IgM	  
allows	  B	  lymphocytes	  to	  migrate	  out	  of	  the	  bone	  marrow	  into	  peripheral	  lymphoid	  organs	  such	  
as	   the	   spleen,	   lymph	   nodes,	   and	   gut-­‐associated	   lymphoid	   tissue.	   At	   these	   sites,	   B	   cells	  
encounter	  antigen	  and	  are	  stimulated	  to	  undergo	  CSR	  and	  SHM.	  	  
Class	  switching	  refers	   to	  a	  recombination	  event	   in	  which	  the	  constant	  region	  of	   the	   Ig	  
molecule	   is	   exchanged	   for	   another	   class	   of	   constant	   region	   without	   altering	   antigen-­‐binding	  
specificity	  of	  the	  molecule	  (Keim	  et	  al.,	  2013).	  CSR	  occurs	  in	  mature	  B	  lymphocytes	  and	  unlike	  
V(D)J	  recombination,	  this	  process	  does	  not	  occur	  in	  T	  lymphocytes.	  During	  CSR,	  the	  Cμ	  constant	  
region	  is	  replaced	  by	  downstream	  CH	  exons	  such	  as	  Cγ,	  Cε,	  and	  Cα,	  resulting	  in	  a	  change	  in	  the	  
antibody	  class	  from	  IgM	  to	  IgG,	  IgE,	  or	  IgA,	  respectively	  (Chaudhuri	  et	  al.,	  2007)	  (Figure	  8).	  The	  
recombination	  takes	  place	  between	  S	  regions,	  which	  lie	  just	  upstream	  of	  the	  various	  CH	  genes	  
(Boboila	   et	   al.,	   2012).	   Each	   S	   region	   is	   preceded	   by	   its	   own	   transcriptional	   promoter	   that	   is	  
responsive	  to	  certain	  cytokines	  and	  activators	  from	  the	  germinal	  center	  environment	  (Zhang	  et	  
al.,	  2010).	  Transcription	  through	  the	  S	  region	  directs	  CSR	  to	  specific	  downstream	  CH	  genes.	  This	  
regulation	   ensures	   that	   antibodies	   with	   the	   most	   suitable	   effector	   function	   are	   produced	  
(Chaudhuri	   et	   al.,	   2007).	   To	   complete	   CSR,	   DSBs	   in	   the	   donor	   Sμ	   region	   and	   a	   downstream	  
acceptor	   S	   region	   are	   joined	   and	   the	   intervening	   region	   between	   the	   two	   S-­‐region	   DSBs	   is	  
deleted	   (Boboila	   et	   al.,	   2012).	   The	   synapsis	   and	   joining	   are	   mediated	   by	   general	   DNA	   end-­‐
joining	  and	  DNA	  repair	  pathways	  (Zarrin	  et	  al.,	  2007).	  The	  juxtaposition	  of	  the	  downstream	  CH	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gene	  to	  the	  V(D)J	  exon	  results	  in	  the	  production	  of	  a	  new	  constant	  region	  under	  the	  control	  of	  
the	  V(D)J	  exon	  promoter	  (Chaudhuri	  et	  al.,	  2007)	  (Figure	  8).	  	  	  
Figure	  8.	  Schematic	  representation	  of	  the	  mouse	  IgH	  constant	  region	  locus	  and	  
of	   the	   recombination	  events	  occurring	   in	  CSR.	  CH	   genes	  are	  depicted	  as	  blue	  
rectangles.	   S	   regions	   are	   depicted	   as	   blue	   ovals.	   Enhancer	   elements	   are	  
depicted	  as	  black	  ovals.	  From	  Gostissa	  et	  al.,	  2011.	  	  
	  
Mature	  B	  lymphocytes	  can	  also	  alter	  their	  antigen-­‐binding	  specificity	  via	  SHM	  (Keim	  et	  
al.,	   2013).	   SHM	   introduces	   a	   high	   rate	   of	  mutation	   via	   point	  mutations,	   small	   deletions,	   and	  
insertions	   into	   the	   assembled	   variable	   region	   of	   Ig	   molecules,	   starting	   approximately	   150	  
basepairs	  downstream	  of	  the	   IgV	  promoter	  and	  extending	  over	  2	  kb	  (Wang,	  2013;	  Neuberger	  
and	   Rada,	   2006).	   The	   mutation	   frequency	   is	   estimated	   to	   be	   approximately	   10-­‐3	   to	   10-­‐4	   per	  
basepair	  per	  cell	  division,	  can	  occur	  at	  either	  C/G	  or	  A/T	  pairs,	  and	  can	  be	  either	  transitions	  or	  
transversions	   (Neuberger	   and	   Rada,	   2006).	   These	   mutations	   allow	   for	   the	   selection	   of	   B	  
lymphocytes	  with	  higher	  antigen-­‐binding	  affinity	  BCR	   (Keim	  et	  al.,	   2013).	   The	   combination	  of	  
CSR	  and	  SHM	  helps	  the	  immune	  system	  mount	  a	  more	  effective	  immune	  response.	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CSR	   and	   SHM	   are	   initiated	   by	   activation-­‐induced	   deaminase	   (AID)	   (Muramatsu	   et	   al.,	  
2000).	  AID	  functions	  as	  a	  single-­‐stranded	  (ss)-­‐specific	  DNA	  deaminase.	  It	  catalyzes	  the	  dC-­‐to-­‐dU	  
deamination	   in	   transcribed	   S	   regions	   and	   variable	   gene	   segments	   during	   CSR	   and	   SHM,	  
respectively	   (Chaudhuri	   et	   al.,	   2007).	   AID	   preferentially	   recognizes	   RGYW	   and	   WRCY	   motifs	  
(where	  R	  =	  purine,	  Y	  =	  pyrimidine,	  and	  W	  =	  A	  or	  T	  nucleotide)	  and	  canonical	  palindromic	  motif	  
AGCT,	  which	  are	  enriched	  in	  S	  regions	  and	  within	  variable	  region	  exons	  (Chaudhuri	  et	  al.,	  2007).	  
AID	   is	   recruited	   to	   ssDNA	   by	   transcription.	   Transcription	   through	   the	   S	   region	   results	   in	   the	  
formation	   of	   RNA/DNA	   hybrids	   in	   which	   the	   non-­‐template	   DNA	   strand	   can	   assume	   single-­‐
stranded	  conformation	  termed	  R-­‐loop.	  These	  R	  loops	  provide	  ssDNA	  substrates	  for	  AID	  (Voung	  
and	  Chaudhuri,	  2012).	  The	  V	  regions,	  unlike	  the	  S	  region,	  do	  not	  contain	  the	  G:C-­‐rich	  sequences	  
needed	   for	  R-­‐loop	   formation.	   Therefore,	   to	   complete	  SHM,	  AID	   interacts	  with	   ssDNA	  binding	  
protein	  Replication	  Protein	  A	   (RPA).	  The	  AID:RPA	  complex	  has	  been	  demonstrated	   to	  bind	   to	  
and	   deaminate	   transcribed	   DNA	   in	   vitro	   (Chaudhuri	   et	   al.,	   2004).	   AID	   does	   not	   generate	  
mutation	  or	  DSBs	  directly,	   instead	  it	  generates	  a	  U:G	  mismatch	  DNA	  lesion.	  The	  processing	  of	  
the	   dU:dG	  mismatch	   by	   the	   base-­‐excision	   repair	   (BER)	   or	  mismatch	   repair	   (MMR)	   pathways	  
result	  in	  DNA	  nicks	  that	  lead	  to	  mutations	  or	  DSBs	  (Di	  Noia	  and	  Neuberger,	  2007).	  In	  the	  case	  of	  
CSR,	   the	  DSBs	   in	   the	  donor	  and	  acceptor	  S	   regions	  are	  brought	   together	   for	   joining	  via	  ATM-­‐
dependent	  DSB	  response	  and	  C-­‐NHEJ	   (Boboila	  et	  al.,	  2012).	   In	  the	  absence	  of	  C-­‐NHEJ	   factors,	  
CSR	  can	  still	  be	  carried	  out	  by	  alternative	  end-­‐joining	  pathways	  at	  up	   to	  50%	  of	  normal	   level	  
(Yan	   et	   al.,	   2007).	   The	   A-­‐EJ	   pathways	   will	   be	   discussed	   in	   greater	   detail	   in	   section	   1.4.2.	  
Experiments	  in	  in	  vitro	  stimulated	  B	  cells	  showed	  that	  AID	  activity	  in	  S	  regions	  is	  very	  robust	  and	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can	  generate	  sufficient	  DSBs	  in	  the	  IgH	  locus	  such	  that	  over	  50%	  of	  the	  cells	  can	  be	  induced	  to	  
undergo	  CSR	  (Boboila	  et	  al.,	  2010).	  	  
Multiple	   transcriptional	   and	   post-­‐transcriptional	   regulatory	   mechanisms	   control	   AID	  
activity	  (Keim	  et	  al.,	  2013).	  Enhancers	  and	  promoter	  elements	  have	  been	  shown	  to	  restrict	  the	  
transcription	   level	   of	   the	   aicda	   gene	   that	   encodes	   AID	   in	   a	   cell	   lineage-­‐	   and	   developmental	  
stage-­‐specific	  manner	  (Voung	  and	  Chaudhuri,	  2012).	  At	  least	  two	  microRNAs	  (miR-­‐155	  and	  miR-­‐
181b)	  post-­‐transcriptionally	  downregulate	  AID	  mRNA	  and	  protein	  levels,	  leading	  to	  reduced	  CSR	  
(de	   Yebenes	  et	   al.,	   2008;	  Dorsett	   et	   al.	   2008;	   Teng	  et	   al.	   2008).	  Moreover,	   post-­‐translational	  
modifications	   such	   as	   phosphorylation	   can	   also	   regulate	   AID	   activity.	   AID	   can	   be	  
phosphorylated	  at	  multiple	  residues,	  resulting	  in	  an	  increased	  or	  reduced	  level	  of	  CSR	  and	  SHM	  
(Voung	  and	  Chaudhuri,	  2012).	  Lastly,	  although	  AID	  exhibits	   its	  activity	  on	  DNA	  in	  the	  nucleus,	  
most	  AID	  in	  B	  cells	  is	  found	  in	  the	  cytoplasm,	  suggesting	  that	  AID	  activity	  may	  also	  be	  regulated	  
by	  its	  localization	  (Geisberger	  et	  al.,	  2009).	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1.4.	  The	  Role	  Of	  DNA	  Repair	  Pathways	  In	  V(D)J	  Recombination	  And	  CSR	  
V(D)J	  recombination	  and	  CSR	  generate	  DSBs	  in	  the	  genome	  that	  can	  lead	  to	  undesirable	  
chromosomal	  aberrations.	   To	  maintain	  genomic	   integrity,	  mammalian	   cells	  have	  evolved	   two	  
major	   DNA	   repair	   pathways:	   homologous	   recombination	   (HR)	   and	   classical	   non-­‐homologous	  
end	   joining	   (C-­‐NHEJ)	   (Grabarz	   et	   al.,	   2012).	   HR	   is	   initiated	   by	   single-­‐strand	   DNA	   (ssDNA)	  
resection	   and	   repairs	   DSBs	   with	   high	   fidelity	   using	   a	   stretch	   of	   homologous	   sequence	   as	   a	  
template,	  usually	   from	  the	  sister	  chromatid	  after	  DNA	  replication	  (Jasin	  and	  Rothstein,	  2013).	  
For	  this	  reason,	  HR	  mostly	  functions	  in	  post-­‐replication	  repair	  during	  the	  S/G2	  phase	  of	  the	  cell	  
cycle	  (Grabraz	  et	  al.,	  2012).	  Unlike	  HR,	  C-­‐NHEJ	  can	  join	  DNA	  ends	  without	  sequence	  homology	  
such	  as	  in	  direct	  joining,	  or	  ends	  with	  short	  micro-­‐homologies	  (MHs)	  (Bunting	  and	  Nussenzweig,	  
2013),	   and	   often	   requires	   end	   processing	   to	   prepare	   broken	   ends	   for	   ligation,	   therefore	  
resulting	   in	   imprecise	   joins	   (Boboila	  et	  al.,	  2012).	  C-­‐NHEJ	   is	   functional	   in	  all	  phases	  of	   the	  cell	  
cycle	  and	  is	  the	  dominant	  pathway	  during	  the	  G0/G1	  phase	  when	  HR	  is	  not	  active	  (Saintigny	  et	  
al.,	  2007).	  	  
	   	  	  
1.4.1.	  Classical	  Non-­‐Homologous	  End	  Joining	  
The	   first	   step	   in	   the	   C-­‐NHEJ	   repair	   reaction	   requires	   the	   binding	   of	   Ku70/Ku80	  
heterodimer	  to	  DSBs,	  where	  they	  may	  serve	  a	  protective	  function	  and	  also	  recruit	  other	  repair	  
factors	   (Gu	   et	   al.,	   1997;	   Goedecke	   et	   al.,	   1999).	   Ku70/Ku80	   are	   absolutely	   required	   for	  
subsequent	   completion	   of	   the	   ligation	   reaction	   by	   XRCC4	   and	   DNA	   ligase4	   (Lig4).	   For	   this	  
reason,	  Ku70/Ku80,	  XRCC4	  and	  Lig4	  are	  considered	  “core”	  C-­‐NHEJ	  factors	  (Boboila	  et	  al.,	  2012)	  
which	  are	  sufficient	  for	  ligation	  of	  DNA	  ends	  that	  do	  not	  require	  processing,	  such	  as	  signal	  ends	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generated	  by	  RAG	  during	  V(D)J	  recombination.	  	  For	  the	  joining	  of	  other	  types	  of	  DNA	  ends,	  such	  
as	   hairpin-­‐sealed	   coding	   ends,	   further	   processing	   is	   required:	   binding	   of	   Ku70/Ku80	   to	   DSBs	  
activates	   the	   serine/threonine	   protein	   kinase,	   DNA-­‐PKcs,	   which	   in	   turn	   phosphorylates	   and	  
activates	  the	  Artemis	  nuclease	  (Helmink	  and	  Sleckman,	  2012),	  necessary	  to	  cleave	  the	  hairpins	  
to	  generate	  DNA	  ends	  suitable	  for	  ligation	  (Ma	  et	  al.,	  2002).	  Therefore,	  in	  the	  context	  of	  V(D)J	  
recombination,	  C-­‐NHEJ	  contributes	  to	  the	  diversity	  of	  the	  primary	  antibody	  and	  TCR	  repertoires	  
via	  the	  imprecise	  joining	  resulting	  from	  such	  end-­‐processing,	  combined	  with	  the	  addition	  of	  “N”	  
(nontemplated)	   nucleotides	   by	   the	   template-­‐independent	   DNA	   polymerase	   TdT	   (terminal	  
deoxinucleotdyl	  transferase)	  (Lieber,	  2010).	  	  
Another	  recently	  identified	  factor,	  Cernunnos/XLF,	  has	  been	  proposed	  to	  function	  in	  C-­‐
NHEJ,	  but	  its	  role	  is	  not	  yet	  fully	  clarified	  (Li	  et	  al.,	  2008;	  Zha	  et	  al.,	  2007;	  Ahnesorg	  et	  al.,	  2006;	  
Buck	   et	   al.,	   2006).	   XLF	   directly	   interacts	   with	   the	   XRCC4-­‐Ligase	   4	   complex	   (Ahnesorg	   et	   al.,	  
2006;	  Buck	  et	  al.,	  2006;	  Callebaut	  et	  al.,	  2006)	  and	  it	  is	  believed	  to	  be	  involved	  in	  end-­‐ligation	  
and	  joining	  of	  DSBs	  with	  incompatible	  or	  blunt	  ends	  (Tsai	  et	  al.,	  2007).	  However,	  XLF-­‐deficient	  
mice	   to	   not	   show	   V(D)J	   recombination	   defects	   (Li	   et	   al.,	   2008),	   unless	   the	   ATM	   kinase	   (see	  
below)	   is	   simultaneously	   deleted,	   suggesting	   ATM	   or	   other	   downstream	   factors	   may	   play	   a	  
compensatory	  role	  for	  XLF	  deficiency	  in	  lymphocytes	  (Zha	  et	  al.,	  2011)	  (Figure	  9).	  
C-­‐NHEJ	   plays	   an	   important	   role	   in	   maintaining	   genome	   integrity	   by	   suppressing	  
chromosomal	   translocation	   via	   directing	   DSBs	   to	   join	   within	   a	   chromosome	   as	   opposed	   to	  
joining	   interchromosomally	   (Zhang	  et	   al.,	   2010).	  Moreover,	   it	   is	   absolutely	   required	   for	  V(D)J	  
recombination,	   because	   RAG2	   channels	   the	   repair	   of	   V(D)J	   breaks	   to	   this	   repair	   pathway,	  
thereby	  excluding	  other	  pathways	  (Corneo	  et	  al.,	  2007).	  Accordingly,	  mice	  deficient	  for	  core	  C-­‐
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NHEJ	  factors	  show	  severe	  phenotypes,	  including	  immunodeficiency,	  growth	  retardation	  (in	  the	  
case	  of	  Ku	  deficiency)	  or	  embryonic	  lethality	  due	  to	  neuronal	  apoptosis	  (in	  the	  case	  of	  XRCC4	  or	  
Lig4	  deficiency),	  and	  increased	  sensitivity	  to	  DNA	  damage	  (Frank	  et	  al.,	  1998;	  Gu	  et	  al.,	  1997;	  Li	  
et	  al.,	  1995;	  Taccioli	  et	  al.,	  1994).	  
Figure	  9.	   Schematic	   representation	  of	   joining	  of	  RAG-­‐initiated	  DSBs	  by	  C-­‐NHEJ.	  
Adapted	  from	  Zhang	  et	  al.,	  2010	  
	  
1.4.2.	  Alternative	  End	  Joining	  
Even	   though	   V(D)J	   recombination	   is	   dependent	   on	   C-­‐NHEJ,	   joining	   of	   other	   types	   of	  
DSBs,	   including	   those	   involved	   in	   chromosomal	   translocations	   (Zhu	   et	   al.,	   2002)	   and	   those	  
generated	  during	  CSR	   (Soulas-­‐Sprauel	  et	  al.,	  2007;	  Yan	  et	  al.,	  2007)	  can	  still	   take	  place	   in	   the	  
absence	  of	  C-­‐NHEJ,	  suggesting	  the	  existence	  of	  alternative	  end	  joining	  (A-­‐EJ)	  pathways	  (Boboila	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et	  al.,	  2012).	  In	  this	  regard,	  mature	  B	  cells	  deficient	  for	  core	  C-­‐NHEJ	  factors	  still	  undergo	  CSR	  in	  
culture	  at	  levels	  up	  to	  50%	  of	  WT,	  indicating	  the	  robustness	  of	  A-­‐EJ	  (Yan	  et	  al.,	  2007).	  Sequence	  
analysis	  of	  CSR	  junctions	  from	  these	  mice	  revealed	  that	  A-­‐EJ	  preferentially	  repairs	  broken	  DNA	  
ends	  via	  MH-­‐mediated	  mechanisms	  (Boboila	  et	  al.,	  2012).	  However,	  MH	  is	  not	  a	  requirement	  
for	  A-­‐EJ.	   In	   this	   regard,	  direct	   joining	  of	   I-­‐SceI-­‐initiated	  as	  well	  as	  AID-­‐initiated	  DSBs	  has	  been	  
detected	  in	  Ku80-­‐deficient	  and	  Ku70-­‐	  or	  dual	  Ku70/Lig4-­‐deficient	  cells,	  respectively	  (Boboila	  et	  
al.,	  2010;	  Guirouilh-­‐Barbat	  et	  al.,	  2007,	  2004).	  Many	  DNA	  repair	  factors	  have	  been	  implicated	  in	  
A-­‐EJ,	   including	   Parp1,	   Mre11,	   CtIP,	   XRCC1,	   Ligase1,	   and	   Ligase3;	   however,	   their	   exact	   roles	  
remain	   to	   be	   elucidated	   (Boboila	   et	   al.,	   2012).	   Moreover,	   several	   evidences	   point	   to	   the	  
existence	  of	  at	  least	  two	  separate	  A-­‐EJ	  pathways	  (Boboila	  et	  al.,	  2012).	  Therefore,	  to	  date,	  A-­‐EJ	  
is	  best	  defined	  as	  DNA	  end	  joining	  that	  takes	  place	  in	  the	  absence	  of	  C-­‐NHEJ	  factors.	  A-­‐EJ	  is	  also	  
regarded	  as	  a	   “translocation-­‐prone”	  pathways,	  mostly	  based	  on	   the	  observation	  of	   increased	  
MH	  usage	  at	  translocations	  junctions	  (Boboila	  et	  al.,	  2002).	  In	  this	  regards,	  C-­‐NHEJ	  can	  prevent	  
such	   aberrations	   by	   eliminating	   unrepaired	   DSBs	   or	   suppressing	   activity	   of	   A-­‐EJ,	   or	   both	  
(Gostissa	  et	  al.,	  2011).	  	  
	  
1.4.3.	  The	  ATM-­‐Dependent	  DNA	  DSB	  Response	  
Efficient	   repair	   of	   chromosomal	   DSBs	   requires	   not	   only	   the	   above-­‐mentioned	   end	  
joining	  activities,	  but	  also	  the	  function	  of	  a	  series	  of	  proteins	  collectively	  referred	  to	  as	  the	  DNA	  
damage	   response	   (DDR)	   factors.	  One	  of	   the	   initial	   steps	  of	   the	  DDR	   is	   activation	  of	   the	  ATM	  
kinase,	   a	   member	   of	   the	   PI3-­‐kinase-­‐related	   kinases	   (PI3KKs),	   which	   in	   turn	   phosphorylates	  
many	   downstream	   substrates,	   including	   H2AX,	   53BP1,	   MDC1,	   and	   RNF8	   (Puebla-­‐Osorio	   and	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Zhu,	   2008).	   Upon	   phosphorylation,	   these	   factors	   associate	   to	   form	   large	   macromolecular	  
complexes,	   called	   foci,	   on	   the	   chromatin	   surrounding	   the	   site	   of	   damage,	  where	   they	   tether	  
broken	  DNA	  ends	  and	  recruit	  repair	  factors	  (Alt	  et	  al.,	  2013;	  Bassing	  and	  Alt,	  2004a).	  In	  addition,	  
the	  activation	  of	  ATM	  initiates	  cell	  cycle	  checkpoints	  to	  arrest	  cell	  cycle	  progression	  while	  repair	  
takes	  place	  (Alt	  et	  al.,	  2013)	  (Figure	  10).	  
Figure	  10.	  Schematic	   representation	  of	  ATM-­‐dependent	  DNA	  damage	  response	  
pathway.	  Adapted	  from	  Bassing	  et	  al.,	  2004.	  	  
	  
ATM	   is	   present	   as	   an	   inactive	   homodimer	   that	   is	   recruited	   to	   sites	   of	   DSB	   by	   the	  
Mre11/Rad50/Nbs1	   (MRN)	   complex.	   Upon	   binding	   to	   MRN,	   ATM	   becomes	   activated	   via	   an	  
autophosphorylation	   process	   that	   converts	   it	   into	   active	  monomers	   (Helmink	   and	   Sleckman,	  
2012).	  One	  of	  the	  first	  DDR	  responses	  initiated	  by	  activated	  ATM	  is	  the	  phosphorylation	  of	  the	  
histone	  H2A	  variant	  H2AX;	  once	  phosphorylated	  on	  serine	  139,	  H2AX	  is	  referred	  to	  as	  γ-­‐H2AX	  
and	   serves	   as	   a	   docking	   site	   to	   which	   other	   DDR	   factors,	   such	   as	   53BP1	   and	   MDC1	   bind	  
(Fernandez-­‐Capetillo	   et	   al.,	   2004).	   Additionally,	   γ-­‐H2AX	   is	   proposed	   to	   stabilize	   broken	   DNA	  
ends	  in	  repair	  complexes,	  thereby	  facilitating	  effective	  DNA	  repair	  (Bassing	  and	  Alt,	  2004b).	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MDC1	   is	  best	   characterized	  as	  an	  adaptor	  protein	   that	   recruits	  other	   repair	   factors	   to	  
the	   site	   of	   DNA	   breaks	   so	   that	   they	   can	   be	   activated	   by	   ATM-­‐dependent	   phosphorylation	  
(Coster	  and	  Goldberg,	  2010).	  This	  process	  results	  in	  an	  accumulation	  as	  well	  as	  an	  amplification	  
of	   the	   DDR	   signal	   (Giunta	   and	   Jackson,	   2011).	   MDC1	   binds	   directly	   with	   γ-­‐H2AX	   and	   ATM,	  
resulting	   in	   the	   generation	   of	   a	   positive	   feedback	   loop	   to	   promote	   DNA	   repair	   and	   ATM	  
retention	  (Derheimer	  and	  Kastan,	  2011;).	  RNF8,	  a	  RING-­‐finger	  E3	  Ubiquitin	  ligase,	  is	  recruited	  to	  
the	   repair	   complex	   upon	   phosphorylation	   of	   MDC1	   (Yan	   and	   Jetten,	   2008).	   RNF8	   mediates	  
ubiquitylation	   of	   H2AX,	   which	   is	   required	   for	   remodeling	   of	   chromatin	   and	   downstream	  
recruitment	  and	  retention	  of	  53BP1	  at	  DSB	  sites	   (Mailand	  et	  al.,	  2007).	  The	   important	  role	  of	  
DDR	  factors	   in	  promoting	  DNA	  repair	   is	   indicated	  by	  the	  fact	  that	  deficiency	   in	  many	  of	  them	  
(including	  ATM,	  H2AX	   and	  MDC1)	   results	   in	   CSR	  defects	   and	   increased	   genomic	   instability	   in	  
murine	   B	   cells	   (Franco	   et	   al.,	   2006;	   Ramiro	   et	   al.,	   2006).	   Strikingly,	   53BP1	   deficiency,	   while	  
leading	   to	   the	  most	   severe	   reduction	   in	   CSR,	   only	  modestly	   affects	   general	   DNA	   breaks	   and	  
translocations,	   suggesting	   still	   unidentified	   specific	   functions	   of	   this	   factor	   in	   class	   switching	  
(Reina-­‐San-­‐Martin	  et	  al.,	  2007;	  Franco	  et	  al.,	  2006;	  Ward	  et	  al.,	  2004;	  Manis	  et	  al.,	  2004).	  	  
In	   the	   context	   of	   V(D)J	   recombination,	   ATM	   plays	   a	   pivotal	   role	   in	   repairing	   RAG-­‐
initiated	  DSBs.	  ATM	  has	  been	   shown	   to	  promote	   the	   stability	  of	   coding	  ends	   in	  postcleavage	  
complexes	   as	   coding	   ends	   are	   lost	   from	   the	   postcleavage	   complexes	   in	   ATM-­‐deficient	   cells	  
(Huang	   et	   al.,	   2007;	  Matei	   et	   al.,	   2007;	   Vacchio	   et	   al.,	   2007;	   Bredemeyer	   et	   al.,	   2006).	   Such	  
stabilization	  of	  DSBs	  occurs	  through	  the	  phosphorylation	  of	  downstream	  substrates	  of	  ATM,	  all	  
of	  which	   play	   a	   role	   in	   tethering	   DNA	   ends	   as	   discussed	   above.	   In	   the	   absence	   of	   ATM,	   the	  
dissociation	   of	   these	   RAG-­‐initiated	   DSBs	   allows	   them	   to	   join	   aberrantly	   to	   other	   unrepaired	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DSBs,	   resulting	   in	   chromosomal	   deletions,	   inversions,	   and	   translocations	   (Mahowald	   et	   al.,	  
2009;	  Bredemeyer	  et	  al.,	  2006).	  
	  
1.4.4.	  The	  p53-­‐dependent	  cell	  cycle	  checkpoint	  
ATM	   also	   initiates	   cell	   cycle	   checkpoints,	  mostly	   through	   activating	   tumor	   suppressor	  
p53.	  Phosphorylation	  of	  p53	  directly	  by	  ATM	  and	   indirectly	  by	  downstream	  kinases	  Chk1	  and	  
Chk2,	  activates	  the	  protein	  through	  the	  stabilization	  and	  increase	  of	  its	  transactivation	  activity	  
(Roos	   and	   Kaina,	   2013).	   Upon	   activation,	   p53	   acts	   as	   a	   potent	   transcriptional	   activator	   or	  
repressor	  that	   initiates	  a	  signaling	  cascade	  to	  prevent	  cell	  cycle	  progression	  and	  regulate	  pro-­‐	  
and	   anti-­‐apoptotic	   genes,	   ultimately	   leading	   to	   the	   elimination	   of	   cells	   with	   persistent	  
unrepaired	  DSBs	   (Vousden	   and	   Prives,	   2009).	   The	   gene	   that	   encodes	   p53,	  TP53,	   is	   the	  most	  
frequently	  mutated	  gene	  found	  in	  human	  cancers,	  highlighting	  the	  crucial	  role	  of	  this	  protein	  in	  
safeguarding	   genome	   integrity	   (Meek,	   2009).	   The	   role	   of	   p53	   in	   tumor	   suppression	   is	   also	  
demonstrated	   in	   mouse	   models.	   p53-­‐deficient	   mice	   are	   prone	   to	   develop	   cancers,	   mostly	  
thymic	  lymphomas	  while	  a	  small	  percentage	  of	  these	  mice	  develop	  B	  lineage	  lymphoma	  as	  well	  
as	   other	   types	   of	   cancers	   such	   as	   sarcoma	   (Jacks	   et	   al.,	   1994;	   Donehower	   et	   al.,	   1992).	   The	  
majority	   of	   p53-­‐deficient	   thymic	   lymphomas	   is	   characterized	   by	   the	   predominance	   of	  
aneuploidy	  and	  the	  lack	  of	  translocation	  in	  Tcr	  loci	  (Liao	  et	  al.,	  1998).	  A	  recent	  study	  by	  Gostissa	  
and	   colleagues	   revealed	   that	   inactivation	   of	   p53	   in	   mature	   B	   cells	   in	   mice	   led	   to	   the	  
development	   of	   IgM-­‐positive	   peripheral	   B	   cell	   lymphomas	  with	   clonal	   translocations	   that	   did	  
not	  involve	  Ig	  loci	  or	  the	  c-­‐myc	  oncogene	  (Gostissa	  et	  al.,	  2013).	  These	  translocations	  were	  not	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recurrent	  and	  each	  tumor	  harbored	  different	  translocations,	  suggesting	  that	  the	  tumors	  did	  not	  
arise	  from	  a	  common	  oncogenic	  event	  (Gostissa	  et	  al.,	  2013).	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1.5.	  Chromosomal	  Aberrations	  and	  Cancer	  
Genomic	   rearrangements	   in	   cancer	   stem	   from	   alterations	   of	   chromosomes.	   These	  
alterations	   include	   deletions,	   insertions,	   amplifications,	   duplications,	   inversions	   and	  
translocations	  (Chen	  et	  al.,	  2010,	  Zhang	  et	  al.,	  2010).	  Chromosomal	  translocations	  result	  from	  
the	  joining	  of	  large	  segments	  of	  DNA	  belonging	  to	  two	  non-­‐homologous	  chromosomes	  (Zhang	  
et	   al.,	   2010),	   and	   from	   faulty	   repair	   of	   DSBs	   generated	   through	   various	   mechanisms	   (see	  
below).	   There	   are	   two	   types	   of	   chromosomal	   translocations:	   reciprocal	   and	   nonreciprocal.	  
Reciprocal	   translocations	   take	   place	   when	   genetic	   material	   is	   exchanged	   between	   two	  
chromosomes.	  They	  can	  be	  balanced,	  if	  the	  overall	  copy	  number	  of	  any	  section	  of	  the	  genome	  
is	  not	  affected,	  or	  unbalanced,	  if	  they	  lead	  to	  deletion	  or	  duplication	  of	  genomic	  regions	  at	  the	  
chromosomal	   breakpoints	   (Zhang	   et	   al.,	   2010).	   Translocations	   can	   promote	   oncogenic	  
transformation	   if	   they	   affect	   copy	   number	   or	   expression	   of	   genes	   involved	   in	   control	   of	   cell	  
proliferation	  and	  survival	  such	  as	  tumor	  suppressor	  genes	  and	  proto-­‐oncogenes.	  	  
Recurrent	  translocations	  have	  been	  identified	   in	   lymphoid	  and	  solid	  tumors	  (Mitelman	  
et	   al.,	   2007;	   Kuppers	   and	  Dalla-­‐Favera,	   2001).	   In	   the	   context	   of	   developing	   lymphocytes,	   the	  
frequent	  DSBs	   generated	   at	   the	   Ig	   and	  TCR	   loci	   render	   these	   cells	   particularly	   susceptible	   to	  
chromosomal	   aberrations.	   In	   humans,	   recurrent	   translocations	   fusing	   Ig	   or	   TCR	   loci	   to	   an	  
oncogene	  are	  the	  hallmarks	  of	  B	  and	  T	  cell	  lymphomas	  and	  leukemias,	  respectively	  (Gostissa	  et	  
al.,	   2011).	   Such	   a	   fusion	   event	   can	   lead	   to	   the	   deregulation	   of	   oncogene	   expression	   in	   two	  
ways:	   by	   putting	   it	   under	   the	   control	   of	   potent	   IgH	   or	   TCR	   transcriptional	   enhancers	   or	  
regulatory	   regions	   (Gostissa	  et	  al.,	   2011,	  see	   below),	  or	  by	  activating	   the	  oncogenes	   through	  
the	   generation	   of	   oncogenic	   chimeric	   proteins.	   For	   example,	   the	   T(9;22)	   recurrent	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translocations,	   referred	   to	   as	   the	   Philadelphia	   chromosome,	   are	   detected	   in	   the	  majority	   of	  
chronic	   myelogenous	   leukemia	   (CML)	   patients	   and	   in	   a	   subset	   of	   adult	   patients	   with	   acute	  
lymphoblastic	   leukemia	   (ALL)	   (Zhang	  and	  Rowley,	  2011).	  This	  T(9;22)	   recurrent	   translocations	  
result	   in	   a	   novel	   fusion	   of	   the	   BCR	   and	   ABL1	   genes,	   leading	   to	   constitutively	   activated	   ABL	  
kinase.	  The	  activated	  ABL	  kinase	  activates	  a	  downstream	  signaling	  cascade	  leading	  to	  enhanced	  
cell	  proliferation	  (Jabbour	  and	  Kantarjian,	  2012).	  	  
	  
1.5.1.	  Factors	  that	  Influence	  Oncogenic	  Chromosomal	  Translocation	  in	  Lymphocytes	  
Oncogenic	   translocation	   is	   a	   multi-­‐step	   process	   that	   can	   be	   influenced	   by	   numerous	  
factors.	  The	  generation	  of	  a	  translocation	  requires	  that	  at	  least	  two	  DSBs	  occur	  in	  a	  cell	  at	  the	  
same	  time,	  and	  these	  breaks	  should	  be	  in	  relatively	  close	  spatial	  proximity	  in	  order	  to	  be	  joined	  
together.	  Moreover,	   DNA	   repair	   pathways	  must	   fail	   to	   correctly	   repair	   these	   DBSs,	   allowing	  
them	   to	  persist	   and	  be	  erroneously	   joined.	  Recurrent	   translocations	  appearing	   in	   tumors	   are	  
subjected	   to	   cellular	   selection,	   in	   that	   cells	   harboring	   the	   translocation	   have	   proliferative	  
advantages	  over	  the	  cells	  that	  did	  not	  have	  the	  translocation.	  	  
	  
1.5.2.	  Role	  of	  DSBs	  in	  Chromosomal	  Translocations	  
The	  level	  of	  DSBs	  present	  in	  cells	  at	  a	  given	  time	  is	  one	  of	  the	  mechanistic	  factors	  that	  
influence	  translocation	  frequencies	  (Alt	  et	  al.,	  2013).	  DSBs	  can	  result	  from	  cell-­‐intrinsic	  factors,	  
such	  as	  (1)	  oxidative	  stress	  from	  cellular	  metabolism	  byproducts,	  or	  (2)	  mistakes	  made	  during	  
DNA	   replication	   or	   transcription	   (Alt	   et	   al.,	   2013;	   Tsai	   and	   Lieber,	   2010;	   Hoeijmakers,	   2009).	  
Several	   studies	   have	   also	   shown	   that	   particular	   DNA	   sequences	   such	   as	   chromosome	   fragile	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sites,	   repetitive	  elements,	   and	  various	   forms	  of	  non-­‐B	  DNA	   structure	   can	   serve	  as	   sources	  of	  
DSBs	  in	  the	  genome	  (Zhao	  et	  al.,	  2010;	  Hoeijmakers,	  2009).	  Additionally,	  cell-­‐extrinsic	  factors,	  
such	  as	  type	  II	  topoisomerase	  inhibitors	  therapy,	  X-­‐rays,	  and	  ionizing	  radiation	  can	  induce	  DSBs	  
(Tsai	  and	  Lieber,	  2010).	  	  
In	  lymphoid	  cells,	  DSBs	  can	  result	  from	  programmed	  DSBs	  that	  occur	  during	  lymphocyte	  
development,	  or	  upon	  antigenic	  stimulation	   in	  germinal	  centers.	  DSBs	  from	  these	  events	  give	  
rise	   to	   chromosomal	   translocations	   that	   can	   lead	   to	   lymphoid	  malignancies.	   The	  majority	   of	  
lymphomas	  are	  of	  B	  cell	  origin	  and	  involve	  cells	  from	  all	  developmental	  stages	  (Kuppers,	  2005).	  
Many	   of	   these	   malignancies	   harbor	   chromosomal	   translocations	   that	   involve	   Ig	   genes	   and	  
oncogenic	  partner	  genes.	  Several	  lines	  of	  evidence	  indicate	  that	  breakpoints	  in	  the	  Ig	  loci	  result	  
from	  RAG-­‐	  or	  AID-­‐initiated	  DSBs	  during	  V(D)J	  recombination	  or	  CSR,	  respectively	  (Nussenzweig	  
and	   Nussenzweig,	   2010)	   while	   recurrent	   translocations	   observed	   in	   T	   cell	   leukemias	   or	  
lymphomas	  involved	  RAG-­‐initiated	  DSBs	  in	  the	  Tcr	  loci	  (Larmonie	  et	  al.,	  2013;	  Zha	  et	  al.,	  2010).	  
Even	  though	  the	  generation	  of	  DSBs	  in	  Ig	  or	  TCR	  loci	  are	  well	  characterized,	  the	  source	  of	  DSBs	  
in	  partner	  oncogene	  loci	  are	  not	  completely	  understood.	  In	  many	  cases,	  these	  DSBs	  have	  been	  
proposed	  to	  arise	  from	  off-­‐target	  RAG	  or	  AID	  activity	  (see	  1.5.2.1.	  and	  1.5.2.2.)	  (Figure	  11).	  
	  
1.5.2.1.	  Role	  of	  RAG	  Activity	  in	  Translocations	  
RAG-­‐initiates	  DSBs	  at	   the	  RSSs	   flanking	  coding	  segments	  during	  antigen	  receptor	  gene	  
assembly	   in	   developing	   B	   or	   T	   lymphocytes	   (Schatz	   et	   al.,	   2008).	   Such	   DSBs	   have	   been	  
implicated	   in	   initiating	   oncogenic	   translocations	   involving	   IGH	   and	   TCR	   loci	   in	   many	   human	  
lymphoid	  malignancies	  (Kuppers,	  2005).	  For	  example,	  in	  Burkitt’s	  lymphomas	  (BL),	  the	  hallmark	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T(8;14)	  translocation	  juxtaposes	  the	  c-­‐myc	  oncogene	  to	  the	  IgH	  locus,	  resulting	  in	  deregulation	  
of	   the	   oncogene	   (Janz,	   2006).	   Studies	   in	   C-­‐NEHJ/p53-­‐deficient	   mouse	  models	   provide	   direct	  
evidence	   for	   the	   role	   of	   RAG-­‐initiated	   DSBs	   in	   oncogenic	   translocations	   and	   lymphoma	  
development.	   These	   mice	   routinely	   develop	   pro-­‐B	   cells	   lymphomas	   with	   translocation	  
breakpoints	  that	   link	  the	   IgH	   JH	  region	  to	  sequences	  near	  c-­‐myc	  (Gostissa	  et	  al.,	  2011).	  These	  
IgH/c-­‐myc	   translocations	   are	   also	   RAG-­‐dependent	   as	   RAG-­‐deficiency	   in	   these	   backgrounds	  
abrogates	  pro-­‐B	  cell	  development	  (Vanasse	  et	  al.,	  1999).	  
Figure	   11.	   Schematic	   representation	   of	   chromosomal	   translocations	   involving	   aberrant	   V(D)J	  
recombination	   and	   CSR.	   Left	   panel	   depicts	   aberrant	   V(D)J	   recombination	   between	   canonical	  
RSS	   in	   the	   IgH	   locus	   and	   cryptic	   RSS	   near	   an	   oncogene.	  Middle	   panel	   depicts	   chromosomal	  
translocation	   between	   RAG-­‐initiated	   DSBs	   in	   the	   IgH	   locus	   to	   DSB	   generated	   by	   other	  
mechanisms.	  The	  expression	  of	  the	  translocated	  oncogene	  is	  under	  the	  control	  of	  3’RR	  or	   iEµ	  
(depicted	  as	  broken	  arrows).	  Right	  panel	  depicts	  translocation	  involving	  aberrant	  joining	  of	  AID-­‐
initiated	  DSB	  in	  S	  region	  to	  DSBs	  generated	  by	  AID	  or	  other	  mechanisms,	  resulting	  in	  activation	  
of	  the	  translocated	  oncogene	  by	  3’RR	  (depicted	  as	  solid	  arrow).	  From	  Zhang	  et	  al.,	  2011.	  
	  
Regarding	   the	   sources	   of	   DSBs	   in	   non-­‐Ig	   or	   non-­‐Tcr	   translocation	   partner	   loci,	   it	   is	  
proposed	  that	  DSBs	  may	  result	  from	  off-­‐target	  RAG	  activity	  that	  allows	  cleavage	  of	  cryptic	  RSSs	  
outside	  of	  Ig	  or	  Tcr	  loci	  (Ji	  et	  al.,	  2010).	  Cryptic	  RSS	  is	  a	  7-­‐bp	  DNA	  sequence	  that	  shares	  the	  first	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three	   nucleotides	   with	   a	   canonical	   heptamer	   sequence	   of	   RSS	   in	   Ig	   or	   Tcr	   loci	   (Zhang	   and	  
Swanson,	  2008).	  	  It	  is	  estimated	  that	  over	  10	  million	  cryptic	  RSSs	  might	  be	  present	  throughout	  
the	  human	  genome	  (Lewis	  et	  al.,	  1997).	  A	  recent	  study	  also	  showed	  that	  changes	  in	  the	  4th	  and	  
5th	  nucleotide	  from	  the	  consensus	  heptamer	  RS	  sequence	  result	  in	  premature	  release	  of	  signal	  
ends	  from	  the	  postcleavage	  complex,	  leading	  to	  DSB	  repair	  by	  translocation-­‐prone	  A-­‐EJ	  and	  HR	  
(Arnal	   et	   al.,	   2010).	   In	   addition	   to	   sequence-­‐specific	   cleavage,	   RAG	   can	   also	   exhibit	   DNA-­‐
structure-­‐dependent	   cleavage.	   Raghavan	   and	   colleagues	   showed	   that	   RAG	   can	   misrecognize	  
and	   cleave	   non-­‐B	   DNA	   structure	   in	   the	   major	   breakpoint	   region	   (Mbr)	   of	   the	   BCL2	   gene,	  
suggesting	   that	   the	   translocations	   between	   IgH	   and	  BCL2	   in	   human	   follicular	   lymphoma	   (FL)	  
arise	  as	  a	  result	  of	  misdirected	  V(D)J	  recombination	  (Raghavan	  et	  al.,	  2004).	  
A	   recent	   large-­‐scale	   analysis	   of	   translocation	   breakpoints	   in	   T-­‐ALLs	   demonstrates	   the	  
role	   of	   RAG	   in	   translocations	   involving	   TCR	   loci.	   These	   aberrant	   translocations	   result	   in	  
juxtaposition	   of	   oncogenes	   to	   TCR	   loci,	   thereby	   putting	   them	   under	   the	   control	   of	   TCR	  
regulatory	   elements	   and	   enhancers	   (Dik	   et	   al.,	   2007).	   Two	   categories	   of	   TCR	   translocation	  
mechanisms	  have	  been	  proposed.	  In	  “Type	  1”,	  the	  translocations	  result	  from	  the	  joining	  of	  two	  
RAG-­‐initiated	   DSBs	   together.	   For	   example,	   in	   T-­‐ALL	   patients	   harboring	   a	   TCR-­‐LMO2	  
translocation,	  the	  translocation	   junctions	  revealed	  a	   joining	  of	  bona	  fide	  RSS	   in	  TCR	   to	  cryptic	  
RSS	  in	  LMO2	  (Larmonie	  et	  al.,	  2013).	  In	  “Type	  2”,	  the	  most	  frequently	  detected	  type	  in	  human	  
T-­‐ALLs,	  the	  translocations	  result	  from	  the	  joining	  of	  RAG-­‐initiated	  DSBs	  in	  antigen	  receptor	  loci	  
or	  at	  cryptic	  RSSs	  in	  non-­‐TCR	  loci	  to	  non-­‐RAG-­‐initiated	  DSBs	  (Larmonie	  et	  al.,	  2013).	  Both	  “Type	  
1”	  and	  “Type	  2”	  translocations	  can	  also	  lead	  to	  interstitial	  deletions	  of	  genomic	  region	  such	  as	  
the	   frequently	   observed	   SIL-­‐TAL	   deletion	   (Larmonie	   et	   al.,	   2013).	   Strikingly,	   this	   study	   also	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revealed	   that	   the	   majority	   of	   translocations	   involving	   the	   TCR	   loci	   occur	   in	   the	   TCRD	   locus,	  
analogous	   to	   the	   involvement	   of	   murine	   Tcrd	   loci	   in	   ATM-­‐deficient	   thymic	   lymphomas	  
(Larmonie	   et	   al.,	   2013;	   Zha	   et	   al.,	   2010).	   Together,	   these	   results	   suggest	   that	   similar	  
mechanisms	   may	   be	   responsible	   for	   oncogenic	   transformation	   in	   human	   T-­‐ALL	   and	   ATM-­‐
deficient	  thymic	  lymphomas.	  	  
	  
1.5.2.2.	  AID-­‐Initiated	  Translocations	  
	   The	  DSBs	  generated	  as	  an	  intermediate	  for	  CSR,	  if	  unrepaired,	  can	  serve	  as	  a	  substrate	  
for	   chromosomal	   translocation,	   as	   demonstrated	   by	   the	   accumulation	   of	   AID-­‐dependent	   IgH	  
locus	  breaks	  and	  translocations	  found	  in	  cultured	  B	  cells	  from	  mice	  deficient	  in	  C-­‐NHEJ	  or	  DDR	  
factors	  (Franco	  et	  al.,	  2006;	  Ramiro	  et	  al.,	  2006).	  AID	  has	  been	  shown	  to	  be	  required	  for	  IgH/c-­‐
myc	  translocations	  in	  primary	  B	  cells	  and	  mouse	  plasmacytomas	  (Casellas	  et	  al.,	  2008).	  Analysis	  
of	   human	   lymphoid	  malignancies	   has	   revealed	   that	   recurrent	   oncogenic	   translocations	   often	  
involve	  IgH	  S	  regions,	  such	  as	  the	  IgH/c-­‐myc	  translocation	  found	  in	  sporadic	  Burkitt’s	  lymphoma	  
(BL)	   and	   the	   IgH/bcl-­‐6	   translocation	   in	   diffuse	   large	   B	   cell	   lymphoma	   (DLBCL),	   among	   others	  
(Kuppers,	  2005).	  	  
The	   role	   of	   AID	   in	   generating	   DSBs	   at	   non-­‐Ig	   translocation	   partners	   has	   been	   firmly	  
established.	  Approximately	  25%	  of	  the	  genes	  expressed	  in	  germinal	  center	  B	  cells	  are	  mutated	  
by	  AID	   (Pasqualucci	   et	   al.,	   2001),	   some	  of	  which,	   such	   as	   c-­‐myc,	   Pim1,	   Pax5,	   and	  Rhoh	   have	  
been	  implicated	  in	  mouse	  and	  human	  lymphoid	  malignancies	  (Liu	  et	  al.,	  2008).	  Even	  though	  the	  
mutation	  rates	  of	   these	  off-­‐target	  sites	  are	  100-­‐fold	   lower	  than	  the	   Ig	  variable	  and	  S	  regions,	  
cellular	  selection	  for	  oncogenic	  translocations	  during	  tumor	  development	  is	  believed	  to	  account	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for	  recurrent	  translocation	  of	  the	  oncogenes	  (Gostissa	  et	  al.,	  2011;	  Liu	  et	  al.,	  2008).	  Moreover,	  
AID	   activity	   has	   been	   shown	   to	   be	   necessary	   for	   c-­‐myc	   locus	   breaks	   that	   participate	   in	  
translocations	  with	  IgH	  in	  activated	  murine	  B	  cells	  (Robbiani	  et	  al.,	  2008)	  and	  overexpression	  of	  
AID	   in	   p53-­‐deficient	  mice	   lead	   to	   widespread	   genomic	   instability	   and	   development	   of	   B	   cell	  
lymphomas	  with	  chromosomal	  translocations	  (Robbiani	  et	  al.,	  2009).	  Finally,	  recent	  studies	  of	  
translocation	  patterns	  in	  murine	  activated	  B	  cells	  clearly	  showed	  the	  involvement	  of	  AID	  in	  the	  
generation	  of	  DSBs	  genome-­‐wide	  (Chiarle	  et	  al,	  2011;	  Klein	  et	  al.,	  2011).	  	  
	  
1.5.2.3.	  Partnership	  of	  RAG	  and	  AID	  in	  Translocations	  
	   RAG	  and	  AID	  are	  usually	  expressed	  in	  different	  B	  cell	  developmental	  stages.	  High	  levels	  
of	  RAG	  are	  detected	  in	  developing	  B	  cells	  in	  the	  bone	  marrow	  whereas	  AID	  is	  mostly	  expressed	  
in	  mature	   B	   cells	   responding	   to	   antigenic	   stimulation	   in	   the	   periphery.	  With	   functional	   DDR,	  
RAG-­‐	  and	  AID-­‐initiated	  DSBs	  should	  not	  be	  present	   in	  the	  same	  cells	  since	  RAG-­‐initiated	  DSBs	  
would	  have	  been	  repaired	  before	  AID	  can	  induce	  DSBs.	  However,	  AID	  is	  also	  expressed	  at	  low	  
levels	  in	  bone	  marrow	  B	  cells	  (Crouch	  et	  al.,	  2007;	  Feldhahn	  et	  al.,	  2007;	  Mao	  et	  al.,	  2004),	  and	  
a	  recent	   investigation	  suggested	  that	  AID	  may	  facilitate	  off-­‐target	  RAG	  activity	   in	  this	  context.	  
According	   to	   this	   model,	   AID	   deamination	   activity	   at	   CpG	   islands	   would	   lead	   to	   C-­‐to-­‐T	  
mutations,	   giving	   rise	   to	   T:G	   mismatches	   that	   serve	   as	   substrates	   for	   RAG-­‐initiated	   DNA	  
cleavage	   (Tsai	   et	   al.,	   2008).	   This	  model	   is	   supported	   by	   the	   breakpoint	   sequence	   analysis	   of	  
human	  lymphoid	  malignancies,	  demonstrating	  that	  DSBs	  at	  the	  bcl-­‐2	  major	  breakpoint	  region	  in	  
FL	  and	   bcl-­‐1	  major	   translocation	   cluster	   in	  mantle	   cell	   lymphoma	  were	  enriched	  around	  CpG	  
sites	  (Tsai	  et	  al.,	  2008).	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In	  the	  absence	  of	  ATM,	  unrepaired	  RAG-­‐initiated	  DSBs	  have	  been	  shown	  to	  persist	   for	  
multiple	  rounds	  of	  cell	  division	  and	  are	  detected	  in	  mature	  B	  cells	  in	  the	  periphery	  (Callen	  et	  al.,	  
2007).	   In	   this	   context,	   cells	   with	   unrepaired	   V(D)J	   DSBs	   can	   escape	   cell	   cycle	   checkpoints,	  
complete	   developmental	   stages,	   and	   harbor	   translocations	   that	   join	   RAG-­‐initiated	   DSBs	  with	  
AID-­‐initiated	  DSBs	   in	  mature	  B	  cells.	  For	  example,	  AID-­‐initiated	  DSBs	  at	  the	   IgH	  S	  regions	  and	  
RAG-­‐initiated	   DSBs	   at	   the	   Igλ locus	  have	   been	   reported	   to	   participate	   in	   translocations	   in	  
mature	   B	   cells	   lacking	   the	   C-­‐NHEJ	   factor	   XRCC4	   (Wang	   et	   al.,	   2009).	   Furthermore,	  
IgH/Igλ translocations	   are	   frequently	   found	   in	  mature	   B	   cell	   lymphomas	   arising	   in	  mice	  with	  
mature	  B	  cell-­‐specific	  inactivation	  of	  XRCC4	  and	  p53	  (Wang	  et	  al.,	  2008).	  These	  findings	  indicate	  
that	   RAG	   is	   active	   in	   a	   subset	   of	  murine	  mature	   B	   cells,	   potentially	   as	   it	   drives	   the	   receptor	  
editing	   process,	   and	   that	   some	   translocations	   found	   in	   human	   mature	   B	   cell	   tumors	   may	  
similarly	  be	  ascribed	  to	  RAG	  and	  AID	  activity	  in	  the	  periphery.	  	  
	  
1.5.3.	  Role	  of	  Spatial	  Genome	  Organization	  in	  Translocation	  Frequency	  
Recent	   studies	   of	   spatial	   genome	   organization	   reveal	   its	   role	   in	   the	   arrangement	   of	  
chromosomal	   territories	   and	   impact	   on	   the	   formation	   of	   chromosomal	   translocations.	   In	   the	  
interphase	   nucleus,	   chromosomes	   occupy	   discrete	   three-­‐dimensional	   regions,	   known	   as	  
chromosome	   territories	   (Cavalli	   and	   Misteli,	   2013).	   These	   territories	   are	   arranged	   in	   non-­‐
random	   patterns:	   gene-­‐rich	   chromosomes	   preferentially	   locate	   towards	   the	   nuclear	   interior	  
and	  gene-­‐poor	  chromosomes	  preferentially	  locate	  towards	  the	  nuclear	  periphery	  (Meaburn	  et	  
al.,	   2007).	   There	   is	   a	   strong	   correlation	   between	   spatial	   proximity	   of	   chromosomes	   in	  
interphase	   nuclei	   and	   translocation	   frequencies,	   whereby	   more	   proximal	   chromosomes	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undergo	   translocation	   events	   more	   frequently	   than	   distantly	   located	   ones	   (Meaburn	   et	   al.,	  
2007).	   A	   cytogenetic	   study	   by	   Parada	   and	   colleagues	   showed	   that	   translocations	   in	   ATM-­‐
deficient	   mouse	   lymphoma	   cell	   lines	   often	   involve	   chromosomes	   12,	   14,	   and	   15,	   and	   these	  
chromosomes	  are	  frequently	  found	  to	  be	  proximal	  to	  one	  another	  in	  normal	  mouse	  splenocytes	  
(Parada	  et	  al.,	  2002).	  Other	  translocations	  such	  as	  T(9;22)	  involving	  BCR-­‐ABL	  and	  and	  T(15;17)	  
involving	  PML-­‐RARα	  in	  human	  lymphocytes	  also	  exhibit	  the	  same	  pattern	  (Neves	  et	  al.,	  1999).	  	  
Similar	   cytogenetic	   studies	   with	   individual	   gene	   resolution	   showed	   a	   correlation	  
between	   translocation	   frequency	   and	   translocation	   partner	   loci	   proximity.	   For	   example,	   in	  
Burkitt’s	   lymphoma,	   where	   c-­‐myc	   undergoes	   translocation	   with	   IgH,	   Igκ,	   and	   Igλ	   at	   varying	  
frequency,	   the	   distance	   between	   c-­‐myc	   and	   its	   translocation	   partners	   corresponds	   with	   its	  
frequency	   of	   translocation	   (Roix	   et	   al.,	   2003).	   Specifically,	   c-­‐myc	   was	   more	   frequently	  
colocalized	  with	  its	  preferred	  translocation	  partner	  IgH,	  as	  compared	  to	  Igκ	  and	  Igλ	  loci	  (Roix	  et	  
al.,	   2003).	   Likewise,	   IgH	   frequently	   colocalized	  with	  CCND1,	  bcl-­‐2,	   or	  bcl-­‐6	   loci	   in	  mantle	   cell	  
lymphoma	  (MCL),	  FL,	  and	  DLBCL,	  respectively	  (Roix	  et	  al.,	  2003).	  	  
Though	  proximity	  of	  loci	  and	  frequency	  of	  translocations	  are	  broadly	  correlated,	  both	  of	  
these	  factors	  can	  also	  be	  tissue	  type-­‐	  and	  cell	  type-­‐specific.	  Studies	  of	  translocation	  frequency	  
and	   spatial	   genome	   organization	   in	   different	   cell	   types	   revealed	   that	   tissue-­‐specific	  
translocation	  frequencies	  correlate	  with	  tissue-­‐specific	  loci	  proximity	  (Parada	  et	  al.,	  2004).	  For	  
example,	   chromosomes	   12	   and	   15,	   which	   frequently	   translocate	   in	   B	   cell	   lymphomas,	   are	  
proximal	   in	   lymphocytes	  but	  not	   in	  hepatocytes,	  whereas	  chromosomes	  5	  and	  6,	  which	  often	  
translocate	   in	  hepatomas,	  are	  proximal	   in	  hepatocytes,	  but	  not	   in	   lymphocytes	  (Parada	  et	  al.,	  
2004).	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Direct	   evidence	   for	   the	   influence	   of	   loci	   proximity	   in	   translocation	   frequency	   comes	  
from	   Hi-­‐C	   studies	   where	   chromatin	   interactions	   were	   analyzed	   in	   the	   absence	   of	   cellular	  
selection	   to	   provide	   high-­‐resolution	   maps	   of	   the	   genome-­‐wide	   chromatin	   interactions	  
(Lieberman-­‐Aiden	   et	   al.,	   2009).	   These	   studies	   show	   that	   in	   the	   interphase	   nucleus	   of	   both	  
cycling	  and	  G1-­‐arrested	  mammalian	  cells,	  organization	  of	  chromosomal	  territories	  is	  such	  that	  
intra-­‐chromosomal	  interactions	  are	  largely	  favored	  over	  inter-­‐chromosomal	  interactions	  (Zhang	  
et	   al.,	   2012;	   Lieberman-­‐Aiden	  et	   al.,	   2009),	   in	  particular	   at	  distances	  of	   about	  one	  megabase	  
(Dixon	  et	  al.,	  2012).	  Accordingly,	  in	  G1-­‐arrested	  ATM-­‐deficient	  pro-­‐B	  cell	  lines	  treated	  with	  IR	  to	  
saturate	  the	  genome	  with	  DSBs,	  intra-­‐chromosomal	  spatial	  genome	  organization	  causes	  regions	  
along	   the	   entire	   length	   of	   an	   individual	   chromosome	   to	   become	   preferential	   partners	   for	  
translocation	  with	   a	   fixed	   DSB,	   rather	   than	   regions	   on	   all	   other	   chromosomes	   (Zhang	   et	   al.,	  
2012).	  These	  studies	  demonstrate	  that	  when	  DSB	  frequency	  at	  translocation	  partner	  loci	  is	  not	  
a	   dominant	   factor	   (such	   as	   in	   the	   case	   when	   a	   large	   number	   of	   DSBs	   are	   induced	   by	   IR	  
treatment	   in	  ATM-­‐deficient	   pro-­‐B	   cell	   lines	   or	  when	  DSBs	   are	   rare)	   spatial	   proximity	   of	  DSBs	  
becomes	   an	   influential	   factor	   in	   determining	   genome-­‐wide	   translocations	   (Alt	   et	   al.,	   2013;	  
Zhang	  et	  al.,	  2012).	  These	  findings	  may	  have	  implications	  for	  the	  identification	  of	  mechanisms	  
that	   control	   joining	   of	   random	  DSBs	   in	   tumor	   cells	   following	   chemo-­‐	   or	   radiotherapy	  where	  
numerous	  DSBs	  are	  the	  side	  effects	  of	  the	  treatment.	  
	  
1.5.4.	  Roles	  of	  Antigen	  Receptor	  Locus	  Enhancers	  in	  the	  Selection	  of	  Oncogenic	  Translocation	  
	   Ig	   and	   TCR	   genes	   are	   regulated	   by	   an	   array	   of	   cis-­‐acting	   promoters	   and	   enhancers.	  
These	   elements	   help	   to	   regulate	   the	   ordered	   assembly	   of	   antigen	   receptor	   loci	   during	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lymphocyte	   development	   and	   control	   the	   high-­‐level	   expression	   of	   functionally	   assembled	   Ig	  
and	   TCR	   loci	   in	   mature	   cells.	   These	   elements	   are	   also	   regarded	   as	   responsible	   for	  
overexpression	  of	  oncogenes	  that	  lead	  to	  lymphomas.	  In	  the	  Tcr	  loci,	  major	  enhancer	  elements	  
reside	   in	   various	   locations	   in	   each	   locus.	   In	   the	  Tcrb	   locus,	   the	  enhancer	   Eβ	   lies	  upstream	  of	  
Cβ2.	  In	  the	  Tcra/d	  locus	  the	  Eδ	  lies	  between	  the	  Jδ	  and	  Jδ	  while	  the	  Eα	  lies	  downstream	  of	  the	  
Cα	   (Dudley	   et	   al.,	   2005).	   Some	  of	   these	   enhancers	   have	   been	   shown	   to	   play	   a	   role	   in	   T	   cell	  
tumor	   translocations	   and	   lymphoma	   development.	   For	   example,	   analysis	   of	   translocation	  
junction	  in	  human	  T-­‐ALLs	  revealed	  that	  approximately	  28%	  of	  translocations	  involving	  TCR	  loci	  
occur	  in	  TCRB,	  which	  corresponded	  with	  juxtaposition	  of	  Eβ	  to	  TLX1,	  resulting	  in	  overexpression	  
of	  the	  oncogene	  	  (Larmonie	  et	  al.,	  2013;	  Le	  Noir	  et	  al.,	  2012)	  	  
Major	  known	  control	  elements	  in	  the	  IgH	   locus	  include	  the	  intronic	  enhancer	  (iEμ)	  and	  
the	   IgH	   3’	   regulatory	   region	   (IgH	   3’RR),	  both	  of	  which	  have	  been	   linked	   to	  overexpression	  of	  
oncogenes	   following	   translocations	   in	   mature	   B	   cell	   tumors	   such	   as	   BL,	   FL,	   and	   DLBCL.	   In	  
transgenic	   mouse	   models	   of	   c-­‐myc	   overexpression,	   iEμ	   leads	   to	   development	   of	   pre-­‐B	   cell	  
tumors	   in	   the	   majority	   of	   cases	   (Janz,	   2006),	   while	   the	   IgH	   3’RR	   promotes	   development	   of	  
mature,	  Burkitt-­‐like	  B	  cell	  lymphomas	  (Truffinet	  et	  al.,	  2007;	  Wang	  and	  Boxer,	  2005).	  Moreover,	  
deletion	   of	   the	   IgH	   3’RR	   abrogates	   tumor	   development	   in	   a	  murine	   peripheral	   B	   cell	   tumor	  
model	  based	  on	  inactivation	  of	  XRCC4	  and	  p53	  in	  mature	  B	  cells	  (Gostissa	  et	  al.,	  2009).	  	  
In	   humans,	   approximately	   80%	  of	   BL	   cases	   can	  be	   traced	   to	   the	   T(8;14)	   translocation	  
that	   juxtaposes	   c-­‐myc	   to	   IgH,	   leading	   to	   deregulation	   of	   the	   oncogene	   (Magrath,	   2012).	  
Detailed	  analysis	  of	   the	  BL	   translocation	  breakpoints	   revealed	   two	   categories	  of	   junctions.	   In	  
endemic	  BL,	   the	   IgH	   translocation	  breakpoints	  are	   located	   in	   the	  variable	   region	  upstream	  of	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iEμ,	  resulting	   in	  the	  retention	  of	  both	  iEμ	  and	  IgH3’RR	  	  (Truffinet	  et	  al.,	  2007).	   In	  sporadic	  BL,	  
breakpoints	  are	   located	   in	   the	  S	   regions,	   linking	  c-­‐myc	   to	   the	  downstream	  portion	  of	   the	   IgH	  
locus	  and	  retaining	  only	  the	  IgH	  3’RR	  in	  the	  translocated	  allele	  (Hecht	  and	  Aster,	  2000;	  Truffinet	  
et	  al.,	  2007).	  These	  findings	  suggest	  the	  hypothesis	  that	  oncogenic	  translocations	  occur	  during	  
SHM	  and	  CSR	  in	  endemic	  and	  sporadic	  BL,	  respectively.	  However,	  it	  is	  possible	  that	  endemic	  BL	  
translocations	   take	   place	   during	   V(D)J	   recombination	   in	   progenitor	   or	   precursor	   B	   cells,	   but	  
then	  remain	  inactive	  until	  later	  stages	  of	  development	  (Gostissa	  et	  al.,	  2011;	  Kuppers	  and	  Dalla-­‐
Favera,	  2001).	  In	  this	  regard,	  c-­‐myc	  breakpoints	  in	  endemic	  BL	  are	  usually	  located	  far	  upstream	  
of	  the	  gene,	  at	  distances	  where	   iEμ	  may	  not	  be	  effective.	  These	  translocations	  may	  therefore	  
become	  oncogenic	  only	  later	  in	  development,	  when	  the	  IgH	  3’RR,	  which	  promotes	  transcription	  
over	  large	  distances,	  becomes	  active	  (Gostissa	  et	  al.,	  2011).	  In	  line	  with	  this	  hypothesis,	  knock-­‐
in	  of	  c-­‐myc	  between	  JH	  and	  iEμ	  did	  not	  lead	  to	  pro-­‐	  or	  pre-­‐B	  cell	  lymphomas,	  but	  only	  to	  mature	  
B	  cell	  tumors	  (Janz,	  2006),	  and	  pro-­‐B	  cell	  tumors	  arising	  in	  C-­‐NHEJ/p53-­‐deficient	  mice	  routinely	  
amplify	  c-­‐myc	  (Difilippatonio	  et	  al.,	  2002;	  Zhu	  et	  al.,	  2002),	  suggesting	  that	  activity	  of	  iEμ	  alone	  
is	  insufficient	  to	  activate	  c-­‐myc.	  	  
Overall,	  these	  findings	  implicate	  the	   IgH	  3’	  RR	  as	  a	  potent	  transcriptional	  element	  that	  
can	  activate	  a	  high	  level	  of	  oncogene	  expression,	  and	  whose	  action	  may	  extend	  over	  hundreds	  
of	  kilobases.	  Conversely,	  iEμ	  may	  have	  a	  more	  “local”	  and	  less	  potent	  activity	  that	  can	  still	  lead	  
to	   transformation	   via	   deregulated	   expression	   of	   translocated	   genes,	   such	   as	   in	   the	   case	   of	  
DLBCLs	  carrying	  IgH/bcl-­‐6	  translocations,	  which	  retain	  iEμ	  but	  not	  the	  IgH	  3ʹ′RR	  (Pasqualucci	  et	  
al.,	  2003).	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1.6.	  Role	  of	  DNA	  Repair	  in	  Suppressing	  Chromosomal	  Translocations	  
1.6.1.	  C-­‐NHEJ/p53-­‐deficient	  Mouse	  Models	  
Components	  of	  C-­‐NHEJ	  pathway	  are	  essential	  for	  the	  repair	  of	  RAG-­‐initiated	  DSBs	  during	  
V(D)J	  recombination	  and	  have	  been	  implicated	  in	  maintaining	  genomic	  integrity	  via	  suppression	  
of	   chromosomal	   rearrangements	   (Nussenzweig	   and	  Nussenzweig,	   2010).	   Ku70,	   Ku80,	   XRCC4,	  
and	   Lig4	   are	   considered	   “core”	   C-­‐NHEJ	   factors,	   which	   are	   absolutely	   required	   for	   all	   C-­‐NHEJ	  
reactions	  (Boboila	  et	  al.,	  2012).	  Ku70-­‐	  or	  Ku80-­‐deficient	  mice	  exhibit	  growth	  defects,	  increased	  
sensitivity	   to	   DNA	   damaging	   agents,	   chromosomal	   instability,	   and	   severe	   combined	  
immunodeficiency	   (SCID)	   due	   to	   an	   inability	   to	   carry	   out	   end-­‐joining	   to	   complete	   V(D)J	  
recombination	   (Gostissa	   et	   al.,	   2011).	   XRCC4	   or	   Lig4	   deficiency	   results	   in	   late	   embryonic	  
lethality	   due	   to	   neuronal	   lethality;	   but	   developing	   embryos	   exhibit	   similar	   defects	   to	   those	  
associated	   with	   Ku-­‐deficiency	   including	   a	   block	   in	   B	   and	   T	   cell	   development	   due	   to	   a	   V(D)J	  
recombination	  defect	   (Gao	  et	  al.,	  2000;	  Frank	  et	  al.,	  1998).	  On	  the	  contrary,	  mice	  deficient	   in	  
DNA-­‐PKcs	  or	  Artemis	  do	  not	  display	  growth	  defects	  and	  have	  “leaky”	  SCID	  phenotypes	  because	  
they	  can	  still	  undergo	  a	  low	  level	  of	  V(D)J	  recombination	  (Gao	  et	  al.,	  1998;	  Rooney	  et	  al.,	  2003;	  
Rooney	  et	  al.,	  2002;	  Taccioli	  et	  al.,	  1998).	  	  
Despite	   significant	   genomic	   instability	   observed	   in	   the	   absence	   of	   C-­‐NHEJ,	   C-­‐NHEJ	  
deficient	   mice	   do	   not	   develop	   lymphoid	   or	   other	   neoplasia,	   most	   likely	   because	   C-­‐NHEJ-­‐
deficient	  cells	  containing	  unrepaired	  G1	  DSBs	  are	  actively	  eliminated	  via	  cell	  cycle	  checkpoints	  
(Puebla-­‐Osorio	   and	   Zhu,	   2008).	   In	   this	   regard,	   combined	   deficiency	   for	   a	   C-­‐NHEJ	   and	   p53	   in	  
mice	   leads	   to	   recurrent	   development	   of	   pro-­‐B	   cell	   lymphomas	   (Gostissa	   et	   al.,	   2011).	   The	  
hallmark	  of	  pro-­‐B	  cell	  lymphomas	  in	  these	  backgrounds	  is	  the	  complex	  translocations	  with	  gene	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amplification,	   referred	   to	  as	   complicons,	   involving	   the	   IgH	   locus	   (chromosome	  12)	  and	  c-­‐myc	  
gene	   (chromosome	  15)	   (Zhu	  et	  al.,	  2002).	  Detailed	  characterization	  of	   these	   tumors	   revealed	  
clonal	  rearrangement	  of	  the	  JH	  gene	  segments	  with	  translocation	  breakpoints	  in	  the	  JH	  region	  
joining	  to	  breakpoints	  located	  70-­‐700	  kb	  downstream	  of	  c-­‐myc	  locus	  on	  chromosome	  15	  (Zhu	  et	  
al.,	   2002).	   This	   aberrant	   joining	   between	   chromosome	   12	   and	   15	  mediates	   the	   formation	   of	  
dicentric	  chromosomes	  that	  ultimately	   lead	  to	  oncogenic	  amplification	  of	  the	  c-­‐myc	  genes	  via	  
breakage-­‐fusion-­‐bridge	   (BFB)	   mechanism,	   resulting	   in	   overexpression	   of	   c-­‐myc	   and	   cellular	  
transformation	   (Gostissa	   et	   al.,	   2011;	   Zhu	   et	   al.,	   2002).	   Subsequent	   studies	   further	  
demonstrated	   that	   these	   tumors	   are	   RAG-­‐dependent,	   since	   C-­‐NHEJ/p53/RAG2-­‐deficient	  mice	  
did	   not	   succumb	   to	   pro-­‐B	   cell	   lymphomas,	   instead	   they	   developed	   thymic	   lymphoma,	   as	  
commonly	   observed	   in	   p53-­‐deficient	   background	   (Vanasse	   et	   al.,	   1999).	   It	   is	   notable	   that	  
inactivation	   of	   XRCC4	   in	   p53-­‐deficient	  mature	   B	   cells	   leads	   to	   surface	   Ig-­‐negative	   lymphoma	  
development	  with	  recurrent	  T(12;15)	  translocations	  that	  join	  IgH	  S	  region	  to	  region	  upstream	  of	  
c-­‐myc,	  resulting	  in	  ectopic	  activation	  of	  the	  oncogene	  (Gostissa	  et	  al.,	  2009;	  Wang	  et	  al.,	  2008).	  	  
	  
1.6.2.	  C-­‐NHEJ	  Deficiency	  in	  Human	  
Defects	   in	   C-­‐NHEJ	   proteins	   in	   humans	   are	   associated	  with	   primary	   immunodeficiency	  
and	   occasional	   development	   of	   lymphoid	   malignancy	   (O’	   Driscoll	   and	   Jeggo,	   2006).	   For	  
example,	  null	  mutations	  of	  the	  Artemis	  gene	  give	  rise	  to	  a	  SCID	  phenotype	  and	  the	  patients	  are	  
unable	   to	  produce	   immunoglobulins	   (Moshous	  et	   al.,	   2001).	  Artemis-­‐deficient	  patients	   suffer	  
from	   pneumonitis,	   persistent	   viral	   diarrhea,	   growth	   defects,	   and	   radiosensitivity	   (Gennery	   et	  
al.,	  2006).	  Hypomorphic	  Artemis	  mutations	  give	  rise	  to	  Omenn	  syndrome,	  a	  disorder	  typically	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associated	   with	   hypomorphic	   RAG	   mutations,	   where	   patients	   present	   with	   a	   progressive	  
combined	   immunodeficiency	   (CID)	   characterized	   by	   recurrent	   sinopulmonary	   or	  
gastrointestinal	   infection,	  partial	  B-­‐	  and	  T-­‐cell	  deficiency,	  hypogammaglobulinemia,	  and	  some	  
patients	   develop	   Epstein-­‐Barr	   virus	   (EBV)-­‐associated	   B	   cell	   lymphomas	   (Evans	   et	   al.,	   2006;	  
Moshous	  et	  al.,	  2003).	  	  
Patients	  with	  hypomorphic	  mutations	  of	  LIG4	  present	  with	  variable	  symptoms,	  believed	  
to	  result	  from	  varying	  residual	  mutant	  LIG4	  activity.	  Some	  patients	  exhibit	  developmental	  delay,	  
microcephaly,	  CID,	  and	  in	  one	  case,	  a	  predisposition	  to	  multiple	  myeloma	  (O’	  Driscoll	  and	  Jeggo,	  
2006;	   Roddam	   et	   al.,	   2002).	   Others	   had	   normal	   features	   and	   were	   not	   associated	   with	  
immunodeficiency	   but	   exhibited	   cellular	   radiosensitivity	   following	   therapy	   for	   T-­‐ALL	   (Dvorak	  
and	   Cowan,	   2011).	   Another	   rare	   form	   of	   human	   primary	   immunodeficiency	   is	   caused	   by	  
mutations	  in	  Cernunnos/XLF	  gene.	  Clinical	  phenotypes	  of	  Cernunnos/XLF	  deficiency	  are	  similar	  
to	   those	   observed	   in	   patients	   with	   LIG4	   syndrome:	   CID,	   microcephaly,	   growth	   retardation,	  
radiosensitivity,	  and	  recurrent	  bacterial	  and	  opportunistic	  infection	  (Buck	  et	  al.,	  2006).	  Some	  of	  
the	   patients	   exhibited	   hypogammaglobulinemia,	   suggesting	   a	   role	   for	   Cernunnos/XLF	   in	   CSR	  
(Buck	  et	  al.,	  2006).	  
	  
1.6.3.	  DNA	  Damage	  Response	  Deficiency	  in	  Mouse	  and	  Human	  	  
ATM	  functions	  at	  the	  apex	  of	  the	  DNA	  damage	  response	  (DDR)	  pathway	  by	  promoting	  
DSBs	   repair	   by	   C-­‐NHEJ	   and	  mediating	   cell	   cycle	   checkpoints	   via	   activation	   of	   its	   downstream	  
substrates	  (Bednarski	  and	  Sleckman,	  2012).	  ATM	  deficiency	  in	  mice	  recapitulates	  many	  aspects	  
of	  ataxia	  telangiectasia	  (AT)	  including	  increased	  predisposition	  to	  developing	  T	  cell	  lymphomas,	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which	  will	  be	  discussed	  in	  greater	  detail	  in	  Section	  6.	  Deficiency	  of	  downstream	  ATM	  substrates	  
lead	   to	   unrepaired	   chromosomal	   breaks	   and	   translocation.	   However,	   unlike	   ATM-­‐deficiency,	  
other	   DDR-­‐deficient	   mice	   showed	   little	   predisposition	   to	   lymphoid	   or	   other	   malignancies,	  
unless	   p53	   was	   also	   simultaneously	   inactivated.	   Genomic	   instability	   in	   DDR-­‐deficient	   cells	  
activates	  cell	  cycle	  checkpoints,	  resulting	   in	  the	  elimination	  of	  cells	  with	  unrepaired	  DSBs	  and	  
translocations	  (Gostissa	  et	  al.,	  2011).	  Lymphoid	  malignancies	  in	  ATM-­‐deficient	  background	  are	  
reflective	  of	  the	  role	  of	  ATM	  in	  both	  DSB	  repair	  and	  activation	  of	  cell	  cycle	  checkpoints	  through	  
the	  p53-­‐dependent	  pathway.	  	  
For	   instance,	   H2AX-­‐deficient	   mice	   exhibit	   increased	   genomic	   instability,	   growth	  
retardation	   (Bassing	   et	   al.,	   2002;	   Celeste	   et	   al.,	   2002),	   and	   are	   prone	   to	   tumor	   development	  
when	   also	   p53	   in	   inactivated	   (Bassing	   et	   al.,	   2003;	   Celeste	   et	   al.,	   2003).	  H2AX-­‐deficient	  mice	  
have	  reduced	  numbers	  of	  lymphocytes	  and	  impaired	  CSR.	  Cytogenetic	  studies	  of	  H2AX-­‐deficient	  
B	  cells	  activated	  for	  CSR	  revealed	  that	  AID-­‐initiated	  DSBs	  in	  the	  S	  region	  of	  the	  IgH	  locus	  were	  
unrepaired	   and	   they	   accumulate	   as	   chromosomal	   breaks	   and	   translocations	   (Franco	   et	   al.,	  
2006).	   Mice	   deficient	   for	   other	   DDR	   factors,	   including	   MDC1,	   53BP1,	   or	   NBS1,	   also	   exhibit	  
similar	  phenotypes	  of	  increased	  genomic	  instability	  and	  frequent	  unrepaired	  IgH	  chromosomal	  
breaks	  upon	  activation	  for	  CSR	  (Franco	  et	  al.,	  2006;	  Lou	  et	  al.,	  2006;	  Ramiro	  et	  al.,	  2006;	  Reina-­‐
San-­‐Martin	  et	  al.,	  2005).	  	  
In	  DDR-­‐deficient	  background,	  p53-­‐deficiency	  leads	  to	  increased	  B	  and	  T	  cell	   lymphoma	  
incidence.	  For	  example,	  H2AX/p53-­‐deficient	  mice	  succumb	  to	  either	  thymic	  lymphomas	  that	  do	  
not	  involve	  Tcr	  loci	  or	  pro-­‐B	  cell	  lymphoma	  with	  RAG-­‐dependent	  clonal	  translocation	  similar	  to	  
those	  observed	  in	  C-­‐NHEJ/p53-­‐deficient	  background	  (Bassing	  et	  al.,	  2003).	  53BP1/p53-­‐deficient	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mice	   succumb	   to	   thymic	   lymphomas	   with	   occasional	   involvement	   of	   Tcra/d	   loci	   and	  
infrequently	  develop	  B	  cell	  lymphomas	  (Morales	  et	  al.,	  2006;	  Ward	  et	  al.,	  2004).	  
Some	  DDR	  components	  are	  essential	   in	  normal	  development	  of	  an	  organism	  such	  that	  
lack	  of	  functional	  proteins	  lead	  to	  embryonic	  lethality,	  as	  observed	  in	  the	  case	  of	  Mre11,	  Rad50,	  
and	   Nbs1	   knockout	   mice	   (Bohgaki	   et	   al.,	   2010).	   Nbs1	   or	   Mre11	   hypomorphic	   mutant	   mice	  
exhibit	   increased	  radiosensitivity,	  defective	  cell	  cycle	  checkpoints,	  chromosome	  instability	  and	  
immunodeficiency	  (Bohgaki	  et	  al.,	  2010).	  Rad50	  hypomorphic	  mutants	  show	  partial	  embryonic	  
lethality	   and	   exhibit	   progressive	   hematopoietic	   stem	   cell	   failure	   without	   increased	  
radiosensitivity	  or	  defective	  cell	  cycle	  checkpoints	  (Bender	  et	  al.,	  2002).	  
Mutations	  of	  DDR	  components	  cause	  hereditary	  disorders	  in	  human.	  For	  example,	  NBS1	  
mutations	  are	  associated	  with	   the	  Nijmegen	  breakage	   syndrome,	  a	  disorder	   characterized	  by	  
microcephaly,	  radiosensitivity,	  growth	  defects,	  immunodeficiency,	  and	  increased	  predisposition	  
to	   cancer	   (Gennery,	   2006).	   Hypomorphic	   mutations	   of	   the	   MRE11	   gene	   result	   in	   ataxia	  
telangiectasia	   like	   disorder	   (ATLD),	   characterized	   by	   cerebellar	   atrophy	   and	   radiosensitivity.	  
Unlike	   AT,	   ATLD	   patients	   have	   almost	   normal	   immune	   responses,	   do	   not	   exhibit	   increased	  
cancer	  predisposition	  or	  telangiectasia	  (Stewart	  et	  al.,	  1999).	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1.7.	  Cancer	  Development	  and	  ATM	  Deficiency	  
1.7.1.	  Clinical	  Features	  of	  Ataxia-­‐Telangiectasia	  
Ataxia-­‐telangiectasia	  (AT)	  is	  a	  rare	  autosomal	  recessive	  disorder	  caused	  by	  mutations	  in	  
the	   ataxia-­‐telangiectasia	  mutated	   (ATM)	   gene.	   In	   human,	   ATM	  deficiency	   leads	   to	   cerebellar	  
ataxia,	  ocular	  telangiectasia,	   immunodeficiency,	   increased	  sensitivity	  to	  ionizing	  radiation,	  and	  
a	  predisposition	  to	  cancers	  (Perlman,	  2012).	  Approximately	  30%	  of	  AT	  patients	  develop	  cancer	  
over	   their	   lifetime	   (McKinnon,	   2012).	   Of	   these,	   lymphoid	   malignancies	   were	   found	   most	  
frequently,	   representing	   a	   200-­‐fold	   increased	   likelihood	   compared	   with	   non-­‐AT	   individuals	  
(Matei	   et	   al.,	   2006).	   AT	   children	   primarily	   develop	   T	   cell	   acute	   lymphocytic	   leukemia	   (T-­‐ALL)	  
with	   an	   immature	   or	   mixed	   immature/mature	   phenotype	   while	   AT	   adults	   more	   commonly	  
develop	  T	  cell	  prolymphocytic	   leukemia	   (T-­‐PLL)	  or	  T	  cell	   chronic	   lymphocytic	   leukemia	   (T-­‐CLL)	  
with	  a	  more	  mature	  phenotype,	  suggesting	  a	  thymic	  and	  post-­‐thymic	  cancer	  origin,	  respectively	  
(Matei	   et	   al.,	   2006).	   Although	   rarer	   than	   T	   cell	   malignancies,	   B	   cell	   leukemias	   (B-­‐ALL)	   and	  
lymphomas	   (in	   particular	   non-­‐Hodgkin’s	   lymphoma,	   B-­‐NHL)	   are	   also	   more	   frequent	   in	   AT	  
patients	  than	  in	  the	  general	  population	  (Boultwood,	  2001;	  Taylor	  et	  al,	  1996).	  	  
	  
1.7.2.	  Cytogenetic	  Aberrations	  in	  AT	  Lymphocytes	  	  
The	   role	  of	  ATM	   in	  maintaining	  genomic	   integrity	   is	  demonstrated	  by	   the	  presence	  of	  
chromosomal	  alterations	  in	  nonmalignant	  cells	  from	  AT	  patients.	  Studies	  have	  shown	  that	  10%	  
of	  all	  T	  cells	  from	  AT	  patients	  harbor	  translocations	  involving	  chromosome	  7	  and	  14,	  including	  
inv(7)(p13;q35)	  and	  T(7;7)(p13;q35)	  that	  join	  TCRB	  to	  TCRG,	  T(7;14)(p13;q11)	  that	  join	  TCRG	  to	  
TCRA/D,	   and	   T(7;14)(q35;q11)	   that	   join	   TCRB	   to	   TCRA/D	   (Taylor	   et	   al.,	   1996).	   These	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translocations	  are	  believed	  to	  be	  non-­‐oncogenic	  and	  are	  detected	  at	  much	   lower	   frequencies	  
also	   in	  non-­‐AT	   individuals	   (Taylor	  et	  al.,	  1996).	   Studies	   in	  nonmalignant	  B	  cells	   from	  adult	  AT	  
patients	  revealed	  T(2;14)	  translocations	  involving	  IGK	  and	  IGH	  (Taylor	  et	  al.,	  1996;	  Metcalfe	  et	  
al.,	   1991;	   Butterworth	   and	   Taylor,	   1986;	   Kirsch	   et	   al.,	   1985).	   This	   presumably	   non-­‐oncogenic	  
translocation	   is	   specific	   to	   B	   cells,	   as	   it	   is	   not	   detected	   in	   T	   cells	   from	   the	   same	   patients	  
(Butterworth	  and	  Taylor,	  1986).	  Albeit	  less	  frequent,	  this	  type	  of	  translocations	  may	  arise	  from	  
similar	  mechanisms	  as	  T	  cells	  translocation	  involving	  two	  TCR	  loci	  (Taylor	  et	  al.,	  1996).	  Based	  on	  
recent	   findings	   in	   ATM-­‐deficient	   murine	   lymphocytes,	   impaired	   V(D)J	   recombination	   due	   to	  
ATM	  deficiency	  most	   likely	  account	   for	   these	   translocations	   (Huang	  et	  al.,	  2007;	  Matei	  et	  al.,	  
2007;	  Vacchio	  et	  al.,	  2007;	  Bredemeyer	  et	  al.,	  2006).	  	  	  
	  
1.7.3.	  Recurrent	  Translocations	  In	  ATM-­‐Deficient	  Human	  Lymphoid	  Tumors	  
Although	   T-­‐ALL	   is	   the	   most	   common	   malignancy	   in	   young	   AT	   patients,	   cytogenetic	  
characterization	  of	   these	   tumors	  has	  been	   reported	  only	   for	   a	   very	   limited	  number	  of	   cases.	  
Three	   studies	   from	   several	   years	   ago	   described	   patients	   carrying	   T(9;16)(q12;p13),	  
T(7;14)(q35;q32),	  and	  T(14;14)(q11;q32)	   (Minegeshe	  et	  al.,	  1991;	  Vitolo	  et	  al.,	  1984;	  Wake	  et	  
al.,	   1982).	   While	   exact	   translocation	   breakpoints	   have	   not	   been	   cloned,	   cytogenetic	   studies	  
revealed	   that	   the	   T(7;14)	   and	   T(14;14)	   translocations	   involved	   the	   TCRA/D	   locus	   on	  
chromosome	  14q32	  and	  the	  TCRB	  locus	  on	  chromosome	  7q35	  (Minegeshi	  et	  al.,	  1991;	  Vitolo	  et	  
al.,	   1984;	   Wake	   et	   al.,	   1982).	   More	   recently,	   another	   report	   described	   amplification	   of	  
sequences	  on	  chromosome	  14q22	  in	  a	  fourth	  AT	  T-­‐ALL	  case,	  which	  correlates	  with	  recurrently	  
amplified	  region	  in	  T	  cell	  lymphomas	  from	  ATM-­‐deficient	  mice	  (see	  below)	  (Zha	  et	  al.,	  2010).	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Translocations	   are	   better	   characterized	   in	   T-­‐PLLs	   arising	   in	   adult	   AT	   patients,	   where	  
common	  inv(14)(q11;q32),	  T(14;14)(q11;q32),	  and	  T(X;14)(q28;q11)	  involve	  the	  TCRA/D	  locus	  at	  
14q11	  and	  oncogenes	  belonging	  to	  the	  TCL1	  family,	  TCL1	  and	  1b	  at	  14q32,	  downstream	  of	  IGH	  
and	  MTCP1	  at	  Xq28	   (Taylor	   et	   al.,	   1996).	   Sequencing	   analysis	   of	   some	  of	   these	   translocation	  
breakpoints	  identified	  the	  14q11	  breakpoint	  in	  the	  Jα	  region,	  suggesting	  involvement	  of	  V(D)J	  
recombination	   breaks	   (Russo	   et	   al.,	   1989;	   Davey	   et	   al.,	   1988).	   These	   translocations	   are	   also	  
commonly	   detected	   in	   sporadic	   T-­‐PLL,	   suggesting	   shared	   mechanisms	   of	   oncogenic	  
transformation	   between	   AT	   and	   non-­‐AT	   T-­‐PLL	   patients	   (Taylor	   et	   al.,	   1996;	   Stankovic	   et	   al.,	  
2002).	   Of	   note,	   translocations	   between	   TCRA/D	   or	   TCRB	   and	   TCL1	   oncogenes	   can	   also	   be	  
detected	   in	   normal	   lymphocytes	   from	   AT	   patients,	   albeit	   less	   frequently	   than	   translocations	  
involving	  two	  TCR	  loci.	  Studies	  following	  the	  evolution	  of	  T	  cells	  bearing	  these	  aberrations	  over	  
time	  revealed	  that	  they	  expand	  into	  large	  clones	  and	  acquire	  further	  mutations,	  and	  eventually	  
develop	  into	  fully	  malignant	  tumors	  (Taylor	  et	  al.,	  1996).	  	  
Reflective	  of	   less	   frequent	   cases	  of	  B	   lineage	   lymphoma	  or	   leukemia	   in	  AT	  patients,	   a	  
limited	  number	  of	   studies	  have	  analyzed	  chromosomal	  aberrations	   in	   this	   subset	  of	  patients.	  
Sandlund	  and	  colleagues	  characterized	  one	  AT	  patient	  with	  Burkitt’s	  lymphoma	  (BL)	  who	  lacked	  
the	  classical	  T(8;14)	  translocation	  joining	  MYC	  to	  IGH	  normally	  found	  in	  BL	  patients	  (Sandlung	  et	  
al.,	   2006).	   Instead,	   this	   patient	   harbored	   T(3;8)	   translocation	   joining	   BCL6	   to	   MYC	   with	  
duplications	   of	   both	   oncogenes	   on	   other	   chromosomes	   (Sandlung	   et	   al.,	   2006).	   Given	   the	  
limited	  number	  of	   studies,	   this	   finding	  does	  not	   rule	  out	   the	   involvement	  of	   immunoglobulin	  
loci	  in	  the	  formation	  of	  translocations	  in	  AT	  B	  lineage	  cancers	  but	  highlight	  the	  need	  for	  further	  
investigations	  of	  chromosomal	  abnormalities	  in	  ATM-­‐deficient	  B	  cells.	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1.7.4.	  ATM	  Mutations	  in	  Sporadic	  Lymphomas	  
Intensive	   efforts	   have	   been	   put	   into	   characterizing	   sporadic	   ATM	   mutations	   in	  
neoplasia.	  Somatic	  ATM	  inactivation,	  often	  biallelic,	  has	  been	  reported	  in	  sporadic	  T-­‐	  and	  B-­‐ALL	  
(up	  to	  25%	  of	  cases),	  T-­‐PLL	  (up	  tp	  40%	  of	  cases),	  B	  cell	  chronic	  lymphocytic	  leukemia	  (B-­‐CLL,	  up	  
to	   40%	  of	   cases)	   and	   adult	   B	   cell	   lymphomas,	   such	   as	  mantle	   cell	   lymphomas	   (MCL)	   (Gumy-­‐
Pause	   et	   al.,	   2004).	   Such	   ATM	   inactivation	   commonly	   results	   from	   deletion	   of	   chromosomal	  
regions	  encompassing	  the	  ATM	  gene	  on	  human	  chromosome	  11	  or	  from	  missense	  or	  truncating	  
mutations	   (Stankovic	   et	   al.,	   2002).	   Chromosomal	   translocations	   commonly	   found	   in	  AT	   T-­‐ALL	  
and	  T-­‐PLL	  are	  detected	  in	  the	  sporadic	  forms	  of	  these	  tumors,	  suggesting	  shared	  mechanisms	  of	  
oncogenic	   transformation	  between	  AT	  and	  non-­‐AT	  cases	   (Taylor	  et	  al.,	  1996;	  Stankovic	  et	  al.,	  
2002).	  
B-­‐CLL	   is	   a	   heterogenous	   disease	   that	   result	   from	   the	   transformation	   of	   pre-­‐	   or	   post-­‐
germinal	  center	  B	  cells.	  The	  origins	  of	  B	  cells	  that	  give	  rise	  to	  B-­‐CLL	  impact	  clinical	  outcome	  of	  
the	  disease	  as	  evident	  by	  better	  prognosis	  of	  B-­‐CLL	  with	  somatic	  hypermutation	  than	  the	  subset	  
lacking	  the	  mutation	  (Klein	  and	  Dalla-­‐Favera,	  2010).	  Of	  note,	  ATM	  mutations,	  and	  occasionally	  
deletion,	  are	  specifically	  found	  in	  the	  subset	  of	  B-­‐CLL	  cases	  that	  arise	  from	  pre-­‐germinal	  center	  
B	   cells,	  whereas	  B-­‐CLL	  without	  ATM	  mutation	  derives	   from	  post-­‐germinal	   center	  B	   cells,	   and	  
usually	  carry	  mutations	  of	  other	  genes	  involved	  in	  tumor	  suppression,	  such	  as	  p53	  	  (Stankovic	  
et	   al.,	   2002).	   B-­‐CLL	   has	   not	   been	   linked	   to	   recurrent	   translocations	   but	   is	   associated	   with	  
genomic	   instability	   that	   give	   rise	   to	   chromosomal	   deletions	   and	   amplifications.	   These	  
aberrations	  consequently	  lead	  to	  deregulated	  oncogene	  expression	  (via	  deletion	  of	  DLEU-­‐2	  on	  
13q14),	   impaired	   DSB	   response	   (via	   deletion	   of	   ATM	   on	   11q22),	   or	   deletion	   of	   tumor	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suppressors	   (via	  deletion	  of	  TP53	   on	  17p13)	   (Klein	  and	  Dalla-­‐Favera,	  2010).	   It	   is	  notable	   that	  
deregulation	  of	  apoptotic	  pathways,	  such	  as	  Bcl2	  overexpression,	  is	  also	  frequently	  observed	  in	  
B-­‐CLL	  (Guipaud	  et	  al.,	  2003).	  	  	  
ATM	  mutations	   are	   also	   frequently	   found	   in	  MCL,	   an	   aggressive	   non-­‐Hodgkin’s	   B	   cell	  
lymphoma	   that	   usually	   derive	   from	   pre-­‐germinal	   center	   B	   cells,	   although	   also	   a	   somatically	  
hypermutated	   subgroup	   has	   been	   identified	   (Menanteau	   and	  Martinez-­‐Climent,	   2013).	  MCLs	  
with	   ATM	  mutations	   display	   higher	   level	   of	   chromosomal	   aberrations	   than	   the	   tumors	   with	  
wild-­‐type	   ATM	   (Gumy-­‐Pause	   et	   al.,	   2004).	   The	   signature	   translocation	   of	   MCL	   is	  
T(11;14)(q13;32)	   which	   puts	   the	   cyclinD1	   gene	   (CCND1)	   under	   the	   influence	   of	   IgH	  
transcriptional	  control	  elements,	  leading	  to	  cyclinD1	  overexpression	  and	  cellular	  transformation	  
(Pileri	   and	   Falini,	   2009).	   Approximately	   20%	   of	   MCL	   cases	   show	   complex	   chromosomal	  
rearrangements,	   including	   amplification	   of	   the	   CCND1/IGH	   translocation	   (Menanteau	   and	  
Martinez-­‐Climent,	  2013)	  and	  secondary	  rearrangement	  or	  amplification	  of	  c-­‐myc	  (Setoodeh	  et	  
al.,	   2013).	   In	   some	   cases,	   high	   level	   amplification	  of	   other	  putative	  oncogenes	  has	   also	  been	  
reported.	  
	  
1.7.5.	  ATM	  Deficiency	  and	  Lymphoma	  Development	  in	  Mice	  
Several	  mouse	  models	   for	   AT	   have	   been	   generated	  with	   phenotypes	   similar	   to	   those	  
observed	   in	   AT	   patients.	   ATM-­‐deficient	   mice	   display	   growth	   retardation,	   neurologic	  
dysfunction,	  and	  infertility	  (Barlow	  et	  al.,	  1996).	  Additionally,	  these	  mice	  are	  immunodeficient	  
with	   severe	   defects	   in	   T	   cell	   maturation,	   hypersensitivity	   to	   gamma-­‐irradiation,	   and	   highly	  
predisposed	  to	  T	  cell	  lymphomas	  (Elson	  et	  al.,	  1996;	  Xu	  et	  al.,	  1996).	  T	  cell	  lymphoma	  in	  ATM-­‐
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deficient	  mice	  is	  of	  thymic	  origin	  that	  leads	  to	  enlargement	  of	  the	  thymus,	  resulting	  in	  fatality	  
from	   heart	   or	   lung	   compression	   (unpublished	   observations).	   Approximately	   12%	   of	   splenic	   T	  
cells	  isolated	  from	  ATM-­‐deficient	  mice	  harbor	  T(12;14)	  translocations	  involving	  the	  Tcra/d	  locus	  
similar	   to	   nonmalignant	   T	   cells	   from	   AT	   patients	   (Liyanage	   et	   al.,	   2000).	   In	   contrast	   to	   the	  
corresponding	  translocations	  found	  in	  AT	  patients,	  the	  majority	  of	  mouse	  T(12;14)	  translocation	  
lead	  to	  deletion	  of	  Tcl1	  oncogene	  due	  to	  deletion	  of	  the	  telomeric	  portion	  of	  chromosome	  12	  
(Zha	   et	   al.,	   2010;	   Liyanage	   et	   al.,	   2000).	   T	   cell	   lymphomas	   from	   ATM-­‐deficient	   mice	   show	  
translocation	   that	   join	   chromosome	   14	   to	   other	   chromosomes	   such	   as	   12,	   15,	   or	   X	   with	  
T(12;14)	   found	   most	   commonly	   (Zha	   et	   al.,	   2010;	   Liyanage	   et	   al.,	   2000).	   All	   ATM-­‐deficient	  
tumors	  had	  either	  partial	  chromosome	  15	  duplications	  or	  trisomy	  15,	  resulting	  in	  copy	  number	  
increase	  of	  the	  c-­‐myc	  gene	  (Zha	  et	  al.,	  2010;	  Liyanage	  et	  al.,	  2000).	  	  
Chromosome	   14	   translocations	   in	   ATM-­‐deficient	   T	   cell	   lymphomas	   were	   initially	  
believed	  to	  involve	  Tcra,	  as	  the	  tumors	  comprise	  of	  CD4+CD8+	  DP	  thymocytes,	  a	  developmental	  
stage	   where	   thymocytes	   undergo	   Tcra	   rearrangement	   (Callen	   et	   al.,	   2009;	   Liyanage	   et	   al.,	  
2000).	  Moreover,	   such	   translocations	  were	   thought	   to	  confer	  cellular	   selection	  advantage	  via	  
deregulation	  of	   oncogenes	  by	   the	  Tcra	   enhancer	   (Eα).	  On	   the	   contrary,	   a	  more	   recent	   study	  
demonstrated	  that	  chromosome	  14	  translocations	   in	  ATM-­‐deficient	  T	  cell	   lymphomas	   instead	  
originated	  from	  RAG-­‐initiated	  DSBs	  in	  the	  Tcrd	  locus	  as	  evident	  by	  the	  translocation	  breakpoint	  
residing	  in	  the	  Tcrd	  locus	  and	  containing	  unrearranged	  Cδ	  region	  (Zha	  et	  al.,	  2010).	  Additionally,	  
Eα	  is	  not	  required	  for	  the	  development	  of	  ATM-­‐deficient	  T	  cells	  lymphomas	  since	  ATM-­‐deficient	  
mice	   lacking	   Eα	   still	   develop	   CD4+CD8+	   T	   cell	   lymphomas	   similar	   to	   those	   arising	   in	   ATM-­‐
deficient	  mice,	  with	   recurrent	   T(12;14)	   translocations	   (Zha	   et	   al.,	   2010).	   In	   addition,	   detailed	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analysis	   of	   these	   tumors	   showed	   a	   recurrent	   amplification	   of	   a	   500-­‐kb	   genomic	   sequence	  
located	   approximately	   10	   Mb	   upstream	   of	   the	   Tcra/d	   locus	   on	   the	   residual	   centromeric	  
fragment	  of	  chromosome	  14,	  not	  the	  derivative	  T(12;14)	  (Zha	  et	  al.,	  2010).	  Although	  no	  known	  
oncogene	  has	  been	  identified,	  the	  findings	  suggest	  that	  the	  amplification	  of	  this	  genomic	  region	  
may	   be	   associated	   with	   the	   oncogenic	   cellular	   transformation	   of	   T	   cells	   in	   ATM-­‐deficient	  
background	  (Zha	  et	  al.,	  2010).	  	  
Zha	  and	  colleagues	  proposed	  that	  the	  mechanisms	  that	  lead	  to	  recurrent	  translocations	  
and	   gene	   amplification	   in	   ATM-­‐deficient	   background	   are	   analogous	   to	   the	   formation	   of	  
complicon	   involving	   IgH	   and	  c-­‐myc	   in	  C-­‐NHEJ/p53-­‐deficient	  pro-­‐B	   cell	   lymphomas	   (Zhu	  et	   al.,	  
2002).	   In	   the	   case	  of	  ATM	  deficiency,	  because	  of	   the	   combined	  defect	   in	  DSB	   repair	   and	   cell	  
cycle	   checkpoints,	  RAG-­‐initiated	  breaks	   in	   the	  Tcrd	   locus	  are	  not	  properly	   joined.	  These	  DSBs	  
can	   persist	   in	   developing	   thymocytes	   and	   be	   propagated	   as	   dicentrics,	   either	   by	   replication	  
through	  the	  original	  DSB	  (Zha	  et	  al.,	  2010;	  Zhu	  et	  al.,	  2002)	  or	  by	  joining	  to	  DSBs	  on	  the	  other	  
chromosomes,	  including	  the	  other	  chromosome	  14	  (Zha	  et	  al.,	  2010).	  Dicentrics	  chromosomes	  
are	  unstable	  during	  cell	  cycle	  and	  can	  subsequently	  undergo	  continuous	  breakage	  and	  rejoining	  
in	  a	  BFB	  mechanism,	  thereby	  allowing	  for	  amplification	  of	  the	  region	  upstream	  of	  Tcra/d	  (Zha	  et	  
al.,	  2010).	   It	  was	  proposed	  that	   the	  high	   frequency	  of	  T(12;14)	  may	  reflect	   (1)	  a	  high	   level	  of	  
RAG-­‐initiated	   DSBs	   on	   chromosome	   12	   that	   provide	   the	   most	   frequent	   substrate	   for	  
translocation	  with	   chromosome	   14,	   (2)	   the	   relative	   proximity	   of	   IgH	   to	  Tcra/d	   in	   developing	  
thymocytes,	  or	  (3)	  cellular	  selection	  of	  T(12;14)	  for	  deletions	  of	  a	  tumor	  suppressor	  located	  in	  
the	   telomeric	   portion	  of	   chromosome	  12	   (Zha	   et	   al.,	   2010).	   In	   this	   regards,	   analysis	   of	   T	   cell	  
lymphomas	   in	  ATM-­‐deficient	  background	  also	  revealed	  a	  deletion	  of	  Bcl11b,	  which	   lies	   in	   the	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telomeric	  end	  of	  chromosome	  12,	  a	  genomic	  region	  frequently	  deleted	  in	  these	  tumors,	  leading	  
to	   hemizygous	   loss	   of	   this	   tumor	   suppressor	   gene	   (Zha	   et	   al.,	   2010).	   The	   loss	   of	  Bcl11b	  may	  
confer	   growth	   advantage	   and	   impose	   cellular	   selection	   for	   cells	   harboring	   T(12;14)	  
translocations.	   Of	   note,	   BCL11B	   was	   shown	   to	   be	   inactivated	   via	   deletion	   or	   missense	  
mutations	   in	   a	   subset	   of	   human	   T-­‐ALL,	   further	   demonstrating	   the	   role	   of	   Bcl11b	   as	   a	   tumor	  
suppressor	  (Gutierrez	  et	  al.,	  2011).	  	  
	  
1.7.6.	  The	  Link	  Between	  ATM-­‐Deficient	  Mouse	  Models	  And	  Cancer	  Development	  In	  AT	  
Patients	  
	  
The	   involvement	   of	   the	   Tcrd	   locus	   in	   murine	   T	   cell	   lymphomas	   in	   ATM-­‐deficient	  
background	  indicate	  the	  possibility	  of	  the	  TCRD	  locus	  being	  the	  frequent	  translocation	  partner	  
in	   AT	   patients	   with	   T-­‐ALL	   or	   T-­‐PLL.	   Even	   though	   the	   occurrence	   of	   this	   event	   is	   not	   yet	  
established	  due	   to	   the	  very	   limited	   information	  available	  on	   translocations	  breakpoints	   in	  AT	  
tumors,	   a	   recent	   characterization	   of	   translocation	   junctions	   in	   a	   large	   cohort	   of	   adult	   T-­‐ALL	  
showed	  that	   the	  majority	   (67%)	  of	  TCR	   translocations	   involve	   the	  TCRD	   rather	   than	  the	  TCRA	  
locus	  (Larmonie	  et	  al.,	  2013).	  In	  these	  tumors,	  the	  status	  of	  ATM	  was	  not	  verified;	  however	  to	  
date,	   there	   is	  no	  evidence	   indicating	  differences	  between	  T-­‐ALL	   in	  AT	  compared	  with	  non-­‐AT	  
individuals,	  and	  indeed	  it	  is	  likely	  that	  the	  majority	  of	  T-­‐ALL	  has	  mutated	  ATM	  alleles	  (Stankovic	  
et	   al.,	   2002).	   Therefore,	   it	  would	  be	   expected	   that	   T-­‐ALL	   developing	   in	  AT	  patients	   harbored	  
translocation	  involving	  the	  TCRD	  locus	  as	  well.	  	  
ATM	  mutations	   can	  give	   rise	   to	   the	   same	   lymphoid	  malignancies	  whether	   it	   occurs	   in	  
the	  germline	  or	  in	  somatic	  cells.	  However,	  the	  predominance	  of	  the	  cancer	  subtypes	  is	  different	  
between	  inherited	  mutation	  or	  acquired	  mutation	  in	  hematopoietic	  cells.	  In	  this	  context,	  T	  cell	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lymphomas/leukemia	   with	   recurrent	   translocation	   involving	   the	   TCR	   loci	   are	   found	   more	  
frequently	   in	   AT	   patients	   as	   well	   as	   ATM-­‐deficient	  mouse	  models.	   On	   the	   contrary,	   somatic	  
ATM	  inactivation	  leads	  primarily	  to	  B	  cell	  tumor	  development.	  The	  study	  by	  Zha	  and	  colleagues	  
is	   the	   first	   to	   propose	   mechanisms	   of	   T	   cell	   lymphoma	   development	   in	   ATM-­‐deficient	  
background.	   This	   study	   may	   provide	   insights	   into	   mechanisms	   that	   account	   for	   the	  
amplification	  of	  the	  region	  upstream	  of	  chromosome	  14q22	   in	  human	  T	  cell	   lymphomas.	  Few	  
investigations	  have	  been	  done	   in	  B	   cell	   tumors	   in	  AT	  patients	   and	  no	  B	   lineage	  malignancies	  
have	  been	  observed	  in	  ATM-­‐deficient	  mice.	  Therefore,	  the	  study	  described	  here	  demonstrates	  
the	   first	   cases	   of	   mature	   B	   cell	   lymphomas	   in	   ATM-­‐deficient	   background.	   Detailed	  
characterization	  of	  this	  tumor	  may	  shed	  light	  on	  mechanisms	  of	  B	  cell	  lymphoma	  development	  
in	  AT	  patients	  or	  patients	  with	  somatic	  ATM	  mutation.	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CHAPTER	  2:	  MATURE	  B	  CELL	  LYMPHOMA	  DEVELOPMENT	  IN	  ATM-­‐DEFICIENT	  BACKGROUND
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2.1.	  Summary	  	  
	  
	   ATM	   senses	   DNA	   double-­‐stranded	   breaks	   (DSBs)	   and	   facilitates	   their	   repair.	   ATM-­‐
deficiency	  predisposes	  to	  B	  and	  T	  cell	   lymphomas	   in	  humans	  but	  only	   to	  T	  cell	   lymphomas	   in	  
mice.	  We	  now	  describe	  compound	  mutant	  mice	  that,	  when	  ATM	  deficient,	  consistently	  develop	  
IgM+	  mature	  B	  cell	  lymphomas.	  These	  tumors	  harbor	  oncogenic	  c-­‐myc	  amplifications	  generated	  
by	   a	   breakage-­‐fusion-­‐bridge	   mechanism	   (BFB)	   from	   dicentric	   chromosomes	   formed	   through	  
fusion	  of	  V(D)J	  recombination-­‐initiated	  IgH	  DSBs	  to	  sequences	  downstream	  of	  c-­‐myc.	  	  Genome-­‐
wide	   cloning	   of	   c-­‐myc	   DSB	   translocations	   in	   ATM-­‐deficient	   IgM+	  mature	   B	   cells	   activated	   by	  
various	   methods	   revealed	   a	   30	   megabase	   region	   downstream	   of	   IgH	   to	   be	   a	   translocation	  
hotspot	  due	  to	  frequent	  DSBs	  newly	  generated	  by	  BFB.	  We	  propose	  that	  ATM-­‐deficiency	  allows	  
V(D)J	  recombination	  DSBs	  within	  IgH	   in	  developing	  B	  cells	  to	  generate	  dicentric	  translocations	  
that	   via	   BFB	   cycles	   generate	  new	  DSBs	   and	   c-­‐myc	   gene	   amplifications	   that	   can	   contribute	   to	  
oncogenic	  transformation	  of	  	  mature	  B	  cells.	  
	  
2.2.	  Introduction	  
The	   B	   cell	   antigen	   receptor	   (BCR)	   and	   its	   secreted	   antibody	   form	   are	   heterodimers	  
comprised	  of	  immunoglobulin	  (Ig)	  heavy	  (IgH)	  and	  light	  (IgL)	  chains	  (Jackson	  et	  al.,	  2013).	  T	  cell	  
antigen	  receptors	  are	  similarly	  comprised	  of	  either	  αβ	  or	  γδ	  heterodimers	  (Cobb	  et	  al.,	  2006).	  
The	  N-­‐terminal	  portion	  of	   Ig	  and	  TCR	  chains	  contains	   the	  antigen	  binding	  variable	   (V)	   region.	  
Exons	  that	  encode	  Ig	  or	  TCR	  variable	  regions	  are	  assembled	  in	  developing	  bone	  marrow	  (BM)	  B	  
cells	   and	  developing	   thymic	   T	   cells	   by	  V(D)J	   recombination	  of	   germline	  V,	  D,	   and	   J	   segments	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(Jackson	  et	  al.,	  2013).	  V(D)J	  recombination	  is	  initiated	  in	  progenitor	  B	  	  and	  T	  cells	  by	  the	  "RAG"	  
endonuclease	  (Nishana	  and	  Raghavan,	  2012).	  RAG	  initiates	  V(D)J	  recombination	  by	  introducing	  
DNA	   double-­‐strand	   breaks	   (DSBs)	   at	   borders	   of	   a	   pair	   of	   V,	   D,	   or	   J	   segments	   and	   short	  
conserved	   flanking	   recombination	   signal	   sequences	   (RSSs)	   (Schatz	   et	   al.,	   2008).	   RAG-­‐initiated	  
DSBs	  at	  two	  participating	  V,	  D,	  or	  J	  segments	  occur	   in	  the	  G1	  cell	  cycle	  phase	  where	  they	  are	  
joined	   exclusively	   by	   the	   classical	   non-­‐homologous	   DNA	   end-­‐joining	   (C-­‐NHEJ)	   DSB	   repair	  
pathway	  (Helmink	  and	  Sleckman,	  2012).	  	  
	   	  The	  C-­‐terminal	  constant	  region	  of	  IgH	  chains	  can	  be	  encoded	  by	  several	  different	  sets	  of	  
exons	  (CHs)	  that	  determine	  Ig	  class	  (e.g	  IgM,	  IgG,	  IgA)	  and	  effector	  function	  (Cobb	  et	  al.,	  2006).	  
IgH	  V(D)J	  exons	  are	  assembled	  at	  the	  germline	  JH	  region	  just	  upstream	  of	  the	  Cμ	  exons,	  the	  first	  
set	  of	  CH	  exons	  expressed.	  Transcription	  from	  the	  V(D)J	  exon	  is	  terminated	  downstream	  Cμ	  to	  
generate	  an	  mRNA	  that	  encodes	  a	  μ	  IgH	  chain	  (Perlot	  and	  Alt,	  2008).	  Subsequent	  assembly	  of	  
an	  IgL	  variable	  region	  exon	  and	  expression	  of	  an	  IgL	  protein	  generates	  IgM,	  which	  is	  deposited	  
on	   the	   surface	   of	   the	   resulting	   IgM+	   B	   cells	   (Vettermann	   and	   Schlissel,	   2010).	   Surface	   IgM-­‐
expressing	   B	   cells	   migrate	   from	   the	   BM	   to	   peripheral	   lymphoid	   organs,	   such	   as	   the	   spleen,	  
where	   upon	   antigen	   stimulation	   they	   undergo	   IgH	   class	   switch	   recombination	   (CSR).	   CSR	  
changes	  antibody	  effector	  functions	  by	  replacing	  Cμ	  exons	  with	  one	  of	  several	  sets	  of	  CH	  exons	  
that	  lie	  100-­‐200kb	  downstream	  in	  the	  IgH	  locus	  (Keim	  et	  al.,	  2013).	  CSR	  employs	  DSBs	  initiated	  
by	   activation-­‐induced	   cytidine	   deaminase	   (AID)	   in	   large	   repetitive	   switch	   (S)	   regions	   that	  
precede	  the	  various	  sets	  of	  CH	  exons	  (Chaudhuri	  et	  al.,	  2007).	  DSBs	  in	  the	  donor	  Sμ	  region	  are	  
joined	   to	   the	  DSBs	   in	  an	  acceptor	  S	   region	  by	  end-­‐joining	   to	   complete	  CSR	   (Chaudhuri	  et	   al.,	  
2004).	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   Chromosomal	   translocations	   result	   from	   joining	   two	   separate	   DSBs	   together	   and	   are	  
inter-­‐chromosomal	   if	   they	   join	   DSBs	   on	   two	   different	   chromosomes	   (Zhang	   et	   al.,	   2010).	  
Depending	  on	  how	  DSBs	   are	   joined,	   inter-­‐chromosomal	   translocations	   can	   join	   the	   telomeric	  
end	   of	   one	   chromosome	   to	   the	   centromeric	   end	   of	   another	   or	   they	   can	   result	   in	   dicentric	  
chromosomes	   and/or	   acentric	   chromosome	   fragments	   (Bunting	   and	   Nussenzweig,	   2013).	  
Translocations	  also	  can	  also	  occur	   intra-­‐chromosomally	   if	   they	   join	   two	  separate	  DSBs	  on	  the	  
some	   chromosome.	   Such	   intrachromosomal	   translocations	   might	   result	   in	   deletions	   or	  
inversions	   depending	   which	   ends	   of	   the	   DSBs	   are	   joined	   (Zhang	   et	   al.,	   2010).	   The	   high	  
frequency	   of	   DSBs	   generated	   during	   B	   and	   T	   cell	   development	   by	   V(D)J	   recombination	   and	  
during	  B	  cell	  activation	  for	  CSR	  provide	  substrates	  for	  chromosomal	  translocations	  (Gostissa	  et	  
al.,	  2011).	  Indeed,	  spontaneous	  B	  or	  T	  cell	  lymphomas	  in	  humans	  and	  certain	  mouse	  lymphoma	  
models	  often	  harbor	  recurrent	  translocations	  that	  fuse	  Ig	  or	  TCR	  loci	  to	  oncogenes	  and/or	  join	  
them	  to	  other	  genomic	  DSBs	  in	  a	  way	  that	  deletes	  tumor	  suppressors	  (Mitelman	  et	  al.,	  2007).	  	  	  	  
	   C-­‐NHEJ	   maintains	   genomic	   integrity	   by	   re-­‐joining	   of	   DSBs	   and,	   thereby,	   suppressing	  
chromosome	  breaks	  and	  translocations	  (Gostissa	  et	  al.,	  2011).	  C-­‐NHEJ	  is	  important	  in	  G1	  when	  
homologous	   recombination,	   the	  other	  major	  DSB	   repair	  pathway,	   is	  not	  available	   (Boboila	  et	  
al.,	  2012).	  Despite	  marked	  genomic	  instability,	  C-­‐NHEJ-­‐deficient	  mice	  do	  not	  routinely	  develop	  
lymphoid	   tumors	   or	   other	   cancers,	   at	   least	   in	   part,	   due	   to	   elimination	   cells	   containing	  
unrepaired	  G1	  DSBs	  by	   the	  G1/S	   cell	   cycle	   checkpoint	   (Puebla-­‐Osorio	   and	   Zhu,	   2008).	   In	   this	  
regard,	  combined	  deficiency	  in	  mice	  for	  C-­‐NHEJ	  and	  p53,	  a	  tumor	  suppressor	  that	  activates	  the	  
G1	   checkpoint,	   leads	   to	   recurrent	   pro-­‐B	   cell	   lymphomas	   in	   mice	   (Gostissa	   et	   al.,	   2011).	   A	  
hallmark	   of	   these	   pro-­‐B	   lymphomas	   is	   complex	   translocation	   with	   c-­‐myc	   oncogene	   gene	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amplifications,	  referred	  to	  as	  complicons	  (Zhu	  et	  al.,	  2002).	  Such	  complicons	  derive	  from	  fusion	  
of	  RAG-­‐initiated	   IgH	  DSBs	  on	  chromosome	  12	  to	  DSBs	  downstream	  of	  c-­‐myc	  on	  chromosome	  
15,	   generating	   dicentric	   chromosomes	   that	   lead	   to	   oncogenic	   c-­‐myc	   amplification	   via	   a	  
breakage-­‐fusion-­‐bridge	  (BFB)	  mechanism	  (Zhu	  et	  al.,	  2002).	  A	  key	  aspect	  of	  the	  mechanism	  of	  
complicon	   formation	   is	   the	   persistence	   of	   unrepaired	   RAG-­‐initiated	   IgH	   DSBs	   due	   to	   (1)	   the	  
absence	  of	  C-­‐NHEJ	  and	  (2)	   impaired	  G1	  checkpoint	  due	  to	  the	  absence	  of	  p53.	  Consequently,	  
the	   unrepaired	   DSBs	   are	   replicated	   and	   can	   form	   the	   dicentrics	   that	   promote	   c-­‐myc	  
amplification	  (Zhu	  et	  al.,	  2002).	  
	   Unrepaired	  DSBs	  in	  G1,	  including	  V(D)J	  recombination	  and	  CSR	  associated	  DSBs,	  activate	  
Ataxia	  Telangiectasia-­‐mutated-­‐kinase	   (ATM),	  which	   in	   turn	  activates	  downstream	   factors	   that	  
form	   complexes	   in	   chromatin	   surrounding	   DSBs,	   preventing	   premature	   DSB	   separation	   and	  
promoting	  joining	  by	  C-­‐NHEJ	  (Bednarski	  and	  Sleckman,	  2012).	  Additionally,	  this	  ATM-­‐dependent	  
DSB	  response	  also	  activates	  p53	  to	  enforce	  the	  G1	  checkpoint	  (Helmink	  and	  Sleckman,	  2012).	  
Human	   ATM-­‐deficiency	   leads	   to	   Ataxia	   Telangiectasia	   (AT),	   a	   condition	   that	   includes	  
immunodeficiency	  and	  increased	  predisposition	  to	  T	  and	  B	  cell	  cancers	  (Perlman	  et	  al.,	  2012).	  	  
ATM	  inactivation	  in	  mice	  recapitulates	  several	  aspects	  of	  AT,	  including	  predisposition	  to	  thymic	  
lymphoma,	  but	  does	  not	  predispose	  to	  B	  cell	   lymphoma	  (Jacks	  et	  al.,	  1994;	  Donehower	  et	  al.,	  
1992).	  Murine	  ATM-­‐deficient	  thymic	  lymphomas	  harbor	  recurrent	  translocations	  involving	  RAG-­‐
initiated	  DSBs	  in	  the	  TCRδ	  locus	  on	  chromosome	  14	  that	  lead	  to	  chromosome	  14	  dicentrics	  and	  
complicons,	   as	   well	   joins	   of	   TCRδ	   to	   sequences	   spread	   over	   a	   many	   megabase	   regions	  
downstream	  of	  IgH	  to	  create	  T(12;14)	  translocations	  that	  delete	  the	  Bcl11b	  haploinsufficient	  T	  
cell	   tumor	   suppressor	   (Gutierrez	   et	   al.,	   2011;	   Zha	   et	   al.,	   2010).	   Thus,	   the	   chromosomal	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aberrations	  of	  ATM-­‐deficient	  thymic	  lymphomas	  appear	  mechanistically	  similar	  to	  those	  found	  
in	   C-­‐NHEJ/p53-­‐deficient	   pro-­‐B	   cell	   lymphomas,	   potentially	   because	   ATM	   deficiency	   leads	   to	  
both	   a	   V(D)J	   joining	   defect	   and	   a	   G1-­‐checkpoint	   defect.	   Notably,	   ATM-­‐deficiency	   also	   allows	  
unrepaired	   RAG-­‐initiated	   IgH	   DSBs	   in	   developing	   pro-­‐B	   cells	   to	   persist,	   via	   unknown	  
mechanisms,	  as	   large	  centromeric	  chromosome	  12	   fragments	   into	  mature	  B	  cells	  where	   they	  
can	  participate	  in	  chromosomal	  translocations	  (Callen	  et	  al.,	  2007).	  	  
	   We	   hypothesized	   that	   the	   frequency	   of	   B	   cells	   with	   c-­‐myc	   DSBs	   available	   for	  
translocation	  or	  their	  survival	  may	  be	  rate-­‐limiting	  factors	  for	  B	  cell	  lymphoma	  development	  in	  
the	   ATM-­‐deficient	   background.	   We	   now	   describe	   ATM-­‐deficient	   mature	   B	   cell	   lymphoma	  
mouse	  models	  generated	  on	  the	  basis	  of	  these	  hypotheses.	  Our	  studies	  of	  these	  tumors	  suggest	  
that	  ATM	  suppresses	  mature	  B	  cell	   lymphomas	   in	   susceptible	  backgrounds	  by	  preventing	   the	  
conversion	  of	  unrepaired	  RAG-­‐initiated	   IgH	  breaks	   in	  progenitor	  B	  cells	   from	  progressing	   into	  
dicentric	  chromosomes	  that,	  through	  BFB	  cycles,	  give	  rise	  to	  gene	  amplifications	  that	  promote	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2.3.	  Results	  
2.3.1.	   RAG	   Target	   Sequence	   In	   c-­‐myc	   Leads	   To	  Mature	   B	   Cell	   Lymphoma	   In	   ATM-­‐Deficient	  
Mice	  	  
To	  test	   the	  hypothesis	   that	  DSB	  frequency	   in	  oncogenes	  such	  as	  c-­‐myc	  may	  be	  a	  rate-­‐
limiting	   factor	   for	  B	  cell	   lymphoma	  development	   in	  ATM-­‐deficient	  background,	  we	  generated	  
ATM-­‐deficient	  mice	  with	  a	  RAG	  target	  sequence	  (“DJβ”	  cassette)	  inserted	  in	  intron	  1	  of	  c-­‐myc.	  
This	   cassette	   is	   efficiently	   cut	   by	   RAG	   during	   B	   cell	   development	   (Ranganath	   et	   al.,	   2008),	  
therefore	  providing	  a	  source	  of	  unrepaired	  DSBs	  that	  could	  serve	  as	  translocation	  substrates	  in	  
the	  context	  of	  ATM-­‐deficiency.	  To	  obtain	  the	  experimental	  cohort,	  we	  intercrossed	  ATM+/-­‐mice	  
that	   were	   either	   heterozygous	   or	   homozygous	   for	   the	   c-­‐mycDJβ	   allele	   (see	   Material	   and	  
Methods	   for	   details).	   The	   ATM-­‐/-­‐	   c-­‐mycDJβ/DJβ	   	   and	   ATM-­‐/-­‐	   c-­‐mycDJβ/wt	   	   offspring	   from	   these	  
breedings	  (collectively	  referred	  to	  as	  “DA”)	  was	  monitored	  for	  tumor	  development.	  ATM-­‐/-­‐	  mice	  
lacking	  c-­‐mycDJβ	  allele,	  ATM+/-­‐	  c-­‐mycDJβ/DJβ,	  and	  ATM+/-­‐	  c-­‐mycDJβ/wt	  	  mice	  were	  kept	  as	  controls.	  
Out	  of	  a	  total	  of	  17	  DA	  mice,	  5	  developed	  peripheral	  B	  cell	  lymphoma	  and	  12	  developed	  T	  cell	  
lymphoma,	  based	  on	   surface	  marker	   analysis	   (see	  below).	  DA	  mice	   that	   succumbed	   to	  B	   cell	  
lymphoma	  had	  enlarged	  peripheral	  lymph	  nodes,	  mesenteric	  lymph	  nodes,	  spleen,	  and	  thymus.	  
Metastasis	  to	  the	  liver	  or	  kidney	  was	  also	  observed	  (Table	  1).	  T	  cell	  lymphomas	  from	  DA	  mice	  as	  
well	   as	  ATM-­‐/-­‐	   littermate	  controls	   showed	   the	   same	   tumor	  characteristics	  as	   those	  previously	  
reported	  in	  ATM-­‐deficient	  background	  (Zha	  et	  al.,	  2010)	  (Table	  2).	  None	  of	  the	  ATM+/-­‐	  c-­‐mycDJβ	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Table	  1.	  Summary	  of	  tumor	  mice	  analyzed	  from	  DA	  cohort.	  Cause	  of	  death	  is	  listed	  in	  the	  third	  
column.	  The	  genotype	  of	  c-­‐mycDJβ	  allele	   is	   indicated.	  Results	   from	  Southern	  blot	  analysis	  with	  




Amp.	  =	  Amplified	  signal	  




















Mouse&ID Age&(days) COD c3myc&allele
DA#416 79 thymic#lymphoma DJ/DJ
DA#351 87 thymic#lymphoma DJ/DJ
DA#607 90 IgM+#lymphoma DJ/DJ
DA#64 95 IgM+#lymphoma DJ/DJ
DA#360 96 IgM+#lymphoma DJ/DJ
DA#359 102 thymic#lymphoma DJ/DJ
DA#107 103 IgM+#lymphoma DJ/Myc
DA#306 104 thymic#lymphoma DJ/Myc
DA#366 114 thymic#lymphoma DJ/DJ
DA#268 116 thymic#lymphoma DJ/Myc
DA#458 125 thymic#lymphoma DJ/DJ
DA#403 135 IgM+#lymphoma DJ/DJ
DA#367 141 thymic#lymphoma DJ/DJ
DA#32 160 thymic#lymphoma DJ/Myc
DA#352 189 thymic#lymphoma DJ/DJ
DA#22 207 thymic#lymphoma DJ/DJ
DA#21 220 thymic#lymphoma DJ/DJ
c"myc Cμ JH Jκ
N/D N/D N/D N/D
N/D N/D N/D N/D
Amp. Not#amp. Rearr.#not#Amp. Rearr.
Amp. Amp. Rearr.#and#Amp. Rearr.
Amp. Amp. Rearr.#and#Amp. Rearr.
N/D N/D N/D N/D
Not#amp. Amp. Rearr.#and#Amp. Rearr.
Not#amp. N/D N/D N/D
N/D N/D N/D N/D
N/D N/D N/D N/D
N/D N/D N/D N/D
Amp. Amp. Rearr.#and#Amp. Rearr.
N/D N/D N/D N/D
Not#amp. N/D N/D N/D
N/D N/D N/D N/D
Not#amp. N/D N/D N/D
Not#amp. N/D N/D N/D
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Table	  2.	  Control	  mice	   from	  DA	  cohort.	  Age	  at	  the	  time	  of	  sacrifice	   is	   indicated	  in	  the	  second	  
column.	   Cause	   of	   death	   (COD)	   is	   indicated	   in	   the	   third	   column.	   Genotype	   of	   each	  mouse	   is	  




	   	   *	  indicates	  ATM-­‐/-­‐	  from	  DA	  cohort	  
	   	  
Mouse&ID Age&(days) COD Genotype
288* 91 T'cell'lymphoma ATM3/3
242* 99 T'cell'lymphoma ATM3/3
66* 102 T'cell'lymphoma ATM3/3
353* 118 T'cell'lymphoma ATM3/3
487* 120 T'cell'lymphoma ATM3/3
279* 147 T'cell'lymphoma ATM3/3
115* 148 T'cell'lymphoma ATM3/3
483* 153 T'cell'lymphoma ATM3/3
43 239 sacrificed ATM+/3'DJβ/Myc
34 244 sacrificed ATM+/3'DJβ/DJβ
176 261 sacrificed ATM+/3'DJβ/DJβ
177 261 sacrificed ATM+/3'DJβ/DJβ
179 261 sacrificed ATM+/3'DJβ/DJβ
2 293 sacrificed ATM+/3'DJβ/Myc
3 293 sacrificed ATM+/3'DJβ/Myc
4 293 sacrificed ATM+/3'DJβ/Myc
5 293 sacrificed ATM+/3'DJβ/Myc
13 302 sacrificed ATM+/3'DJβ/Myc
14 302 sacrificed ATM+/3'DJβ/Myc
16 302 sacrificed ATM+/3'DJβ/Myc
9 311 sacrificed ATM+/3'DJβ/Myc
341 325 sacrificed ATM+/3'DJβ/Myc
335 389 sacrificed ATM+/3'DJβ/DJβ
339 389 sacrificed ATM+/3'DJβ/DJβ
12 393 sacrificed ATM+/3'DJβ/Myc
15 393 sacrificed ATM+/3'DJβ/Myc
349 >506 alive ATM+/3'DJβ/DJβ
337 >574 alive ATM+/3'DJβ/DJβ
338 >574 alive ATM+/3'DJβ/DJβ
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2.3.2.	  Bcl-­‐2	  Transgene	  Promotes	  Mature	  B	  Cell	  Lymphoma	  In	  ATM-­‐Deficient	  Mice	  	  
Although	  all	  DA	  mice	   succumbed	   to	   lymphomas,	   the	  penetrance	  of	   B	   cell	   lymphomas	  
was	   approximately	   25%.	   We	   hypothesized	   that	   this	   may	   be	   due	   to	   poor	   survival	   of	   ATM-­‐
deficient	  B	  cells.	  To	  test	  this	  hypothesis,	  we	  seek	  to	  confer	  survival	  advantage	  to	  ATM-­‐deficient	  
B	   cells	   by	   enforcing	   expression	   of	   the	   anti-­‐apoptotic	   factor	   Bcl-­‐2.	   Eμ-­‐Bcl-­‐2	   transgenic	   mice	  
overexpress	   Bcl-­‐2	   in	   the	   B	   cell	   compartment,	   and	   develop	   B	   cell	   hyperplasia	   (Strasser	   et	   al.,	  
1994,	  McDonnell	   et	   al.,	   1989).	  Mice	   harboring	   Eμ-­‐Bcl-­‐2	   transgene	  were	   crossed	  with	   ATM+/-­‐	  
mice	   and	   the	   resulting	   ATM+/-­‐Eμ-­‐Bcl-­‐2	   offspring	   were	   then	   bred	   together	   to	   obtain	  
experimental	   ATM-­‐/-­‐	   Eμ-­‐Bcl-­‐2	   (referred	   to	   as	   “AB”)	   mice.	   ATM-­‐/-­‐	   mice	   lacking	   the	   Eμ-­‐Bcl-­‐2	  
transgene	   and	   ATM+/-­‐Eμ-­‐Bcl-­‐2	   mice	   were	   kept	   as	   controls.	   Of	   eight	   AB	   mice	   analyzed,	   four	  
developed	   B	   lineage	   lymphomas	   (Table	   3).	   Three	   of	   these	   mice	   exhibited	   the	   same	   tumor	  
presentation	   as	   B	   cell	   lymphomas	   in	   DA	   cohort	   while	   AB36	   developed	   a	   tumor	  mass	   in	   the	  
gastrointestinal	   cavity	   with	   enlarged	   spleen,	   but	   normal	   size	   thymus	   and	   peripheral	   lymph	  
nodes.	  The	  other	  four	  AB	  mice	  developed	  T	  cell	  lymphomas	  (Table	  3),	  which	  again	  were	  similar	  
to	  those	  obtained	  in	  ATM-­‐/-­‐	  deficient	  animals	  in	  this	  and	  previous	  studies	  (Table	  4	  and	  Zha	  et	  al.,	  
2010).	   None	   of	   the	   ATM+/-­‐	   Eμ-­‐Bcl-­‐2	   littermate	   controls	   succumbed	   to	   lymphomas	   or	   other	  
neoplasia	   (Table	   4).	   Strikingly,	   when	   we	   generated	   ATM-­‐deficient	   mice	   that	   were	   either	  
heterozygous	   or	   homozygous	   for	   the	   c-­‐mycDJβ	   allele	   and	   carried	   the	   Eμ-­‐Bcl-­‐2	   transgene	  
(referred	  to	  as	  “DAB”),	  we	  obtained	  100%	  penetrance	  of	  B	  cell	  lymphoma	  (Table	  5).	  7	  out	  of	  7	  
mice	   developed	   B	   cell	   lymphomas	   with	   the	   same	   characteristics	   as	   those	   found	   at	   lower	  
frequency	   in	  DA	  and	  AB	  cohorts.	  ATM+/-­‐	  c-­‐mycDJβ	  Eμ-­‐Bcl-­‐2	  or	  ATM+/-­‐	  c-­‐mycDJβ	  control	  mice	  did	  
not	  develop	  lymphomas	  or	  other	  neoplasia	  (Table	  6).	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Table	  3.	  Summary	  of	  tumor	  mice	  analyzed	  from	  AB	  cohort.	  Cause	  of	  death	  is	  listed	  in	  the	  third	  
column.	  The	  genotype	  of	  c-­‐mycDJβ	  allele	   is	   indicated.	  Results	   from	  Southern	  blot	  analysis	  with	  





Amp.	  =	  Amplified	  signal	  




Table	  4.	  Control	  mice	   from	  AB	  cohort.	  Age	  at	  the	  time	  of	  sacrifice	   is	   indicated	   in	  the	  second	  
column.	   Cause	   of	   death	   (COD)	   is	   indicated	   in	   the	   third	   column.	   Genotype	   of	   each	  mouse	   is	  
indicated	  in	  the	  last	  column.	  
	  
^	  indicated	  ATM-­‐/-­‐	  from	  AB	  cohort	  
	  
	  
Mouse&ID Age&(days) COD c3myc&allele
AB#225 84 IgM+#lymphoma +
AB#92 100 thymic#lymphoma +
AB#67 104 IgM+#lymphoma +
AB#117 113 thymic#lymphoma +
AB#143 116 IgM+#lymphoma +
AB#167 157 thymic#lymphoma +
AB#106 133 thymic#lymphoma +
AB#36 297 IgM+#lymphoma +
c"myc Cμ JH Jκ
Amp. Amp. Rearr.#and#Amp. deleted
Not#amp. N/D N/D N/D
Amp. Amp. Rearr.#and#Amp. Rearr.
N/D N/D N/D N/D
Amp. Amp. Rearr.#and#Amp. Rearr.
N/D N/D N/D N/D
N/D N/D N/D N/D
Not#amp. Not#amp. deleted Rearr.
Mouse&ID Age&(days) COD Genotype
116^ 72 T'cell'lymphoma ATM3/3
78^ 106 T'cell'lymphoma ATM3/3
60^ 117 T'cell'lymphoma ATM3/3
86^ 153 T'cell'lymphoma ATM3/3
55^ 154 T'cell'lymphoma ATM3/3
58^ 155 T'cell'lymphoma ATM3/3
101 247 sacrificed ATM+/3'Eμ3Bcl32
90 337 sacrificed ATM+/3'Eμ3Bcl32
42 447 sacrificed ATM+/3'Eμ3Bcl32
33 467 sacrificed ATM+/3'Eμ3Bcl32
34 467 sacrificed ATM+/3'Eμ3Bcl32
20 471 sacrificed ATM+/3'Eμ3Bcl32
31 686 sacrificed ATM+/3'Eμ3Bcl32
24 757 sacrificed ATM+/3'Eμ3Bcl32
21 804 sacrificed ATM+/3'Eμ3Bcl32
	   73 
Table	   5.	   Summary	  of	   tumor	  mice	   analyzed	   from	  DAB	   cohort.	  Cause	  of	  death	   is	   listed	   in	   the	  
third	  column.	  The	  genotype	  of	  c-­‐mycDJβ	  allele	   is	   indicated.	  Results	   from	  Southern	  blot	  analysis	  




Amp.	  =	  Amplified	  signal	  
Rearr.	  =	  Rearrangement	  detected	  
	  
Table	  6.	  Control	  mice	  from	  DAB	  cohort.	  Age	  at	  the	  time	  of	  sacrifice	  is	  indicated	  in	  the	  second	  
column.	   Cause	   of	   death	   (COD)	   is	   indicated	   in	   the	   third	   column.	   Genotype	   of	   each	  mouse	   is	  
indicated	  in	  the	  last	  column.	  
#	  indicates	  DA	  mice	  resulting	  from	  DAB	  cohort	  	  
	  
	   	  
Mouse&ID Age&(days) COD c3myc&allele
DAB$494 48 IgM+$lymphoma DJ/Myc
DAB$496 48 IgM+$lymphoma DJ/Myc
DAB$473 68 IgM+$lymphoma DJ/DJ
DAB$538 69 IgM+$lymphoma DJ/Myc
DAB$361 70 IgM<$lymphoma DJ/Myc
DAB$601 80 IgM+$lymphoma DJ/Myc
DAB$277 95 IgM+$lymphoma DJ/Myc
c"myc Cμ JH Jκ
Amp. Amp. (split$probe) Rearr.
Amp. Amp. (split$probe) Rearr.
Amp. Amp. Rearr.$and$Amp. Rearr.
Amp. Amp. Rearr.$and$Amp. Rearr.
Amp. Amp. Rearr.$and$Amp. deleted
Amp. Amp. Rearr.$and$Amp. Rearr.
Amp. Amp. Rearr.$and$Amp. Rearr.
Mouse&ID Age&(days) COD Genotype Mom Dad
705# 95 T'cell'lymphoma ATM3/3'DJβ/Myc 76 115
685# 176 T'cell'lymphoma ATM3/3'DJβ/Myc 45 49
355# 265 T'cell'lymphoma ATM3/3'DJβ/Myc 76 115
235# 270 T'cell'lymphoma ATM3/3'DJβ/Myc 45 49
462 241 sacrificed ATM+/3'DJβ/Myc'Eμ3Bcl32 76 115
470 261 sacrificed ATM+/3'DJβ/Myc'Eμ3Bcl32 76 115
80 305 sacrificed ATM+/3'DJβ/Myc bcl2'DJ/myc ATM+/3
50 323 sacrificed ATM+/+'Eμ3Bcl32 bcl2'DJ/myc ATM+/3
118 369 sacrificed ATM+/3'DJβ/Myc'Eμ3Bcl32 bcl2'DJ/myc ATM+/3
115 375 sacrificed ATM+/3'DJβ/Myc'Eμ3Bcl32 bcl2'DJ/myc ATM+/3
49 412 sacrificed ATM+/3'DJβ/Myc'Eμ3Bcl32 bcl2'DJ/myc ATM+/3
76 414 sacrificed ATM+/3'DJβ/Myc bcl2'DJ/myc ATM+/3
43 417 sacrificed ATM+/3'DJβ/Myc'Eμ3Bcl32 bcl2'DJ/myc ATM+/3
45 432 sacrificed ATM+/3'DJβ/Myc bcl2'DJ/myc ATM+/3
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2.3.3.	  ATM-­‐Deficient	  Mature	  B	  Cell	  Lymphomas	  Arise	  From	  Naïve	  Mature	  B	  Cells	  Population	  
	  Analysis	   of	   surface	   marker	   by	   flow	   cytometry	   revealed	   that	   13	   of	   16	   B	   cell	   tumors	  
obtained	   in	  DA,	  AB	  and	  DAB	   cohorts	  were	  B220+IgM+,	   suggesting	   they	  arose	   from	  mature	  B	  
cells	  that	  did	  not	  undergo	  CSR.	  Of	  the	  tumors	  that	  were	  IgM+,	  11	  expressed	  Igκ	  and	  2	  (DAB473	  
and	  DAB496)	  expressed	  Igλ	  on	  their	  surface	  (Figure	  12,	  Table	  7).	  Three	  B	  cell	  lymphomas	  (AB36,	  
AB225,	  and	  DAB361)	  lacked	  surface	  IgM	  and	  light	  chain	  expression	  (Table	  7).	  	  
Figure	   12.	   Example	   of	   flow	   cytometry	   analysis	   of	   tumor	   cells	   isolated	   from	  
DAB601	  thymus	  (thy)	  and	  DAB473	  peripheral	  lymph	  nodes	  (pLN).	  Normal	  spleen	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Table	   7.	   Summary	  of	   cell	   surface	  marker	   analysis	   of	   tumor	   cells	   isolated	   from	  DA,	  AB,	   and	  
DAB	  tumors	  by	  flow	  cytometry.	  
	  	  	  	  IgL-­‐	  =	  no	  expression	  of	  IgL	  chain	  
To	   further	   verify	   B	   cell	   origin	   and	   clonality	   of	   these	   tumors,	   we	   examined	   the	  
rearrangement	   status	   of	   the	   IgH	   and	   Igκ	   loci	   by	   Southern	   blot	   analysis,	   using	   probes	   that	  
hybridize	   downstream	   of	   the	   JH	   region	   (JH	   4-­‐3	   probe)	   and	   of	   the	   Jκ	   region	   (Jκ	   probe),	  
respectively	   (Figure	   13	   and	   14).	   The	   results	   showed	   that	   most	   tumors	   contained	   distinct	  
rearranged	  bands	  for	  both	  JH	  and	  Jκ,	  indicative	  of	  monoclonal	  origin	  (Figure	  13	  and	  14).	  Lack	  of	  
rearranged	  JH	  bands	   in	  some	  tumors	   is	   likely	  due	  to	  aberrant	  processing	  of	  V(D)J	   joins	   in	   the	  
absence	  of	  ATM,	  resulting	  in	  deletion	  of	  the	  region	  recognized	  by	  the	  probe	  (Lobrich	  and	  Jeggo,	  
2005).	  Amplification	  of	  the	  JH	  region	  was	  also	  detected,	  suggesting	  that	  the	   IgH	   locus	  may	  be	  
involved	   in	   oncogenic	   translocations	   in	   these	   tumors	   as	   previously	   reported	   for	   C-­‐NHEJ/p53-­‐
deficient	  pro-­‐B	  cell	  tumors	  (Gao	  et	  al.,	  2000;	  Zhu	  et	  al.,	  2002)	  (Figure	  13).	  Tumor	  AB36,	  which	  
was	   surface	   IgM-­‐negative,	   showed	   two	   Igκ	   rearrangements	   (Figure	   15),	   and	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Figure	   13.	   Southern	   blot	   analysis	   of	   tumor	   samples	   from	   DA,	   AB,	   and	   DAB	   cohorts.	   The	  
membrane	  was	  hybridized	  with	  different	  probes	  as	   indicated	  on	  the	  left	  hand	  side.	  Top	  panel	  
shows	   distinct	   rearranged	   bands	   and	   amplification	   of	   JH	   region.	   Second	   panel	   shows	  
amplification	   of	   Cμ	   region.	   Third	   panel	   shows	   c-­‐myc	   amplification	   and	   rearrangement.	   Red	  
boxes	   indicate	  co-­‐migrating	  c-­‐myc	  and	  rearranged	  JH	  bands.	  Position	  and	  size	  of	  germline	  (gl)	  
bands	  are	   indicated.	  Diagrams	  of	   the	   IgH	  and	  c-­‐myc	   loci,	  with	  position	  of	  EcoRI	   (RI)	   sites	  and	  
probes	  used	  are	  shown	  on	  top.	  
	  
positive	  for	   intra-­‐cytoplasmic	   Ig	  staining	  (Figure	  15)	  suggesting	  that	   it	  may	  have	  arisen	  from	  a	  
more	   mature,	   antibody-­‐secreting	   cell	   type.	   Tumors	   DAB361	   and	   AB225,	   which	   also	   lacked	  
surface	  Ig	  expression,	  did	  not	  show	  Igκ	  rearrangements	  by	  Southern	  blot.	  However	  PCR	  analysis	  

































































	   77 
rearrangements	   (Figure	  16).	  This	   indicates	   that	   these	   tumors	  did	  not	  derive	   from	  pro-­‐B	   cells,	  
which	   do	   not	   undergo	   IgL	   rearrangements,	   and	   that	   they	   likely	   deleted	   the	   Igκ	   locus	   during	  
receptor	  editing	  (Wang	  et	  al.,	  2008).	  	  
	  
Figure	  14.	  Southern	  blot	  analysis	  of	  tumor	  samples	  from	  all	  three	  cohorts.	  The	  membrane	  was	  
hybridized	  with	  Jκ	  probe.	  Position	  and	  size	  of	  germline	  (gl)	  bands	  are	  indicated.	  Diagrams	  of	  the	  
Jκ	  locus,	  with	  position	  of	  HindIII	  (H3)	  sites	  and	  probes	  used	  are	  shown	  on	  top.	  
	  
To	  confirm	  that	  the	  tumors	  arose	  from	  cells	  that	  had	  not	  undergone	  CSR,	  the	  status	  of	  
the	  Sμ	  switch	  region	  was	  analyzed	  by	  Southern	  blotting	  with	  a	  probe	  (Cμ	  probe)	  that	  recognizes	  
a	   fragment	  between	  Sμ	  and	  Cμ,	  which	   is	  not	  altered	  by	  V(D)J	   recombination	  (Figure	  13).	  This	  
probe	  would	   detect	   a	   rearranged	  band	   if	   the	   cell	   of	   origin	   of	   the	   tumor	   had	  undergone	  CSR	  
between	  Sμ	  and	  downstream	  S	  regions.	  All	  but	  two	  B	  cell	  lymphoma	  samples	  carried	  germ-­‐line	  
Igk!
Jk probe!
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unrearranged	  Cμ	  bands,	  suggesting	  that	  they	  derived	  from	  naïve	  mature	  B	  cells	  (Figure	  13).	  We	  
also	  performed	  sequencing	  of	  the	  JH	  intronic	  region	  and	  revealed	  that	  none	  of	  the	  B220+IgM+	  
tumors	   harbored	   mutations	   in	   this	   region,	   indicating	   that	   they	   had	   not	   undergone	   somatic	  
hypermutation	   (Figure	   17).	   Taken	   together,	   these	   findings	   suggest	   that	   ATM-­‐deficient	   B	   cell	  
tumors	  arose	   from	  naïve	  mature	  B	   cells	   in	   the	  periphery,	  which	  did	  not	  experience	  antigenic	  
challenge.	  
Figure	  15.	  Immunohistochemistry	  analysis	  of	  AB36	  gut	  mass	  tissue	  section.	  Left	  panel	  shows	  a	  
tissue	  section	  stained	  with	  hematoxylin	  and	  eosin.	  Right	  panel	  shows	  a	   tissue	  section	  stained	  
with	  anti-­‐B220	  antibodies.	  	  
	  
	  
Figure	  16.	  Sequencing	  results	  of	  PCR	  products	  in	  DAB361	  and	  AB225	  tumor	  samples.	  The	  blue	  
region	  represents	  Vλ	  genes.	  The	  green	  region	  represents	  Jλ	  genes.	  The	  red	  letters	  represent	  the	  
junction	  associated	  with	  recombination.	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Figure	  17.	   Somatic	   hypermutation	   analysis	   in	   a	   subset	  of	   tumors.	  Diagram	  of	   the	  V,	  D,	   and	   J	  
gene	  segments	  and	  the	  positions	  of	  primers	  are	  shown	   in	   top	  panel.	  Results	  of	   the	  assay	  are	  
shown	   in	   the	   bottom	   panel.	   Tumor	   samples	   are	   indicated	   in	   the	   first	   column.	   Forward	   and	  
reverse	   primer	   that	   yielded	   PCR	   amplicons	   are	   indicated	   in	   second	   and	   third	   column,	  
respectively.	  The	  utilization	  of	  J	  segment	  is	  shown	  in	  the	  forth	  column.	  Level	  of	  mutation	  (MUT)	  
is	  indicated.	  Mouse	  strain	  alignment	  is	  indicated	  in	  the	  eighth	  column.	  










DAB361! J558! JH4int! JH3! 1900! 1466! NO! B6!
DAB494! J558! JH4E! JH2! 1150! 1102! NO! 129!
DAB494! 7183! JH4E! JH2! 1300! 875! NO! 129!
DAB601! J558! JH4E! JH1! 1400! 1400! NO! 129!
AB67! J558! JH4int! JH4! 1350! 1132! NO! 129!
DA64! J558! JH4E! JH1! 1400! 1312! NO! 129!
DA107! J558! JH4int! JH1! 1400! 1000! NO! 129!
DA360! J558! JH4int! JH4! 1350! 1138! NO! 129!
DA403! J558! JH4int! JH4! 1350! 1113! NO! 129!
AB143! J606! JH4int! JH4! 1350! 1112! NO! 129!
DA607! 7183! JH4E! JH2! 1300! 1075! NO! 129!
JH1! JH2! JH3! JH4! iEµ!Ds!Vs!
JH4E! JH4int!
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2.3.4.	   ATM-­‐Deficient	   B	   Cell	   Lymphomas	   Harbor	   Complex	   Translocations	   Involving	  
Chromosome	  12	  And	  15.	  
One	   of	   the	   hallmark	   features	   of	   human	   and	   mouse	   B	   cell	   lymphomas	   is	   the	   clonal	  
translocation	  juxtaposing	  oncogenes,	  such	  as	  c-­‐myc,	  to	  Ig	  loci.	  To	  determine	  if	  this	  was	  also	  the	  
case	   for	   B	   cell	   lymphomas	   in	   our	   mouse	   cohorts,	   Southern	   blot	   analysis	   was	   performed	   to	  
examine	   the	   c-­‐myc	   locus	  with	   a	   probe	   downstream	   of	   c-­‐myc	   exon3	   (3’Myc)	   (Figure	   13).	  We	  
detected	   c-­‐myc	   amplification	   in	   all	   samples	   analyzed	   except	   DAB473	   (see	   below)	   and	   AB36,	  
which	  may	  have	  arisen	  from	  a	  different	  mechanism	  (Figure	  13).	  In	  all	  but	  one	  DAB	  samples,	  the	  
c-­‐myc	   locus	   was	   also	   rearranged	   (Figure	   13).	   To	   verify	   c-­‐myc	   overexpression,	   we	   performed	  
Northern	   blot	   analysis	   on	   a	   subset	   of	   tumor	   samples,	   which	   showed	   high	   levels	   of	   c-­‐myc	  
transcripts	  in	  all	  cases	  (Table	  8-­‐10).	  
Of	  note,	  Southern	  blot	  analysis	  showed	  that,	   in	  6	  of	   the	  tumors,	   the	  size	  of	   the	  c-­‐myc	  
fragment	  was	  the	  same	  as	  the	  size	  of	  the	  JH	  4-­‐3	  fragment,	  suggesting	  that	  these	  tumors	  contain	  
translocation	   that	   juxtaposes	   c-­‐myc	   to	   IgH.	   To	   confirm	   this	   hypothesis,	   we	   performed	  
fluorescent	   in	   situ	   hybridization	   (FISH)	   experiments	   on	   tumor	   metaphases.	   First,	   the	  
metaphases	  were	  hybridized	  with	  paint	  probes	  specific	  for	  chromosome	  12	  and	  15,	  where	  the	  
IgH	  and	  c-­‐myc	  loci	  reside,	  respectively.	  After	  image	  acquisition,	  the	  paint	  signals	  were	  stripped	  
and	   the	   metaphases	   re-­‐hybridized	   with	   BAC	   probes	   spanning	   IgH	   and	   c-­‐myc.	   Translocation	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Table	  8.	  Detailed	  analysis	  of	  B	  cells	  lymphoma	  from	  DA	  cohort.	  Fold	  amplification	  (x	  amp.)	  of	  
c-­‐myc	  gene	  in	  indicated	  in	  the	  9th	  row.	  The	  level	  of	  c-­‐myc	  mRNA	  expression	  is	  indicated	  in	  the	  
10th	   row.	   Translocation	   breakpoint	   on	   chromosome	   12	   is	   indicated	   in	   the	   12th	   row.	  
Translocation	   breakpoint	   on	   chromosome	   15	   is	   indicated	   in	   the	   13th	   row.	   The	   number	   of	  
homology	  (hom)	  is	  indicated	  in	  samples	  with	  translocation	  junction	  derived	  from	  sequencing.	  	  
	  
Mouse	  ID	   DA64	   DA107	   DA360	   DA403	   DA607	  
Age	  (days)	   95	   103	   96	   135	   90	  
Surface	  
Marker	  
B220+	  IgM+	  IgK+	   B220+	  IgM+	  IgK+	   B220+	  IgM+	  IgK+	   B220+	  IgM+	  IgK+	   B220+	  IgM+	  IgK+	  
c-­‐myc	  allele	   DJ/DJ	   DJ/WT	   DJ/DJ	   DJ/DJ	   DJ/DJ	  
JH	   Rearr.	  Amplified	   Rearr.	  Not	  amp.	   Rearr.	  Amplified	   Rearr.	  Amplified	   Rearr.	  Amplified	  
Cμ	   GL	  Amplified	   GL	  Amplified	   GL	  Amplified	   GL	  Amplified	   GL	  Amplified	  
Iμ	   GL	  Amplified	   GL	  Amplified	   GL	  Amplified	   GL	  Amplified	   GL	  Amplified	  
Jκ	   Rearr.	   Rearr.	   Rearr.	   Rearr.	   Rearr.	  








GL	  Amplified	  14x	  
amp.	  
c-­‐myc	  exp.	   NA	   2.6x	   NA	   11.8x	  amp.	   NA	  
Cytogenetics	   t(12;15)	  with	  




3'IgH	  and	  O21	  
(no	  D14)	  
t(12;15)	  with	  3'IgH	  
and	  O21	  (no	  D14)	  
t(12;15;14)	  (AMP	  
3'IgH,	  AMP	  D14)	  
t(12;8)	  no	  other	  











1	  normal	  12,	  1	  
normal	  15,	  	  
(AMP	  3'IgH,	  AMP	  
D14)	  
	  (AMP	  C10,	  AMP	  









deletion	  DJb	  to	  
224kb	  DN	  Myc	  
1	  normal	  12,	  2	  
normal	  15	  
1	  normal	  12,	  1	  
normal	  15	  
1	  normal	  12,	  1	  
normal	  15	  
1	  normal	  12,	  1	  
normal	  15	  
	  	   	  	  
Chr12	  Bpt	   214bp	  DN	  JH3	   -­‐	   248bp	  DN	  JH2	   -­‐	   -­‐	  
Chr15	  Bpt	   114kb	  DN	  c-­‐myc	   est.	  10kb	  DN	  	  
c-­‐myc	  
140kb	  DN	  c-­‐myc	   est.	  >100kb	  DN	  
c-­‐myc	  
10-­‐100kb	  DN	  	  
c-­‐myc	  2bp	  hom	   no	  hom	  
Translocation	  
Allele	  
Not	  rearr.	  DJb	   Aberrant	  rearr.	  
DJb	  




Downstream	  is	  abbreviated	  as	  DN.	  	  
Germline	  is	  abbreviated	  as	  GL.	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Table	  9.	  Detailed	  analysis	  of	  B	  cells	  lymphoma	  from	  AB	  cohort.	  Fold	  amplification	  (x	  amp.)	  of	  
c-­‐myc	  gene	  in	  indicated	  in	  the	  8th	  row.	   	  The	  level	  of	  c-­‐myc	  mRNA	  expression	  is	  indicated	  in	  the	  
9th	  row.	  The	  estimated	  translocation	  breakpoint	  on	  chromosome	  15	  is	  indicated	  in	  the	  11th	  row.	  	  
	  
Mouse	  ID	   AB67	   AB36	   AB143	   AB225	  
Age	  (days)	   104	   297	   116	   84	  
Surface	  
Marker	  
B220+	  IgM+	   B220-­‐	  pan-­‐Ig+	   B220+	  IgM+	  IgK+	   B220+	  IgM-­‐	  IgL-­‐	  
JH	   Rearr.	  Amplified	   Deleted	   Rearr.	  Amplified	   Rearr.	  Amplified	  
Cμ	   GL	  Amplified	   GL	  Not	  Amplified	   GL	  Amplified	   GL	  Amplified	  
Iμ	   GL	  Amplified	   Deleted	   GL	  Amplified	   GL	  Amplified	  
Jκ	   Rearr.	   Rearr.	   Rearr.	   Deleted	  
c-­‐myc	   GL	  Amplified	  9.3x	  amp.	   GL	  Not	  Amplified	   GL	  Amplified	  8.5x	  amp.	   GL	  Amplified	  5.6x	  amp.	  
c-­‐myc	  exp.	   9x	   NA	   9.8x	   NA	  
Chr12	  Bpt	   -­‐	   -­‐	   -­‐	   -­‐	  
Chr15	  Bpt	   est.	  100kb	  DN	  c-­‐myc	   -­‐	   est.	  >100kb	  DN	  c-­‐myc	   10-­‐100kb	  DN	  c-­‐myc	  
Cytogenetics	   t(12;15)	  with	  3'IgH	  and	  
O21	  
	  








AMP	  3'IgH	  and	  D14	  on	  
unknown	  chr.	  
	  




1	  normal	  12,	  2	  normal	  
15	  
	  
	   1	  normal	  12,	  1	  
normal	  15	  
	   	  
Downstream	  is	  abbreviated	  as	  DN.	  	  
Germline	  is	  abbreviated	  as	  GL.	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Table	  10.	  Detailed	  analysis	  of	  B	  cells	  lymphoma	  from	  DAB	  cohort.	  Fold	  amplification	  (x	  amp.)	  
of	  c-­‐myc	  gene	  in	  indicated	  in	  the	  9th	  row.	  The	  level	  of	  c-­‐myc	  mRNA	  expression	  is	  indicated	  in	  the	  
10th	   row.	   Translocation	   breakpoint	   on	   chromosome	   12	   is	   indicated	   in	   the	   11th	   row.	  
Translocation	   breakpoint	   on	   chromosome	   15	   is	   indicated	   in	   the	   12th	   row.	   The	   number	   of	  




DAB277	   DAB361	   DAB473	   DAB494	   DAB496	   DAB538	   DAB601	  
Age	  
(days)	  



















DJ/WT	   DJ/WT	   DJ/DJ	   DJ/WT	   DJ/WT	   DJ/WT	   DJ/WT	  




































Jκ	   Rearr.	   Rearr.	   Rearr.	   Rearr.	   Rearr.	   Rearr.	   Rearr.	  
















NA	   NA	   4.3x	   7.1x	   NA	   NA	   8.7x	  
Chr12	  
Bpt	  















5.5kb	  DN	  of	  
c-­‐myc	  
99bp	  DN	  of	  
c-­‐myc	  
4kb	  DN	  of	  c-­‐
myc	  
2.8kb	  DN	  of	  
c-­‐myc	  
1.1kb	  DN	  of	  
c-­‐myc	  
4kb	  DN	  of	  c-­‐
myc	  


















1	  normal	  12,	  
2	  normal	  15	  
1	  normal	  12,	  
2	  normal	  15	  




1	  normal	  12,	  
2	  normal	  15	  
	   1	  normal	  12,	  
2	  normal	  15	  
	   	   	   1	  normal	  12,	  
1	  normal	  15	  
















Downstream	  is	  abbreviated	  as	  DN.	  	  
Germline	  is	  abbreviated	  as	  GL.	  	  
Rearranged	  allele	  is	  indicated	  as	  Rearr.	  




Figure	  18.	  FISH	  analysis	  on	  metaphases	  from	  DAB601	  and	  DA64	  tumor	  samples.	  Details	  of	  12;15	  
complicons	  (C),	  12;15	  translocation	  with	  no	  amplification	  t(12;15),	  and	  normal	  chromosome	  12	  
(n12)	   and	   15	   (n15)	   are	   shown.	   Probes	   used	   are	   indicated.	   The	   diagrams	   on	   top	   represent	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In	   line	   with	   Southern	   blot	   results,	   complex	   translocations	   with	   gene	   amplification	  
(complicons)	  were	  detected	   in	  all	   tumors	  analyzed,	   similarly	   to	  what	  previously	  described	   for	  
pro-­‐B	  cell	  tumors	  developing	  in	  C-­‐NHEJ/p53-­‐deficient	  mice	  (Difilippantonio	  et	  al.,	  2002;	  Zhu	  et	  
al.,	   2002).	   We	   identified	   two	   types	   of	   complicons,	   that	   we	   refer	   to	   as	   15-­‐based	   (retain	   the	  
centromeric	   portion	   of	   chromosome	   15)	   and	   12-­‐based	   (retain	   the	   centromeric	   portion	   of	  
chromosome	  12)	  complicons	  (Figure	  18).	  Both	  types	  of	  complicons	  harbor	  amplification	  of	  IgH	  
and	  c-­‐myc	  and	  were	  present	   in	  all	   three	  cohorts.	   In	   tumors	  where	  a	  15-­‐based	  complicon	  was	  
present,	   a	   T(12;15)	   translocation	   juxtaposing	   the	  3’	   region	  of	   IgH	   to	   chromosome	  15	   regions	  
downstream	  of	  c-­‐myc	  was	  also	  detected,	   in	  addition	   to	  one	  normal	  chromosome	  12	  and	  one	  
normal	  chromosome	  15.	  The	  T(12;15)	  translocation	  was	  not	  detected	  in	  tumors	  with	  12-­‐based	  
complicon,	  which	  instead	  carried	  one	  normal	  chromosome	  12	  and	  two	  normal	  chromosome	  15.	  
These	   two	   types	   of	   complicon	   were	   previously	   reported	   in	   pro-­‐B	   cell	   lymphomas	  
(Difilippantonio	   et	   al.,	   2002;	   Zhu	   et	   al.,	   2002),	   suggesting	   that	   both	   pro-­‐B	   and	  mature	   B	   cell	  
lymphomas	  may	  undergo	  similar	  transformation	  events	  that	  lead	  to	  lymphoma	  development.	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2.3.5.	   Translocation	   Breakpoints	   Downstream	   Of	   c-­‐myc	   Lead	   To	   Gene	   Amplification	   Via	  
Breakage-­‐Fusion-­‐Bridge	  Mechanism	  	  
The	  c-­‐myc	  gene	  amplification	  in	  C-­‐NHEJ/p53-­‐deficient	  pro	  B	  cell	  lymphomas	  is	  proposed	  
to	   arise	   via	   a	   breakage-­‐fusion-­‐bridge	   mechanism	   that	   require	   the	   formation	   of	   dicentrics	  
resulting	  from	  the	  fusion	  of	  RAG-­‐initiated	  IgH	  DSBs	  to	  sequences	  downstream	  of	  c-­‐myc (Zhu	  et	  
al.,	  2002). To	  test	  if	  this	  was	  also	  the	  case	  in	  ATM-­‐deficient	  B	  cell	  lymphomas,	  detailed	  analysis	  
of	  the	  c-­‐myc	  locus	  with	  probes	  upstream	  of	  c-­‐myc	  exon	  1	  (MycA),	  in	  c-­‐myc	  intron	  1	  (MycD)	  and	  
downstream	  of	  c-­‐myc	  exon	  3	   (3’Myc)	  was	  performed.	   In	  some	  tumors	   (DA64,	  DA107,	  DA360,	  
AB67,	  AB143,	  and	  AB225),	  lack	  of	  rearrangement	  yet	  amplification	  of	  c-­‐myc	  was	  detected	  with	  
all	  three	  probes,	  suggesting	  the	  translocation	  junctions	  lay	  outside	  of	  the	  20kb	  EcoRI	  fragment	  
(Figure	  19).	  Other	  tumors	  (DAB277,	  DAB361,	  DAB494,	  DAB496,	  DAB538,	  and	  DAB601)	  showed	  
both	  rearrangement	  and	  c-­‐myc	  amplification	  with	  MycD	  and/or	  3’Myc	  probes,	  suggesting	  that	  
breakpoints	  were	  within	  the	  c-­‐myc	  locus	  (Figure	  19).	  	  
To	   confirm	   that	   the	   translocation	   junctions	   lay	   downstream	   of	   the	   c-­‐myc	   locus,	   we	  
employed	  comparative	  genomic	  hybridization	  (CGH)	  to	  examine	  the	  level	  of	  amplification	  at	  c-­‐
myc	  and	  IgH	  loci	  in	  a	  few	  samples	  from	  each	  cohort.	  This	  analysis	  showed	  that	  amplification	  in	  
the	  IgH	  locus	  began	  downstream	  of	  D	  gene	  segments	  in	  all	  samples	  analyzed	  (DAB494,	  DAB496,	  
DAB601,	   and	   DA64)	   whereas	   amplification	   on	   chromosome	   15	   started	   either	   not	   far	  
downstream	  of	  c-­‐myc	  (DAB494,	  DAB496,	  DAB601)	  or	  in	  the	  Pvt1	  region,	  100kb	  downstream	  of	  
c-­‐myc	  (DA64),	  according	  to	  the	  results	  of	  the	  Southern	  blot	  data	  (Figure	  20).	  These	  data	  helped	  
us	   define	   the	   region	   where	   translocation	   breakpoints	   were	   located.	   Translocation	   junctions	  
from	  these	  and	  four	  more	  tumors	  were	  then	  cloned	  by	  PCR	  approach	  and	  sequenced.	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Figure	  19.	  Detailed	  Southern	  blot	  analysis	  of	  the	  c-­‐myc	   locus.	  The	  membrane	  was	  sequentially	  
hybridized	  with	  three	  probes	  spanning	  c-­‐myc	  represented	  in	  the	  diagram	  on	  top	  and	  indicated	  
on	  the	  left	  hand	  side.	  Position	  and	  size	  of	  germline	  (gl)	  bands	  are	  indicated.	  Note	  that	  the	  top	  
bands	   recognized	   by	   3’Myc	   probe	   in	   tumor	   DAB538	   results	   from	   incomplete	   digestion	   of	  
genomic	  DNA	  as	  repeat	  Southern	  blots	  do	  not	  show	  such	  pattern.	  

































































Figure	   20.	   CGH	   analysis	   on	   a	   subset	   of	   tumor	   samples.	   Dotted	   lines	   represent	   the	   transition	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The	  sequencing	  results	  showed	  juxtaposition	  of	  chromosome	  12	  sequences	  between	  Eμ	  
and	   JH	   segments	   to	   chromosome	  15	   sequences	  downstream	  of	  c-­‐myc,	   ranging	   from	  99bp	   to	  
140kb	   (Figure	   21,	   Table	   8-­‐10).	   The	   orientation	   of	   all	   sequenced	   translocation	   junctions	   was	  
consistent	   with	   amplification	   of	   both	   loci	   via	   a	   breakage-­‐fusion-­‐bridge	   mechanism.	   These	  
sequencing	  results	  also	  corresponded	  with	  rearrangement	  and	  amplification	  patterns	  detected	  
in	   Southern	   blot	   analysis.	   For	   example,	   the	   lack	   of	   amplification	   in	   the	   rearranged	   c-­‐myc	  
fragment	  detected	  by	  Southern	  blot	  with	  3’Myc	  probe	   in	  DAB473	   is	  due	   to	   the	   translocation	  
breakpoint	  being	  immediately	  downstream	  of	  c-­‐myc	  exon	  3,	  therefore	  eliminating	  most	  of	  the	  
genomic	   region	   recognizable	   by	   the	   probe	   (Figure	   21,	   Table	   8-­‐10).	   Likewise,	   the	   lack	   of	  
amplified	   and	   rearranged	   fragments	   detectable	   by	   the	   JH	   4-­‐3	   probe	   in	   tumors	   DAB494	   and	  
DAB496	  is	  the	  result	  of	  translocation	  junctions	  on	  chromosome	  12	  deleting	  most	  of	  the	  region	  
recognized	  by	  the	  probe	  (Figure	  21,	  Table	  8-­‐10).	  In	  tumors	  DAB361,	  DAB473,	  and	  DAB538,	  the	  
lack	   of	   rearranged	   band	   detected	   by	   MycA	   probe	   suggests	   a	   secondary	   rearrangement	  
upstream	  of	  c-­‐myc,	  in	  addition	  to	  the	  oncogenic	  translocation	  junctions	  in	  the	  IgH	  locus.	  
It	   is	   notable	   that	   the	   five	   translocation	   junctions	   lie	   very	   close	   to	   c-­‐myc,	  a	   region	  not	  
previously	  identified	  as	  translocation	  partners	  in	  C-­‐NHEJ/p53-­‐deficient	  pro-­‐B	  tumors	  (Figure	  20,	  
label	  1-­‐5).	  Study	  of	  the	  precise	  location	  of	  these	  junctions	  indicated	  that	  all	  were	  within	  a	  few	  
hundred	  basepairs	  from	  strong	  cryptic	  RSSs,	  with	  the	  closest	  one	  overlapping	  with	  a	  cryptic	  RSS	  
with	   an	   addition	   of	   one	   nontemplated	   nucleotide	   (Table	   11).	   The	   distance	   between	   the	  
translocation	   junction	   and	   the	   cryptic	   RSS	   is	   compatible	   with	   the	   resection	   observed	   in	   the	  
absence	   of	   H2AX	   and	   53BP1;	   both	   are	   ATM	   substrates	   (Helmink	   and	   Sleckman,	   2012),	   and	  
presumably	   would	   be	   the	   case	   in	   ATM	   deficiency.	   Similarly,	   the	   two	   translocation	   junctions	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located	   far	  downstream	  of	  c-­‐myc	   in	  Pvt1	  also	  mapped	   in	   the	  vicinity	  of	  cryptic-­‐RSSs	  although	  
the	   distance	   between	   the	   translocation	   junctions	   and	   cryptic-­‐RSSs	   was	   further	   than	   those	  
located	  close	  to	  c-­‐myc	  (Table	  11).	  	  
Figure	  21.	  Schematic	  of	  translocation	  breakpoints	  in	  tumor	  samples.	  Data	  are	  either	  from	  direct	  
sequencing	  of	  junctions	  (shown	  as	  numbers)	  or	  estimated	  (shown	  as	  symbols)	  from	  Southern	  
blot	  analysis.	  See	  text	  for	  details.	  
	  
To	  estimate	  translocation	  breakpoint	  from	  the	  remaining	  tumors	  we	  used	  Southern	  blot	  
analysis	   with	   various	   digests	   and	   probes.	   SacI	   digestion	   of	   tumor	   DA107	   DNA	   showed	   a	  
rearranged	  band	  recognized	  by	  3’Myc	  probe,	  suggesting	  the	  translocation	  lay	  within	  this	  10kb	  
region	  downstream	  of	  c-­‐myc	  (Figure	  21,	  Figure	  22).	  Examination	  of	  the	  Pvt1	  locus,	  which	  from	  
our	  data	  and	  previous	  reports	  (Zhu	  et	  al.,	  2002)	  is	  frequently	  involved	  in	  complicon	  formation	  
with	   IgH,	  allowed	  us	  to	  estimate	  that	  translocation	  breakpoints	   for	  DA403,	  AB67,	  AB143,	  and	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that	  the	  translocation	  breakpoint	   located	  in	  the	  97kb	  region	  downstream	  of	  c-­‐myc	  (Figure	  21,	  
Figure	  23).	  
	  
Table	  11.	  Mapping	  of	  translocation	  junctions	  from	  a	  subset	  of	  DA	  and	  DAB	  tumors	  in	  relation	  
to	  cryptic	  RSSs	  near	  translocation	  breakpoint.	  Coordinates	  (mm9)	  of	  translocation	  breakpoint	  
downstream	  of	  c-­‐myc	  on	  chromosome	  15	  is	  indicated	  in	  the	  2nd	  column.	  RIC	  scores	  indicate	  the	  
functionality	  of	  cryptic	  RSSs,	  which	  ranges	  from	  -­‐1000	  (very	  bad)	  to	  0	  (very	  good)	  (Cowell	  et	  al.,	  
2002).	   The	   distance	   (in	   basepair	   units)	   between	   cryptic	   RSS	   cut	   site	   and	   the	   observed	  




Figure	   22.	   Southern	   blot	   analysis	   of	   DA107	   showing	   translocation	   close	   to	   the	   c-­‐myc	   locus.	  
Position	  and	  size	  of	  germline	  (gl)	  band	  are	  indicted.	  Diagram	  of	  the	  c-­‐myc	  locus	  with	  position	  of	  
SacI	  sites	  and	  the	  probe	  used	  is	  shown	  on	  top.	  	  
	   	  
coordinate Strand Type RIC1Score Start End Strand Distance
DAB473 61,822,015 A 231RSS A56.26 61,822,577 61,822,615 A 600
DAB361 61,827,453 A 121RSS A34.49 61,827,543 61,827,570 A 117
DAB494 61,825,906 A 231RSS A54.68 61,825,932 61,825,970 A 64
DAB601 61,825,971 A 231RSS A54.68 61,825,932 61,825,970 A 1*
DAB538 61,823,031 A 231RSS A55.64 61,823,369 61,823,407 + 338
DA64 61,936,069 A 231RSS A51.05 61,936,660 61,936,698 + 591
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Figure	  23.	  Southern	  blot	  of	  genomic	  DNA	  from	  DA	  and	  AB	  tumors	  showing	  amplification	  in	  Pvt1	  
in	  AB143,	  DAB277,	  DA403,	   and	  DA607	   samples.	  AB67	   showed	  amplification	  of	   germline	  Pvt1	  
fragment	  with	  SacI	  digestion	  but	  a	  rearranged	  and	  amplified	  EcoRI	  band	  with	  the	  same	  probe.	  
DNA	  from	  WT	  mice	  (129Sve)	  was	  used	  as	  a	  control	  for	  normal	  Pvt1	  level.	  DNA	  from	  DA64	  and	  
DA107	   tumors	   was	   used	   as	   a	   positive	   control	   (+)	   or	   negative	   control	   (-­‐)	   for	   amplification,	  
respectively.	  Diagram	  of	  c-­‐myc	  and	  Pvt1	  locus	  showing	  EcoRI	  and	  SacI	  sites	  and	  probes	  used	  are	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2.3.6.	  Translocation	  In	  DA	  And	  DAB	  B	  Cell	  Lymphoma	  Do	  Not	  Involve	  RAG	  Target	  Sequence	  	  
Sequencing	  of	  translocation	  breakpoints	  and	  Southern	  blot	  analysis	  suggested	  that	  the	  
RAG	   target	   sequence	   inserted	   in	   intron	   1	   of	   c-­‐myc	   was	   not	   the	   main	   driver	   of	   oncogenic	  
translocations	  in	  DA	  and	  DAB	  tumors.	  Given	  that	  six	  out	  of	  seven	  DAB	  mice	  and	  mouse	  DA107	  
were	   heterozygous	   for	   the	   c-­‐mycDJβ	   allele,	   we	   sought	   to	   determine	   which	   c-­‐myc	   allele	   was	  
involved	   in	  translocations	   in	  these	  tumors.	  To	  this	  end,	  Southern	  blot	  analysis	  was	  performed	  
on	  genomic	  DNA	  digested	  with	  SacI	  using	  the	  MycD	  probe,	  which	  hybridizes	  in	  c-­‐myc	   intron	  1	  
upstream	   of	   the	   inserted	   DJβ	   RAG	   target	   sequence	   (Figure	   24).	   This	   strategy	   allows	   us	   to	  
distinguish	   between	   wild-­‐type	   c-­‐myc	   allele,	   unrearranged	   c-­‐mycDJβ	   allele,	   and	   rearranged	   c-­‐
mycDJβ	   allele.	   Based	   on	   our	   previous	   characterization	   of	   these	   tumors,	   we	   are	   able	   to	   link	  
amplification	   of	   the	   region	   recognized	   by	   MycD	   probe	   with	   the	   allele	   harboring	   the	  
translocation.	  	  
Figure	  24. Map	  of	  c-­‐myc	  locus	  showing	  Southern	  blot	  strategy	  with	  SacI	  sites	  and	  location	  of	  the	  
MycD	  probe.	  
	  
The	  results	  showed	  that	  in	  all	  tumors	  for	  which	  we	  could	  get	  unequivocal	  results	  (6	  out	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in	   line	  with	  Southern	  blot	  data	   indicating	  secondary	  breakpoints	  between	  MycA	  and	  MycD	  or	  
3’Myc	   probes.	  With	   the	   same	   approach	  we	  were	   also	   able	   to	   analyze	   the	   status	   of	   the	   DJb	  
cassette	  on	  the	  allele	  involved	  in	  translocation	  in	  the	  six	  c-­‐mycDJβ	  homozygous	  tumors	  (five	  out	  
of	   six	  DA,	   see	   table	  1,	  and	  DAB473):	   two	  of	   them	  harbored	   translocation	  on	  unrearranged	  c-­‐
mycDJβ	   alleles	   (DA64	   and	   DA360)	   whereas	   translocations	   in	   the	   other	   four	   tumors	   were	  
associated	  with	  aberrant	   rearrangements	  of	   the	  genomic	  region	  containing	   the	  DJβ	  sequence	  
(Figure	  25).	  We	  conclude	  that	  even	  though	  the	  translocation	  does	  not	  directly	  involve	  the	  DJβ	  
cassette,	   the	   presence	   of	   this	   sequence	  within	   c-­‐myc	   renders	   the	   locus	  more	   susceptible	   to	  
translocation.	  	  
	  
Figure	  25.	  Southern	  blot	  of	  genomic	  DNA	  from	  DA	  and	  DAB	  tumors.	  DNA	  from	  spleen	  (SPL)	  or	  
thymus	   (THY)	  of	  WT	  mice	   (129Sve)	   and	  mice	  homozygous	   for	   c-­‐mycDJβ	   allele	   (DJβ/DJβ)	  were	  
used	  as	  controls.	  Running	  position	  of	  WT	  c-­‐myc,	  unrearranged	  c-­‐mycDJB	  and	  rearranged	  c-­‐mycDJB	  
are	  indicated.	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2.4.	  Discussion	  
2.4.1.	  Mouse	  Models	  That	  Spontaneously	  Develop	  IgM+	  B	  Cell	  Lymphomas	  In	  The	  Absence	  Of	  
ATM.	  
	   	  	  ATM-­‐deficient	   humans	   are	   predisposed	   to	   both	   T	   and	   B	   cell	   lymphomas	   but	   ATM-­‐
deficient	  mice	  develop	  only	  thymic	  lymphomas	  (Ambrose	  and	  Gatti,	  2013).	  Studies	  of	  recurrent	  
translocations	  in	  ATM-­‐deficient	  thymic	  lymphomas	  revealed	  that	  they	  involved	  the	  TCRδ	  locus,	  
a	   finding	   quite	   unexpected	   at	   the	   time	   as	   it	   was	   generally	   thought	   that	   such	   translocations	  
would	  involve	  the	  TCRα locus	  (Zha	  et	  al.,	  2010).	  Subsequently,	  TCRδ	   locus	  translocations	  were	  
found	   to	   be	   the	  most	   common	  RAG-­‐initiated	   oncogenic	   translocations	   in	   human	   T-­‐cell	   acute	  
lymphoblastic	   leukemias	   (T-­‐ALLs),	  which	   is	  also	   the	  most	   frequent	   tumor	   type	   in	  pediatric	  AT	  
patients	  (Larmonie	  et	  al.,	  2013;	  Taylor	  et	  al.,	  1996).	  To	  gain	  potential	  insights	  into	  the	  roles	  of	  
ATM	  in	  suppressing	  B	  cell	  lymphoma,	  we	  generated	  three	  different	  mouse	  models	  that	  develop	  
similar	  peripheral	  B	  cell	  lymphomas	  in	  the	  context	  of	  ATM	  deficiency.	  The	  DA	  and	  AB	  model	  are	  
based,	  respectively,	  on	  the	  introduction	  of	  either	  a	  Tcr	  DJβ	  V(D)J	  recombination	  cassette	  into	  c-­‐
myc	   intron	  1	  (Ranganath	  et	  al.,	  2008)	  or	  an	  Eµ-­‐bcl-­‐2	   transgene	  (Strasser	  et	  al.,	  1994)	   into	  the	  
ATM-­‐deficient	   background	   (Borghesani	   et	   al.,	   2000).	   B	   cell	   lymphomas	   arise,	   respectively,	   in	  
approximately	  25%	  of	  the	  DA	  and	  50%	  of	  the	  AB	  mice.	  The	  DAB	  model	  genetically	  combines	  the	  
DA	   and	   AB	   models	   and	   develops	   peripheral	   B	   cell	   lymphomas	   rapidly	   and	   with	   100%	  
penetrance.	  Nearly	  all	  of	  the	  spontaneous	  clonal	  B	  cell	  malignancies	  that	  arose	  in	  each	  of	  these	  
models	   were	   IgM+	   and	   harbored	   clonal	   translocations	   from	   the	   IgH	   JH	   region	   to	   sequences	  
downstream	   of	   c-­‐myc	   to	   form	   dicentric	   translocations	   that	   ultimately	   led	   to	   the	   IgH/c-­‐myc	  
amplification	  in	  the	  context	  of	  complicons.	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2.4.2.	   Recurrent	   Oncogenic	   Translocations	   And	   Amplifications	   In	   ATM-­‐Deficient	   B	   Cell	  
Lymphomas.	   	  
	   It	  is	  striking	  that	  nearly	  all	  DA,	  AB,	  and	  DAB	  peripheral	  B	  cells	  lymphomas	  were	  IgM+	  and	  
shared	  a	  common	  oncogenic	  translocation	  that	  joined	  sequences	  within	  or	  very	  near	  the	  IgH	  JH	  
region	  to	  sequences	  downstream	  of	  c-­‐myc	   to	  create	  dicentrics	  with	  chromosome	  12-­‐based	  or	  
chromosome	   15-­‐based	   complicons.	   These	   translocations	   provide	   the	   basis	   for	   c-­‐myc	   gene	  
amplifications	   via	   the	  breakage-­‐fusion-­‐bridge-­‐based	  mechanism.	   The	   general	   structure	  of	   the	  
IgH/c-­‐myc	   complicons	   and	   the	   presence	   or	   absence	   of	   other	   associated	   translocations	   (e.g.	  
presence	  of	  a	  T(12;15)	  in	  tumors	  with	  a	  chromosome	  15-­‐based	  complicon	  but	  not	  those	  with	  a	  
chromosome	   12-­‐based	   complicon)	   in	   these	   tumors	   were	   strikingly	   similar	   to	   the	   types	   and	  
patterns	  of	  chromosomal	  aberrations	  found	  in	  RAG-­‐dependent	  pro-­‐B	   lymphomas	  that	  arise	   in	  
C-­‐NHEJ/p53-­‐deficient	  mice	   (Zhu	   et	   al.,	   2002;	   Difilippantonio	   et	   al.,	   2002).	   In	   this	   regard,	   the	  
clustering	  of	  the	  IgH	  translocation	  breakpoints	  in	  and	  around	  a	  small	  JH	  region	  in	  both	  the	  ATM-­‐
deficient	  and	   the	  C-­‐NHEJ/p53-­‐deficient	  background	   indicates	   that	   the	   IgH	   breaks	   that	   initiate	  
formation	  of	  the	  complicons	  of	  ATM-­‐deficient	  IgM+	  B	  cell	  lymphomas	  are	  RAG-­‐initiated.	  	  	  
	   The	   question	   of	   how	  RAG-­‐initiated	   chromosomal	   aberrations	   generated	   in	   pro-­‐B	   cells	  
leads	  to	  oncogenic	  translocations	  recurrently	  found	  in	  certain	  types	  of	  human	  peripheral	  B	  cell	  
lymphomas	  has	   long	  been	  discussed.	  Based	  on	  striking	  similarities	  between	  the	  complicons	   in	  
ATM-­‐deficient	  mouse	  peripheral	   B	   cell	   lymphomas	   and	   those	  of	   C-­‐NHEJ/p53-­‐deficient	  mouse	  
pro-­‐B	  tumors,	  we	  suggest	  that	  the	  generation	  of	  the	  IgH/c-­‐myc	  complicons	  is	  initiated	  in	  ATM-­‐
deficient	  progenitor	  B	  cells.	  How	  then	  do	  we	  explain	  why	  C-­‐NHEJ/p53-­‐deficient	  mice	  succumb	  
to	   pro-­‐B	   lymphomas	   but	   the	   susceptible	   ATM-­‐deficient	   mice	   succumb	   to	   peripheral	   B	   cell	  
	   97 
lymphomas?	  In	  this	  regard,	  C-­‐NHEJ-­‐deficiency	  abrogates	  B	  cell	  development	  at	  the	  pro-­‐B	  stage	  
due	  to	  a	  complete	  block	  in	  V(D)J	  recombination	  (Gostissa	  et	  al.,	  2011).	  Thus,	  in	  the	  absence	  of	  
both	   C-­‐NHEJ	   and	   p53,	   pro-­‐B	   cells	   replicate	   persistent	   RAG-­‐initiated	   DSBs	   due	   to	   the	   G1	  
checkpoint	  defect,	  cycling	  them	  into	  dicentrics,	  complicons,	  and	  ultimately	  leading	  to	  pro-­‐B	  cell	  
lymphomas	  (Zhu	  et	  al.,	  2002).	  Like	  dual	  C-­‐NHEJ/p53-­‐defciency,	  ATM-­‐deficiency	  alone	  results	  in	  
both	   V(D)J	   recombination	   joining	   defects	   and	   impaired	   p53	   activation	   that	   causes	   G1	  
checkpoint	   defects	   (Helmink	   and	   Sleckman,	   2012).	   However,	   unlike	   C-­‐NHEJ	   deficiency,	   ATM	  
deficiency	  does	  not	  completely	  block	  V(D)J	  joining	  (Barlow	  et	  al.,	  1996;	  Elson	  et	  al.,	  1996;	  Xu	  et	  
al.,	   1996).	   Thus,	   we	   propose	   that	   some	   ATM-­‐deficient	   pro-­‐B	   cells	   generate	   dicentric	  
chromosomes	   from	   replication	   of	   persistent	   RAG-­‐initiated	   DSBs	   on	   one	   IgH	   allele	   but	   that	  
productive	   V(D)J	   rearrangements	   on	   the	   other	   allele	   allows	   B	   cell	   harboring	   dicentrics,	   and	  
potentially	  their	  downstream	  translocation/amplification	  products,	  to	  survive	  to	  the	  IgM+	  B	  cell	  
stage	  where	  they	  contribute	  to	  B	  cell	  lymphomagenesis.	  
	   We	  hypothesized	  that	  B	  cell	  lymphomas	  in	  ATM-­‐deficient	  background	  can	  be	  promoted	  
by	   increased	  DSBs	   level	   in	  oncogenes	   such	  as	  c-­‐myc	   or	  enhanced	   survival	  of	  ATM-­‐deficient	  B	  
cells.	  The	  AB	  B	  cell	   lymphoma	  model	  was	  based	  on	  the	  hypothesis	   that	  an	  Eµ-­‐bcl2	   transgene	  
could	  promote	  survival	  of	  ATM-­‐deficient	  developing	  or	  mature	  B	  cells	   that	  are	  eliminated	  via	  
apoptosis	   from	  contributing	  to	  B	  cell	   lymphomas.	  Based	  on	  the	  success	  of	   the	  AB	  model,	   this	  
general	  hypothesis	  appears	  validated.	  On	  the	  other	  hand,	  the	  manner	  in	  which	  the	  DJβ	  cassette	  
targeted	   into	   c-­‐myc	   promotes	   peripheral	   B	   cell	   lymphomas	   in	   DA	   or	   DAB	   ATM-­‐deficient	  
backgrounds	   is	  unlikely	  to	  result	  from	  the	  originally	  envisioned	  mechanism	  of	   increasing	  DSBs	  
and	   translocations	   within	   intron	   one	   of	   c-­‐myc.	   We	   found	   that	   all	   of	   the	   primary	   dicentric	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junctions	  on	  chromosome	  15	  that	  gave	  rise	  to	  the	  IgH/c-­‐myc	  complicons	  occurred	  downstream	  
(telomeric)	  of	  the	  c-­‐myc	  gene	  and	  did	  not	  involve	  the	  DJβ	  cassette.	  In	  this	  regard,	  when	  the	  c-­‐
mycDJβ	  mice	  were	   generated,	   the	  DJβ	  cassette	  was	   targeted	   into	   c-­‐myc	   intron	  one	   to	  provide	  
both	  transcription	  to	  target	  RAG	  and	  also	  to	  provide	  a	  potential	  break	  site	  in	  the	  first	  intron,	  a	  
region	  where	  translocation	  junctions	  to	   IgH	  often	  occur	  in	  human	  B	  cell	   lymphomas	  (Wilda	  et	  
al.,	   2004).	   However,	   our	   studies	   of	   a	   mouse	   model	   that	   develops	   B	   cell	   lymphomas	   in	  
association	  with	  recurrent	  IgH/c-­‐myc	  translocations	  revealed	  that	  all	  translocation	  junctions	  are	  
mapped	  to	  a	  region	  upstream	  of	  c-­‐myc	  promoter	  and	  not	  into	  intron	  one	  (Gostissa	  et	  al.,	  2009).	  
Currently,	  it	  seems	  likely	  that	  translocations	  into	  mouse	  c-­‐myc	  intron	  one	  may	  inactivate	  the	  c-­‐
myc	  gene	  by	  disrupting	  an	  alternative	  promoter	  located	  upstream	  of	  c-­‐myc	  exon	  2	  (Bernard	  et	  
al.,	  1983;	  Saito	  et	  al.,	  1983).	  	  	  
	   While	   we	   have	   ruled	   out	   direct	   participation	   of	   the	   DJβ	   cassette	   within	   c-­‐myc	   in	  
translocation	   junctions,	  our	   findings	  still	   implicate	  the	  cassette	  as	  a	  contributing	   factor	   to	  the	  
process.	  Thus,	  all	  (6/6)	   IgH	  translocation	  junctions	  that	  could	  unequivocally	  be	  analyzed	  in	  DA	  
or	  DAB	  mice	  that	  were	  heterozygous	  for	  the	  c-­‐mycDJβ	  allele	  involved	  sequences	  downstream	  of	  
c-­‐myc	  on	  the	  DJβ	  cassette-­‐targeted	  allele,	  a	  highly	  significant	  finding	  (p	  value	  =	  0.0143).	  In	  this	  
context,	   it	   is	  further	  notable	  that	  a	  substantial	  fraction	  of	  the	  DAB	  and	  DA	  junctions	  clustered	  
within	   a	   4kb	   region	   just	   downstream	   of	   c-­‐myc,	   a	   region	   not	   identified	   as	   having	   complicon	  
junctions	   in	   C-­‐NHEJ/p53-­‐deficient	   pro-­‐B	   tumors	   in	   which	   junctions	   occurred	   much	   further	  
downstream	   (Zhu	   et	   al.,	   2002).	   Examination	   of	   the	   precise	   location	   of	   junctions	   within	   the	  
hotspot	   downstream	   region	   just	   downstream	   of	   c-­‐myc	   indicated	   that	   all	   were	   within	   a	   few	  
hundred	  bp	  of	  a	  set	  of	  strong	  cryptic	  RSSs,	  with	  one	  actually	  joined	  within	  1bp	  of	  a	  cryptic	  RSS.	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Based	   on	   these	   observations,	   we	   hypothesize	   that	   DJβ	   cassette	   indirectly	   contributes	   to	  
downstream	   DSBs	   by	   providing	   proximal	   12/23	   RSSs	   for	   pairing	   with	   closely	   linked	   cryptic	  
downstream	  RSSs	   and,	   thereby,	   enhances	   RAG	   cutting	   at	   these	   sites	   (and	   potentially	   also	   at	  
positions	   further	   downstream).	   In	   the	   absence	   of	   ATM,	   such	   RAG-­‐initiated	   DSBs	   might	   be	  
aberrantly	   repaired	   as	   previously	   described	   (Huang	   et	   al.,	   2007;	   Bredemeyer	   et	   al.,	   2006).	   In	  
this	   regard,	   B	   cell	   lymphomas	  would	   result	   only	   from	   B	   lymphocytes	   in	  which	   DJβ	   DSBs	   are	  
resolved	  within	   the	  cassette	   (for	  example,	  by	  open	  and	  shut	   joins),	   thereby	  preserving	  c-­‐myc	  
integrity	  on	  that	  allele	  while	  partner	  DSBs	  at	  downstream	  cryptic	  RSS	  are	  not	  rejoined	  and	  could	  
lead	  to	  chromosome	  breaks	  and	  dicentrics.	  Similar	  mechanisms	  may	  also	  lead	  to	  the	  generation	  
of	  "off-­‐target"	  RAG-­‐initiated	  DSBs	  that	  contribute	  to	  T	  and	  B	  cell	  lymphomas	  in	  humans.	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3.1.	  Results	  
3.1.1.	  ATM	  Suppresses	  Genome-­‐Wide	  Translocations	  In	  Stimulated	  B	  Cells	  
Findings	   from	   the	   tumor	   cohorts	   prompted	   us	   to	   investigate	   the	   role	   of	   ATM	   in	  
suppressing	   translocations	   in	   mature	   B	   cells.	   To	   this	   end,	   we	   employed	   high-­‐throughput	  
genome-­‐wide	   translocation	   sequencing	   (HTGTS)	   to	   map	   translocation	   junctions	   in	   in	   vitro	  
stimulated	  splenic	  B	  cells	   (Chiarle	  et	  al.,	  2011).	  B	  cells	  were	   isolated	  from	  wild-­‐type	  (WT)	  and	  
ATM-­‐deficient	  mice	  harboring	  25	  consecutive	   I-­‐SceI	   recognition	   sites	   (referred	   to	  as	  25xI-­‐SceI	  
cassette)	  inserted	  into	  c-­‐myc	  intron	  1,	  in	  the	  same	  location	  as	  the	  RAG	  target	  sequence	  used	  for	  
the	   tumor	   studies.	   Upon	   expression	   of	   I-­‐SceI	   enzyme	   in	   B	   cells,	   specific	   DSBs	   are	   efficiently	  
generated	   at	   these	   sites,	   and	   can	   be	   used	   as	   anchor	   to	   capture	   genome-­‐wide	   translocations	  
(Chiarle	   et	   al.	   2011).	   We	   used	   primers	   located	   about	   100	   bp	   centromeric	   to	   the	   25xI-­‐SceI	  
cassette	  to	  detect	  translocation	  junctions	  involving	  broken	  ends	  (BEs)	  on	  the	  5’	  side	  of	  c-­‐myc	  I-­‐
SceI	  DSBs	  (‘‘5’	  BEs’’).	  Based	  on	  convention,	  translocation	  partner	  sequences	  joined	  to	  5’	  BEs	  are	  
in	   (+)	   orientation	   if	   read	   from	   the	   junction	   in	   centromere	   to	   telomere	   direction	   and	   in	   (-­‐)	  
orientation	   if	   read	   in	   the	   opposite	   direction	   (Chiarle	   et	   al.,	   2011).	   HTGTS	   libraries	   were	  
generated	  from	  WT	  and	  ATM-­‐/-­‐	  B	  cells,	  stimulated	  for	  CSR	  with	  α-­‐CD40	  and	  IL4.	  Results	  from	  3	  
independent	  samples	  per	  each	  genotype	  yielded	  comparable	  numbers	  of	  total	  junctions,	  which	  
were	  pooled	  together	  for	  analysis	  (Figure	  6A,	  6B).	  In	  our	  previous	  studies	  (Chiarle	  et	  al.,	  2011),	  
we	   found	   that	  most	  of	  HTGTS	   reads	   from	  WT	  c-­‐myc25xI-­‐SceI	  cultured	  B	   cells	  mapped	   to	  a	  2Mb	  
region	   spanning	   the	   I-­‐SceI	   breaksite	   on	   chromosome	   15,	   with	   the	   vast	   majority	   of	   them	  
corresponding	   to	   resection	  events	   of	   a	   single	   I-­‐SceI	  DSB	   rather	   than	   to	   translocations	   joining	  
two	  independent	  DSBs.	  Here,	  in	  the	  absence	  of	  ATM,	  we	  noticed	  an	  accumulation	  of	  junctions	  
on	  the	  breaksite	  chromosome	  that	  was	  even	  more	  striking	  than	  in	  WT	  cells,	  and	  spanned	  the	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whole	   length	   of	   the	   chromosome	   (Figure	   26),	   similarly	   to	   what	   previously	   reported	   in	   IR-­‐
treated,	  G1-­‐arrested	  ATM-­‐deficient	  pro-­‐B	  cell	  lines	  (Zhang	  et	  al.,	  2012).	  Moreover,	  only	  64%	  of	  
junctions	  was	  in	  the	  2Mb	  region	  around	  the	  breaksite	  in	  ATM-­‐/-­‐	  cells,	  as	  compared	  to	  78%	  in	  WT	  
cells,	  and	  correspondingly	  a	  larger	  percentage	  (36%	  vs	  22%)	  of	  junctions	  mapped	  elsewhere	  in	  
the	   genome	   (Figure	   27).	   We	   then	   determined	   how	   translocations	   distributed	   across	   the	  
genome,	  and	  found	  that	  the	  number	  of	  2	  Mb	  bins	  containing	  1,	  2,	  3,	  or	  4	  junctions,	  which	  may	  
represent	  background	  level,	  were	  similar	   in	  both	  WT	  and	  ATM-­‐deficient	  cells.	  However,	  ATM-­‐
deficient	   cells	   had	   a	   lower	   number	   of	   bins	   containing	   no	   translocation	   junction	   as	   well	   as	   a	  
higher	  number	  of	  bins	  containing	  more	  than	  4	  translocation	   junctions	  (Figure	  28),	  which	  may	  
represent	   potential	   hotspots.	   These	   results	   indicate	   that	   ATM	   suppresses	   genome-­‐wide	  
translocations	  to	  maintain	  genomic	  stability	  in	  B	  cells.	  
	  
Figure	   26.	   Distributions	   of	   genome-­‐wide	   translocation	   in	   HTGTS	   libraries	   from	   α-­‐CD40/IL4-­‐
stimulated	   (A)	   WT	   and	   (B)	   ATM-­‐deficient	   B	   cells. Each	   plot	   represents	   a	   pool	   from	   three	  
independent	  experiments.	  Genotype,	  treatment,	  and	  total	  number	  of	  junctions	  in	  each	  library	  
are	  shown	  above	  each	  plot.	  The	  bin	  size	  is	  2	  Mb.	  Clusters	  of	  translocation	  hits	  are	  represented	  
by	  color	  dots	  as	  showed	  in	  the	  square.	  
	  
WT + α-CD40/Il4 
21219$hits$
A.$








































	   103 
	  
Figure	  27.	  Comparison	  of	  numbers	  of	  translocation	  junctions	  mapped	  to	  a	  ±1Mb	  region	  around	  
I-­‐SceI	  c-­‐myc	  breaksite.	  Statistical	  analysis	  was	  done	  with	  independent	  repeats	  from	  the	  pooled	  
libraries	  showed	  in	  Figure	  26.	  
	  
Figure	  28.	  Statistical	  analysis	  of	  translocations	  distributed	  across	  the	  genome	  of	  in	  α-­‐CD40/IL-­‐4	  
stimulated	   WT	   and	   ATM-­‐deficient	   B	   cells	   shown	   in	   Figure	   26.	   The	   number	   of	   2	   Mb	   bins	  
containing	  1,	  2,	  3,	  or	  4	  junctions	  is	  represented	  on	  the	  X	  axis.	  The	  Y	  axis	  represents	  the	  numbers	  
of	  2Mb	  bins	  containing	  indicated	  number	  of	  junctions.	  The	  mouse	  genome	  was	  divided	  into	  2	  
Mb	  bins,	  and	  the	  number	  of	  bins	  containing	   indicated	  hits	  was	  counted	  separately,	  excluding	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3.1.2.	  ATM	  Prevents	  The	  Formation	  Of	  Dicentrics	  
Given	  that	  ATM-­‐deficient	  B	  cell	  lymphomas	  routinely	  harbor	  translocations	  involving	  IgH,	  
we	  analyzed	  the	  pattern	  of	  HTGTS	  translocation	  junctions	  on	  chromosome	  12.	  In	  WT	  cells,	  most	  
of	   the	   junctions	  were	   found	   in	   the	   IgH	   locus,	   and	   specifically	   in	   the	   Sμ,	   Sγ1,	   and	   Sε	   regions	  
(Figure	   29),	   as	   previously	   reported	   (Chiarle	   et	   al.,	   2011).	   In	   libraries	   from	   ATM-­‐deficient	   α-­‐
CD40/IL4-­‐stimulated	   B	   cells,	   more	   translocations	  mapped	   on	   the	   telomeric	   portion	   of	   chr12	  
(where	  the	  IgH	  locus	  lies)	  as	  compared	  to	  WT	  (Figure	  26).	  However,	  the	  translocations	  not	  only	  
involved	  IgH	  S	  regions,	  but	  also	  accumulated	  over	  a	  30	  Mb	  region	  downstream	  of	  IgH,	  towards	  
the	  centromere	  of	  chromosome	  12	  (Figure	  30).	  In	  the	  absence	  of	  ATM,	  RAG-­‐initiated	  DSBs	  have	  
been	  shown	  to	  persist	  throughout	  B	  cell	  development	  and	  can	  undergo	  extensive	  end	  resection	  
(Callen	  et	   al.,	   2007).	  However,	   closer	   examination	  of	   the	   translocation	   junctions	   in	  our	  ATM-­‐
deficient	   translocation	   libraries	   revealed	   an	   even	   distribution	   of	   junctions	   in	   both	   (+)	   and	   (-­‐)	  
orientations	  (Figure	  20),	  suggesting	  they	  originated	  from	  a	  different	  mechanism.	  In	  this	  regard,	  
formation	  of	  chromosome	  12	  dicentrics	  following	  IgH	  locus	  breaks	  would	  lead	  to	  generation	  of	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Figure	  29.	  Sμ,	  Sγ1,	  and	  Sε	  regions	  are	  translocation	  hotspots	  in	  α-­‐CD40/IL-­‐4	  stimulated	  but	  not	  
RP105	  stimulated	  B	  cells.	  Distributions	  of	  translocation	  junctions	  at	  the	  IgH	  locus	  in	  ATM-­‐/-­‐	  and	  
WT	  stimulated	  B	   cells	  were	   shown	   respectively.	   Y-­‐axis	   shows	   the	  number	  of	  hits	   in	  each	  bin,	  
and	  the	  bin	  size	  is	  2.5kb.	  A	  schematic	  showing	  gene	  structure	  of	  the	  IgH	  switch	  region	  is	  below	  
each	   linear	   plot.	   The	   total	   number	   of	   each	   library	   was	   normalized	   to	   the	   cryptic	   I-­‐SceI	   sites	  
previously	  identified	  (Chiarle	  et	  al.,	  2012).	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Figure	  30.	  Distribution	  of	   translocation	   junctions	  on	  chromosome	  12	   from	  three	   independent	  
HTGTS	  libraries	  of	  α-­‐CD40/IL4-­‐stimulated	  ATM-­‐/-­‐	  or	  WT	  B	  cells.	  The	  total	  translocation	  junction	  
number	   from	   each	   library	  was	   normalized	   to	   number	   of	   junctions	   in	   cryptic	   I-­‐SceI	   sites	   (see	  
Material	  and	  Methods	  section	  for	  details).	  The	  bin	  size	  is	  1.2Mb.	  The	  location	  of	  the	  IgH	  locus	  as	  
well	  as	  the	  numbers	  of	  translocation	  junction	  within	  the	  S	  regions	  are	  indicated.	  The	  number	  of	  
translocation	  junctions	  in	  (+)	  and	  (-­‐)	  orientations	  are	  indicated.	  	  
Figure	  31.	  A	  model	  showing	  types	  of	  translocation	  junction	  that	  can	  be	  captured	  by	  out	  HTGTS	  
assay.	  I-­‐SceI-­‐initiated	  DSB	  in	  c-­‐myc	  can	  join	  to	  both	  ends	  of	  a	  new	  DSB	  downstream	  of	  the	  IgH	  
locus.	  Translocation	  joining	  c-­‐myc	  break	  to	  telomeric	  chromosome	  12	  is	  in	  (+)	  orientation	  while	  
joining	  to	  centromeric	  chromosome	  12	  is	  in	  (-­‐)	  orientation.	  The	  yellow	  box	  represents	  the	  c-­‐myc	  
gene.	  The	  red	  arrow	  indicates	  the	  position	  and	  direction	  of	  the	  HTGTS	  sequencing	  primer.	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We	  next	  wanted	  to	  determine	  whether	  the	  formation	  of	  chromosome	  12	  dicentric	  was	  
initiated	  solely	  by	  AID-­‐dependent	  DSBs	  in	  culture	  (Franco	  et	  al.,	  2006)	  or	  also	  by	  RAG-­‐initiated	  
DSBs	   that	   persisted	   through	   B	   cell	   development.	   To	   this	   end,	   we	   generated	   HTGTS	   libraries	  
from	  RP105-­‐stimulated	  WT	  and	  ATM-­‐deficient	  B	  cells.	  The	  RP105	  stimulation	  allows	  B	  cells	  to	  
survive	   and	   proliferate	   in	   culture	   without	   expressing	   AID	   or	   undergoing	   CSR,	   therefore	  
eliminating	   AID-­‐dependent	   DSBs	   in	   S	   regions.	   As	   expected,	   in	   RP105	   stimulated	   cells,	  
translocation	   junctions	   were	   barely	   found	   at	   S	   regions	   and	   other	   AID-­‐dependent	   hot	   spots	  
previously	  detected	  in	  α-­‐CD40/IL4-­‐stimulated	  B	  cells	  (Figure	  29	  and	  data	  not	  shown).	  However,	  
the	  accumulation	  of	  junctions	  on	  the	  telomeric	  end	  of	  chromosome	  12	  was	  retained	  in	  libraries	  
from	   RP105-­‐stimulated	   ATM-­‐deficient	   cells.	   Additionally,	   translocation	   junctions	   downstream	  
of	   IgH	  were	   distributed	   in	   both	   (+)	   and	   (-­‐)	   orientations	   as	   observed	   above.	  On	   the	   contrary,	  
libraries	   from	   RP105-­‐stimulated	   WT	   cells	   only	   showed	   a	   level	   of	   junctions	   in	   this	   region	  
comparable	  to	  the	  one	  observed	  in	  α-­‐CD40/IL4-­‐stimulated	  WT	  B	  cells	  (Figure	  32	  and	  Figure	  33).	  
Taken	   together,	   these	   results	   indicate	   that	  RAG-­‐initiated	  DSBs	  contribute	   to	   the	   formation	  of	  
chromosome	  12-­‐12	  dicentric	  which	  can	  provide	  a	  source	  of	  further	  DSBs	  in	  later	  stages	  of	  B	  cell	  
development	  and	  that	  such	  DSBs	  can	  be	  substrates	  for	  chromosomal	  translocations.	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Figure	  32.	  Distributions	  of	  genome-­‐wide	  translocation	  in	  HTGTS	  libraries	  from	  RP105-­‐stimulated	  
(A)	   WT	   and	   (B)	   ATM-­‐deficient	   B	   cells.	   Each	   plot	   represents	   a	   pool	   from	   three	   independent	  
experiments.	   Genotype,	   treatment,	   and	   total	   number	   of	   junctions	   in	   each	   library	   are	   shown	  
above	  each	  plot.	  The	  bin	   size	   is	  2	  Mb.	  Clusters	  of	   translocation	  hits	  are	   represented	  by	  color	  
dots	  as	  showed	  in	  the	  square.	  
	  
Figure	  33.	  Distribution	  of	   translocation	   junctions	  on	  chromosome	  12	   from	  three	   independent	  
HTGTS	   libraries	   of	   RP105-­‐stimulated	   WT	   or	   ATM-­‐deficient	   B	   cells.	   The	   total	   translocation	  
junction	  number	  from	  each	  library	  was	  normalized	  to	  number	  of	  junctions	  in	  cryptic	  I-­‐SceI	  sites	  
(see	  Material	  and	  Methods	  section	  for	  details).	  The	  bin	  size	   is	  1.2Mb.	  The	   location	  of	  the	   IgH	  
locus	  as	  well	  as	  the	  numbers	  of	  translocation	   junction	  within	  the	  S	  regions	  are	   indicated.	  The	  
number	  of	  translocation	  junctions	  in	  (+)	  and	  (-­‐)	  orientations	  are	  indicated.	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3.2.	  Discussion	  
3.2.1.	   RAG-­‐Initiated	   DSBs	  May	   Persist	   Developmentally	   As	   Dicentrics	   And	   Give	   Rise	   To	   de	  
novo	  DSBs	  In	  Mature	  B	  Cells.	  	  
	   	  To	  further	  elucidate	  mechanisms	  that	  could	  contribute	  to	  an	  ability	  of	  RAG-­‐initiated	  and	  
other	   types	   of	   DSBs	   to	   generate	   c-­‐myc	   translocations	   in	   context	   of	   ATM-­‐deficient	  mature	   B	  
cells,	  we	   employed	  HTGTS	   to	   study	   the	   fate	   of	   DSBs	   introduced	   into	   c-­‐myc	   in	  wild-­‐type	   and	  
ATM-­‐deficient	   splenic	   B	   cells	   activated	   in	   culture	   under	   conditions	   that	   would	   or	   would	   not	  
promote	  AID-­‐activation.	  Mapping	  of	  genome-­‐wide	  translocation	  junctions	  revealed	  that	  in	  both	  
WT	   and	   ATM-­‐deficient	   B	   cells	   c-­‐myc	   DSBs	   frequently	   translocate	   in	   both	   the	   (+)	   and	   (-­‐)	  
chromosomal	  orientations	  to	  newly	  generated	  AID-­‐initiated	  DSBs	  in	  donor	  and	  acceptor	   IgH	  S	  
regions	  (Chiarle	  et	  al.,	  2011).	  However,	  in	  ATM-­‐deficient	  B	  cells,	  but	  not	  wild-­‐type	  B	  cells,	  c-­‐myc	  
translocation	   junctions	   also	   occurred	   at	   high	   levels	   throughout	   a	   30	   megabases	   region	  
downstream	   (centromeric)	   of	   the	   IgH	   locus.	   This	   broad	   translocation	   hotspot	   region	  
downstream	  of	  IgH	  in	  ATM-­‐deficient	  cells	  contained	  a	  comparable	  distribution	  of	  translocation	  
junctions	   in	  both	   (+)	  and	   (-­‐)	   chromosomal	  orientations,	   indicating	   that	   they	   involved	  de	  novo	  
generated	  DSBs	  downstream	  of	  IgH	  in	  activated	  ATM-­‐deficient	  B	  cells.	  The	  possibility	  that	  these	  
DSBs	   were	   generated	   by	   AID	   off-­‐target	   activity	   over	   large	   region	   of	   chromosome	   12	   was	  
conclusively	  eliminated	  by	  our	  finding	  that	  this	  region	  downstream	  of	  IgH	  was	  still	  a	  hotspot	  for	  
DSBs	  and	  translocations	  to	  c-­‐myc	  in	  ATM-­‐deficient	  B	  cells	  cultured	  under	  conditions	  that	  do	  not	  
lead	  to	  AID	  induction	  or	  IgH	  S	  region	  DSBs	  and	  translocations.	  	  	  
	   How	  could	  de	  novo	  DSBs	  be	  generated	  in	  such	  a	  large	  region	  downstream	  of	  IgH	  in	  ATM-­‐
deficient	   activated	   B	   cells?	   The	   origin	   of	   these	   aberrant	   forms	   of	   chromosome	   12	   has	   been	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thought	   to	   involve	   unrepaired	   RAG-­‐initiated	   IgH	   locus	   DSBs	   that	   persist	   through	   B	   cell	  
development	  in	  the	  form	  of	  telomere-­‐less	  chromosome	  12	  fragments	  and,	  by	  the	  time	  they	  are	  
found	  in	  mature	  B	  cells,	  undergo	  resections	  that	  can	  delete	  large	  regions	  centromeric	  to	  the	  IgH	  
locus	  (Callen	  et	  al.,	  2007).	  As	  a	  significant	  portion	  of	  the	  DSBs	  downstream	  of	  IgH	   in	  activated	  
ATM-­‐deficient	   B	   cells	   identified	   via	   HTGTS	   are	   AID-­‐independent,	   they	   likely	   represent	   these	  
proposed	   persistent	   RAG-­‐initiated	   breaks,	   or	   at	   least	   a	   highly	   overlapping	   subset	   of	   them.	  
However,	  a	  translocation	  mechanism	  based	  on	  persistence	  of	  broken	  telomere-­‐less	  fragments	  
of	   chromosome	   12	   could	   not	   explain	   our	   finding	   of	   equally	   high	   numbers	   of	   translocation	  
junctions	   in	   both	   the	   (+)	   and	   (-­‐)	   chromosomal	   orientations	   within	   the	   30	   Mb	   region	  
downstream	   of	   IgH.	   We	   thus	   conclude	   that	   the	   generation	   of	   both	   (+)	   and	   (-­‐)	   orientation	  
junctions	   require	   the	   presence	   of	   DSB	   ends	   associated,	   respectively,	   with	   centromeric	   and	  
telomeric	  ends	  of	  chromosome	  12	  (Figure	  34).	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Figure	  34.	   Two	  models	   for	  persistence	  of	  RAG-­‐initiated	  DSBs	   in	  ATM-­‐deficient	  B	   lymphocytes	  
that	  provide	  translocation	  substrates	  in	  the	  peripheral	  B	  cells.	  (A)	  Persistence	  of	  IgH	  DSBs	  with	  
resection	   due	   to	   combined	   defect	   in	   DNA	   repair	   and	   G1	   checkpoint	   in	   the	   absence	   of	   ATM	  
(Callen	  et	  al.,	  2007).	  (B)	  Persistence	  of	  IgH	  DSBs	  as	  dicentrics,	  resulting	  in	  generation	  of	  de	  novo	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Franco	  and	   colleagues	  have	   shown	   that	   chromosome	  12	  dicentrics	   can	  be	   formed	  via	  
aberrant	  repair	  of	  AID-­‐initiated	  DSBs	  in	  activated	  ATM-­‐deficient	  peripheral	  B	  cells	  (Franco	  et	  al.,	  
2006).	  Our	  current	  findings	  now	  indicate	  that	  such	  dicentrics	  can	  and	  frequently	  do	  arise	  from	  
AID-­‐independent	   mechanisms,	   and	   can	   generate	   downstream	   DSBs	   that	   are	   substrates	   for	  
translocations	  to	  c-­‐myc.	  We	  propose	  that	  a	  large	  fraction	  of	  AID-­‐independent	  DSBs	  within	   IgH	  
and	   in	  the	  region	  far	  downstream	  of	  the	   locus	   in	  ATM-­‐deficient	  peripheral	  B	  cells	   result	   from	  
BFB	   cycles	   involving	   chromosome	  12	   dicentrics	   generated	   from	  unrepaired	  RAG-­‐initiated	   IgH	  
DSBs	   in	   pro-­‐B	   cells	   by	   the	  mechanisms	   discussed	   above.	   Thus,	   our	   HTGTS	   studies	   reveal	   an	  
unanticipated	  mechanism	  by	  which	  ATM	  suppresses	  the	  generation	  of	  chromosome	  breaks	  and	  
translocations	   in	  peripheral	  B	  cells	  by	  preventing	  unrepaired	  RAG-­‐initiated	  DSBs	   in	  pro-­‐B	  cells	  
from	   propagating	   as	   dicentrics	   during	   development	   which	   can	   further	   generate	   DSBs	   in	  
peripheral	  B	  cells	  that	  can	  contribute	  to	  oncogenic	  translocations.	  	  
	  
3.2.2.	  Implications	  For	  ATM-­‐Deficient	  Mouse	  B	  And	  T	  Cell	  Lymphomas.	  
	   Together	   our	   studies	   indicate	   that,	   in	   certain	   genetic	   backgrounds,	   RAG-­‐initiated	   IgH	  
DSBs	  in	  ATM-­‐deficient	  pro-­‐B	  cells	  can	  result	  in	  the	  development	  of	  peripheral	  B	  cell	  lymphomas	  
with	   complex	   IgH	   locus	   translocations,	  which	   lead	   to	  c-­‐myc	   activation	   via	   gene	  amplification.	  
Our	  findings	  support	  a	  model	   in	  which	  RAG-­‐initiated	  dicentric	  translocations	   involving	  the	   IgH	  
locus	   occur	   in	   pro-­‐B	   cells	   and	   are	   propagated	   developmentally	   by	   a	   BFB	  mechanism.	   In	   this	  
context,	   additional	   translocation	   and	   gene	   amplifications	   leading	   to	   the	   peripheral	   B	   cell	  
lymphomas	  in	  the	  ATM-­‐deficient	  background	  may	  occur	  at	  any	  stage	  of	  development	  including,	  
as	   shown	  by	  our	  HTGTS	   studies,	   in	  mature	  B	   cells.	  Our	   findings	  also	  provide	  a	  model	   for	   the	  
	   113 
generation	   of	   chromosomal	   aberrations	   found	   recurrently	   in	   ATM-­‐deficient	   mouse	   T	   cell	  
lymphomas.	  These	  tumors	  frequently	  harbor	  complex	  chromosome	  14	  translocations	  involving	  
dicentrics	   generated	   during	   the	   Tcrd	   locus	   V(D)J	   recombination	   that	   lead	   to	   amplification	   of	  
genes	   upstream	   of	   the	   Tcrd	   locus	   (Zha	   et	   al.,	   2010).	   Notably,	   these	   tumors	   also	   have	  
characteristic	  T(12;14)	  translocations	  that	  fuse	  Tcrd	  breaks	  on	  chromosome	  14	  to	  chromosome	  
12	  sequences	  that	  lie	  within	  a	  large	  region	  downstream	  of	  the	  IgH	  locus,	  which	  may	  result	  in	  a	  
deletion	   of	   putative	   tumor	   suppressors	   (Zha	   et	   al.,	   2010).	   Based	   on	   our	   current	   findings,	  we	  
propose	   that	   the	   substrates	   for	   translocations	   that	   lead	   to	   the	   large	   chromosome	   12	  
translocations	   could	   be	   RAG-­‐initiated	   DSBs	   in	   the	   JH	   locus,	   which	   are	   known	   to	   occur	   in	  
developing	  T	  cells.	  In	  the	  absence	  of	  ATM,	  the	  RAG-­‐initiated	  DSBs	  form	  dicentrics	  that	  continue	  
to	  undergo	  BFB	  breaks	  and	  serve	  as	  substrates	  for	  translocation	  to	  persistent	  RAG-­‐initiated	  Tcrd	  
breaks.	  	  
Nearly	   all	   of	   the	   peripheral	   DA,	   AB,	   and	  DAB	   B	   cell	   lymphomas	   arise	   from	  peripheral	  
IgM+	   B	   cells	   have	   not	   undergone	   either	   CSR	   or	   SHM.	   Given	   our	   finding	   that	   activated	   ATM-­‐
deficient	   B	   cells	   in	   culture	   form	   AID-­‐initiated	   dicentrics	   and	   other	   translocations	   at	   a	   high	  
frequency	  (Franco	  et	  al.,	  2006),	  one	  might	  expect	  that	  such	  AID-­‐initiated	  DSBs	  would	  also	  give	  
rise	  to	  oncogenic	  translocations.	  The	  lack	  of	  B	  cell	  lymphomas	  derived	  from	  ATM-­‐deficient	  GC	  B	  
cells	  might	   result	   from	  more	   strict	   checkpoints	   in	   GC	   or	   other	   AID-­‐activated	   B	   lymphocytes,	  
which	   eliminate	   cells	   carrying	   off-­‐target	   AID	   DNA	   damage.	   In	   this	   context,	   perhaps	   the	  
susceptible	   ATM-­‐deficient	   IgM+	   B	   cell	   population	   is	   more	   tolerant	   of	   DNA	   damage	   and	  
oncogene	  stress	  than	  in	  vivo	  ATM-­‐deficient	  GC	  or	  CSR	  activated	  B	  cells.	  In	  addition,	  it	  is	  possible	  
that	  progenitors	  for	  ATM-­‐deficient	  IgM+	  B	  cell	  lymphomas	  arrive	  in	  the	  periphery	  with	  activated	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c-­‐myc	   genes	   providing	   proliferative	   advantages,	   allowing	   the	   cells	   to	   achieve	   full	   oncogenic	  
transformation	  at	  this	  developmental	  stage.	  	  
Our	  findings	  could	  be	  relevant	  to	  certain	  pre-­‐germinal	  center	  human	  B	  cell	  lymphomas.	  
For	  example,	  a	  subset	  of	  mantle	  cell	  lymphomas	  (MCLs)	  derive	  from	  pre-­‐germinal	  center	  B	  cells	  
with	   ATM	   mutations	   (Stankovic	   et	   al.,	   2002).	   MCLs	   also	   frequently	   harbor	   translocations	  
between	   chromosome	   14	   and	   chromosome	   11	   that	   lead	   to	   deregulation	   of	   cyclinD1	   gene	  
through	  translocation	  to	   the	   IgH	   JH	  region.	  Moreover,	  a	  number	  of	  MCLs	  are	  documented	  as	  
having	   complex	   chromosomal	   rearrangements	   with	   co-­‐amplifed	   IgH/cyclinD1	   genes	  
(Menanteau	  and	  Martinez-­‐Climent,	  2013;	  Setoodeh	  et	  al.,	  2013).	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CHAPTER	  4:	  FUTURE	  DIRECTIONS	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The	   observation	   that	   the	   DJβ	   cassette,	   despite	   not	   being	   directly	   involved	   in	  
translocations,	   renders	   the	   modified	   c-­‐myc	   allele	   a	   more	   frequent	   translocation	   target	   is	   of	  
substantial	  interest	  and	  warrants	  further	  analysis.	  In	  this	  regard,	  it	  is	  important	  to	  note	  that	  we	  
have	  only	  studied	  one	  DJβ	  cassette	  targeted	  mouse	   line,	  which	  was	  used	  to	  generate	  mice	   in	  
both	   the	   DA	   and	   DAB	   cohorts.	   We	   cannot	   therefore	   exclude	   the	   possibility	   that	   unknown	  
genetic	   alterations	   in	   the	   targeted	   embryonic	   stem	   (ES)	   cell	   clone	   used	   to	   generate	   the	   c-­‐
mycDJβ/WT	  mice	  conferred	  predisposition	  for	  B	  cell	  lymphomas	  carrying	  c-­‐myc	  translocations.	  To	  
unequivocally	   rule	  out	   this	  possibility,	   several	   independently	   targeted	  c-­‐mycDJβ/WT	  mouse	   lines	  
would	   need	   to	   be	   generated	   and	   crossed	   into	   the	   ATM-­‐deficient	   background	   to	   generate	  
cohorts	  that	  would	  be	  monitored	  for	  B	  cell	  lymphoma	  development.	  	  
If	  the	  independently	  targeted	  DA	  and	  DAB	  mouse	  lines	  continued	  to	  develop	  mature	  B	  
cell	   lymphomas	  with	  the	  characteristic	   IgH/c-­‐myc	  amplification,	   it	  would	  indicate	  that	  the	  DJβ	  
cassette	  plays	  a	  role	  in	  tumor	  development.	  If	  this	  was	  the	  case,	  it	  would	  be	  of	  great	  interest	  to	  
determine	   if	   the	   oncogenic	   event	   is	   driven	   by	   the	   cassette	   is	   a	   RAG-­‐independent	   or	   RAG-­‐
dependent	   process.	   In	   the	   latter	   context,	  we	  have	  hypothesized	   that	   the	   generation	  of	  DSBs	  
downstream	  of	  c-­‐myc	  might	  be	   linked	   to	   the	  presence	  of	   the	  DJβ	   cassette	   in	  c-­‐myc	   intron	  1.	  
However,	  we	  cannot	  exclude	  contributions	  of	  an	  unknown	  mechanism,	  for	  example	  some	  form	  
of	  oncogenic	  activation	  post	  amplification,	  by	  which	  the	  insertion	  of	  the	  DJβ	  cassette	  into	  c-­‐myc	  
intron	   that	  dictates	   cellular	   selection	  of	  oncogenic	   translocation/amplification	  of	   the	  c-­‐mycDJβ	  
allele.	  	  We	  outline	  below	  experiments	  that	  would	  help	  distinguish	  these	  alternative	  possibilities.	  
To	  test	   the	  potential	  mechanisms	  by	  which	  the	  DJβ insertion	  contributes	  to	  oncogenic	  
rearrangements/amplifications	  in	  the	  c-­‐myc	  allele	  into	  which	  it	  is	  inserted,	  we	  could	  mutate	  the	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RSSs	  within	  the	  DJβ	  cassette	  such	  that	  it	  cannot	  undergo	  V(D)J	  recombination.	  The	  RSS-­‐mutated	  
DJβ	  cassette	  would	  then	  be	  targeted	  into	  the	  same	  region	  in	  c-­‐myc	   intron	  1	  as	  the	  previously	  
targeted	  the	  c-­‐mycDJβ	  allele,	  generating	  the	  c-­‐mycmut-­‐DJβ	  allele.	  Mice	  containing	  the	  c-­‐mycmut-­‐DJβ	  
allele	   would	   be	   crossed	   into	   ATM-­‐/-­‐	  and	   ATM-­‐/-­‐-­‐Eµ-­‐Bcl2	   background	   to	   generate	  mut-­‐DA	   and	  
mut-­‐DAB	  mouse	  cohorts,	  respectively,	  that	  would	  be	  monitored	  for	  tumor	  development.	  If	  the	  
mut-­‐DA	  and	  mut-­‐DAB	  mice	  developed	  B	   cell	   lymphomas	  with	   the	   same	  characteristics	   as	  DA	  
and	  DAB	  mice,	  it	  would	  suggest	  that	  the	  oncogenic	  event	  is	  RAG-­‐independent	  and	  more	  likely	  
resulted	  from	  other	  mechanisms	  such	  contributing	  to	  further	  activation	  of	  the	  amplified	  c-­‐myc	  
alleles	  that	  were	  selected	  for	  subsequent	  translocations	  and	  initial	  amplifications.	  In	  this	  regard,	  
the	  DJβ	   insertion	  itself	   is	  not	  sufficient	  to	  activate	  c-­‐myc	   for	  tumorigenesis	  since	  all	  of	  the	  DA	  
and	  DAB	  B	  cell	  lymphomas	  harbor	  translocations	  and	  amplifications.	  	  
In	   regards	   to	   cellular	   selection	   against	   translocations	   that	   disrupt	   c-­‐myc	   intron	   1,	   it	  
should	  be	  noted	  that	  a	  translocation	  into	  the	  region	  where	  the	  cassette	  is	  targeted	  might	  lead	  
to	  c-­‐myc	   inactivation,	  via	  a	  disruption	  of	  an	  alternative	  promoter	   that	   lies	  upstream	  of	  c-­‐myc	  
exon	  2	  (Bernard	  et	  al.,	  1983;	  Saito	  et	  al.,	  1983).	  Such	  inactivation	  would	  obviate	  translocations	  
directly	  into	  the	  first	  c-­‐myc	  intron	  from	  contributing	  to	  c-­‐myc	  oncogenic	  activation.	  The	  lack	  of	  
c-­‐myc	   activation	   via	   translocations	   into	   murine	   c-­‐myc	   intron	   1	   is	   further	   demonstrated	   by	  
studies	   of	   an	   Xrcc4/p53-­‐deficient	   peripheral	   B	   cell	   lymphoma	   (CXP)	   mouse	   model.	   Thus,	  
peripheral	   B	   cell	   lymphomas	   from	   this	   background	   harbor	   reciprocal	   T(12;15)	   and	   T(15;12)	  
translocations	  with	  translocation	  junctions	  on	  T(15;12)	  involving	  the	  joining	  of	  sequences	  within	  
or	  around	  IgH	  S	  region	  on	  chromosome	  12	  to	  sequences	  that	  consistently	  lie	  upstream	  of	  c-­‐myc	  
exon	   1	   (Wang	   et	   al.,	   2008).	   Based	   on	   these	   considerations,	   it	   is	   conceivable	   the	   lack	   of	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translocations	   directly	   involving	   the	   DJβ	   cassette	   in	   our	   current	   experimental	   system	   would	  
reflect	  cellular	  selection	  during	  tumorigenesis	  for	  B	  lymphocytes	  with	  breakpoints	  outside	  of	  c-­‐
myc,	  which	  would	  maintain	  the	  c-­‐myc	  transcription	  start	  sites	  located	  within	  intron	  1	  (Stanton	  
et	  al.,	  1983).	  Accordingly,	   the	   retention	  of	   transcription	   start	   site	   in	  c-­‐myc	   intron	  1	   in	  human	  
Burkitt’s	  lymphoma	  T(8;14)	  translocation	  is	  shown	  to	  be	  essential	  in	  ectopic	  activation	  of	  c-­‐myc	  
by	  IGH	  regulatory	  elements	  in	  this	  cancer	  (Janz,	  2006).	  	  
If	  the	  mut-­‐DA	  and	  mut-­‐DAB	  mouse	  cohorts	  did	  not	  succumb	  to	  the	  same	  type	  of	  mature	  
B	  cell	  lymphomas	  development	  as	  in	  the	  DA	  and	  DAB	  mice,	  it	  would	  support	  the	  notion	  that	  the	  
DJβ	   cassette	   contributes	   oncogenic	   event	   through	   an	   indirect	   RAG/V(D)J	   recombination	  
associated	  mechanism.	  To	  test	  the	  hypothesis	  that	  aberrant	  V(D)J	  recombination	  into	  the	  DJβ	  
cassette	  could,	  if	  in	  a	  different	  position	  than	  intron	  1,	  contribute	  to	  B	  cell	  lymphoma	  in	  mice,	  we	  
would	  generate	  ATM-­‐deficient	  experimental	  mouse	  cohorts	  harboring	  the	  c-­‐mycDJβ	  allele	  with	  
the	  DJβ	   cassette	   targeted	   to	   a	   region	  either	  upstream	  or	  downstream	  of	   c-­‐myc	   instead	  of	   in	  
intron	   one.	   Translocations	   upstream	   of	   c-­‐myc	   should	   not	   inactivate	   the	   gene	   but	   could	  
potentially	   lead	  to	   its	  ectopic	  activation	  by	  the	   IgH	   regulatory	  elements	  (Gostissa	  et	  al.,	  2009;	  
Wang	   et	   al.,	   2008),	   while	   translocations	   downstream	   of	   c-­‐myc	   could	   lead	   to	   dicentrics	   that	  
would	  provide	  substrates	  for	  c-­‐myc	  gene	  amplification	  via	  BFB	  mechanism	  as	  discussed.	  	  
If	  we	  do	  find	  evidence	  that	   the	  DJβ	  cassette	  promotes	  c-­‐myc	  oncogenic	   translocations	  
through	   an	   indirect	   V(D)J	   recombination	   associated	   mechanism,	   it	   would	   also	   be	   of	   great	  
interest	   to	   test	   the	  hypothesis	   that	   the	  DJβ	   cassette	  promotes	   translocations	  downstream	  of	  
the	  c-­‐myc	  gene.	  In	  the	  discussion	  section,	  we	  proposes	  a	  potential	  mechanism	  that	  may	  involve	  
increasing	  levels	  of	  DSBs	  in	  the	  downstream	  region,	  which	  then	  provide	  substrates	  for	  dicentric	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translocations	   and	   oncogenic	   amplifications.	   In	   this	   context,	   we	   further	   speculate	   that	   the	  
presence	  of	   the	  DJβ	  cassette	   in	  c-­‐myc	   first	   intron	   increases	   the	   likelihood	  of	  RAG	  cleavage	  at	  
cryptic	   RSSs	   downstream	   of	   c-­‐myc	   by	   providing	   a	   paired	   functional	   RSS	   for	   12/23	   restricted	  
cleavage	   of	   isolated	   cryptic	   RSSs	   downstream	   of	   c-­‐myc.	   To	   test	   this	   hypothesis,	   we	   would	  
design	   a	   PCR	   assay	   with	   one	   primer	   upstream	   of	   the	   Dβ	   segment	   and	   another	   primer	  
downstream	  of	  cryptic	  RSSs	  that	  mapped	  near	  the	  translocation	  junctions	  identified	  in	  DA	  and	  
DAB	  tumors.	  This	  strategy	  would	  allow	  us	  to	  detect	  the	  joining	  of	  RAG-­‐initiated	  DJβ	  DSBs	  to	  the	  
downstream	  cryptic	  RSSs.	  If	  the	  presence	  of	  the	  DJβ	  cassette	  increased	  the	  level	  of	  DSBs	  in	  the	  
region	   downstream	  of	   c-­‐myc,	  we	  would	   detect	   these	   joins	   in	   pro-­‐B	   cells	   from	  pre-­‐tumor	  DA	  
mice.	  	  
Another	  characteristic	  of	  recurrent	  translocations	  in	  mature	  B	  cell	  lymphomas	  from	  the	  
three	  experimental	  cohorts	  in	  this	  study	  is	  the	  joining	  of	  sequences	  downstream	  of	  c-­‐myc	  to	  a	  
small	  region	  in	  and	  around	  the	  IgH	  JH	  segment	  cluster,	  thereby	  linking	  the	  IgH	  intronic	  enhancer	  
(iEµ)	  to	  c-­‐myc.	  Such	   juxtaposition	  may	  contribute	  to	  mature	  B	  cell	   lymphoma	  development	   in	  
ATM-­‐deficient	   background,	   especially	   in	   light	   of	   the	   observation	   that	   in	   some	   tumors	   (e.g.	  
DAB473)	   low	   levels	  of	  c-­‐myc	   amplification	  correlated	  with	   translocation	  breakpoints	  closer	   to	  
the	  c-­‐myc	  gene.	  To	  test	  the	  role	  of	   iEµ	   in	  ATM-­‐deficient	  B	  cell	  tumor	  development,	  we	  would	  
generate	   DAB	  mouse	   line	   that	   also	   lacks	   iEµ	   and	   observe	   the	   experimental	   mice	   for	   tumor	  
development.	   If	   iEµ	   was	   dispensable	   for	   oncogenic	   transformation,	   the	   tumor	   types	   and	  
characteristics	   would	   remain	   the	   same	   in	   mouse	   lines	   lacking	   iEµ.	   Of	   particular	   interest,	   if	  
tumors	   still	   develop	  would	   be	  whether	   or	   not	  we	   observed	   increased	   c-­‐myc	   amplification	   or	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loss	  of	  frequent	  translocations	  close	  to	  c-­‐myc	  since	  iEµ	  activity	  has	  been	  suggested	  to	  be	  limited	  
over	  distance	  (Henderson	  and	  Calame,	  1998).	  
	   It	   is	   of	   relevant	   that	   the	   mapping	   of	   translocation	   junctions	   by	   HTGTS	   in	   in	   vitro	  
stimulated	   ATM-­‐deficient	   splenic	   B	   cells	   isolated	   from	   c-­‐myc25xI-­‐SceI	  B	   cells	   identified	   a	   30	  Mb	  
region	  downstream	  of	   the	   IgH	   locus	  on	  chromosome	  12	  to	  be	  a	   translocation	  hotspot.	  When	  
stimulated	  under	  conditions	  that	  did	  not	  induce	  AID	  or	  CSR,	  this	  region	  was	  still	  a	  hotspot	  for	  
DSBs	  and	  translocations	  to	  c-­‐myc.	  We	  propose	  that	  a	  large	  fraction	  of	  these	  breakpoints	  results	  
from	  BFB	  cycles	  involving	  chromosomes	  12	  dicentrics	  generated	  from	  unrepaired	  RAG-­‐initiated	  
IgH	  DSBs	  in	  pro-­‐B	  cells.	  However,	  the	  finding	  from	  this	  experiment	  does	  not	  tell	  unequivocally	  if	  
the	  source	  of	  the	  putative	  dicentrics	  that	  rise	  to	  the	  AID-­‐independent	  downstream	  IgH	  DSBs	  in	  
these	  experiments	  is	  RAG	  activity	  in	  pro-­‐B	  cells.	  To	  unequivocally	  determine	  the	  potential	  roles	  
of	   RAG	   in	   the	   formation	   of	   chromosome	   12-­‐12	   dicentrics	   that	   lead	   to	   de	   novo	   DSBs	  
downstream	  of	   IgH	   in	  mature	  B	  cells,	  we	  would	  generate	  HTGTS	   libraries	   from	  splenic	  B	  cells	  
isolated	   from	  mice	  with	  dual	  ATM	  and	  RAG	  deficiency	  and	  B	  cells	   from	  mice	  with	  ATM,	  RAG,	  
and	  AID	  deficiency	  that	  also	  harbor	  pre-­‐assembled	  IgH	  and	  IgL	  chain	  variable	  region	  exons	  (HL)	  
knock	   in	   alleles.	   These	   knock	   in	   alleles	   encode	   proteins	   that	   assemble	   to	   form	   a	   complete	  
immunoglobulin	   molecule,	   thus	   allowing	   RAG-­‐deficient	   B	   cells	   to	   progress	   through	  
development	  (Lansford	  et	  al.,	  1998).	  If	  RAG-­‐initiated	  DSBs	  were	  the	  major	  source	  of	  DSBs	  that	  
form	  dicentrics	  which	  subsequently	  result	  in	  de	  novo	  DSBs	  in	  the	  30	  Mb	  region	  downstream	  of	  
IgH	  in	  the	  absence	  of	  ATM,	  we	  would	  expect	  a	  very	  low	  level	  of	  translocation	  in	  this	  region	  in	  
ATM	  and	  RAG	  plus	  AID	  deficient/HL	  compared	  to	  AID-­‐deficient	  ATM-­‐deficient/HL	  background.	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CHAPTER	  5:	  MATERIALS	  AND	  METHODS	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Generation	  of	  DA	  mice.	  To	  introduce	  the	  c-­‐mycDJβ	  allele	  (Ranganath	  et	  al.,	  2008)	  into	  the	  ATM-­‐
deficient	   background	   (Borghesani	   et	   al.,	   2000),	   we	   initially	   bred	   ATM+/-­‐	   mice	   to	   mice	  
homozygous	   for	   the	   c-­‐mycDJβ	   allele.	   We	   then	   intercrossed	   the	   resulting	   ATM+/-­‐	   c-­‐mycDJβ/wt	  
offspring,	   as	   well	   as	   second	   generation	   ATM+/-­‐	   c-­‐mycDJβ/wt	   and	   ATM+/-­‐	   c-­‐mycDJβ/DJβ	   mice,	   to	  
obtain	   experimental	   ATM-­‐/-­‐	   c-­‐mycDJβ/DJβ	   and	   ATM-­‐/-­‐	   c-­‐mycDJβ/wt	   	   (DA)	   mice	   and	   control	   mice.	  
Experimental	   animals	   were	   monitored	   for	   tumor	   development	   and	   killed	   for	   analysis	   when	  
clear	   signs	   of	   disease	   appeared.	   All	   animal	   experiments	   were	   performed	   under	   protocols	  
approved	   by	   the	   Institutional	   Animal	   Care	   and	  Use	   Committee	   of	   Boston	   Children’s	   Hospital	  
(Protocol	  11-­‐11-­‐2074R).	  
	  
Generation	   of	   AB	  mice.	   To	   introduce	   the	  Eμ-­‐Bcl-­‐2	   transgene	   into	  ATM-­‐deficient	  background,	  
we	  bred	  ATM+/-­‐	  mice	  to	  mice	  harboring	  Eμ-­‐Bcl-­‐2	  transgene	  (Strasser	  et	  al.,	  1994).	  The	  resulting	  
offspring	  (ATM+/-­‐Eμ-­‐Bcl-­‐2	  mice)	  were	  then	  bred	  together	  to	  obtain	  experimental	  ATM-­‐/-­‐	  Eμ-­‐Bcl-­‐2	  
(AB)	   and	   control	   mice.	   	   Experimental	   animals	   were	   monitored	   for	   tumor	   development	   and	  
killed	  for	  analysis	  when	  clear	  signs	  of	  disease	  appeared.	  All	  animal	  experiments	  were	  performed	  
under	   protocols	   approved	   by	   the	   Institutional	   Animal	   Care	   and	   Use	   Committee	   of	   Boston	  
Children’s	  Hospital	  (Protocol	  11-­‐11-­‐2074R).	  
	  
Generation	   of	   DAB	  mice.	   To	   introduce	   both	   the	   c-­‐mycDJβ	   allele	   and	   Eμ-­‐Bcl-­‐2	   transgene	   into	  
ATM-­‐deficient	  background,	  we	  first	  generated	  c-­‐mycDJβ/wt	  Eμ-­‐Bcl-­‐2	  mice	  and	  then	  bred	  them	  to	  
ATM+/-­‐	   mice.	   The	   resulting	   ATM+/-­‐	   c-­‐mycDJβ/wt	   Eμ-­‐Bcl-­‐2	   offspring	   were	   then	   bred	   to	   ATM+/-­‐	   c-­‐
mycDJβ/wt	   to	   generate	   experimental	   cohort	   (DAB),	   comprising	   ATM-­‐/-­‐	  c-­‐mycDJβ/wt	   Eμ-­‐Bcl-­‐2	  mice	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and	  ATM-­‐/-­‐	  c-­‐mycDJβ/DJβ	  Eμ-­‐Bcl-­‐2	  mice.	  ATM-­‐/-­‐	  c-­‐mycDJβ/wt,	  ATM+/-­‐	  c-­‐mycDJβ/wt	  Eμ-­‐Bcl-­‐2,	  and	  Eμ-­‐Bcl-­‐
2	  mice	  were	   kept	   as	   controls.	   Experimental	   animals	  were	  monitored	   for	   tumor	  development	  
and	   killed	   for	   analysis	   when	   clear	   signs	   of	   disease	   appeared.	   All	   animal	   experiments	   were	  
performed	  under	  protocols	  approved	  by	   the	   Institutional	  Animal	  Care	  and	  Use	  Committee	  of	  
Boston	  Children’s	  Hospital	  (Protocol	  11-­‐11-­‐2074R).	  
	  
Flow-­‐cytometry	  Analysis.	  Single-­‐cell	  suspensions	  from	  tumor	  masses	  and	  control	  organs	  were	  
stained	  with	  CyChrome	  (CyC)-­‐labeled	  anti-­‐mouse	  B220	  (eBiosciences),	  FITC-­‐labeled	  anti-­‐mouse	  
CD43	  (BD	  Biosciences),	  and	  RPE-­‐labeled	  anti-­‐mouse	  IgM	  (Southern	  Biotech)	  antibodies	  or	  with	  
FITC-­‐labeled	  anti-­‐mouse	   Igκ	   (BD	  Biosciences)	  and	  PE-­‐labeled	  anti-­‐mouse	   Igλ	   (BD	  Biosciences).	  
Data	   acquisition	   was	   performed	   on	   a	   FACSCalibur	   flow	   cytometer	   equipped	   with	   CellQuest	  
software	  (Becton	  Dickinson).	  Analysis	  was	  performed	  with	  FlowJo	  software	  (Tree	  Star).	  
	  
Immunohistochemical	   Analysis.	   Freshly	   isolated	   tumor	   tissues	   were	   fixed	   in	   10%	   (vol/vol)	  
buffered	   formalin	   overnight	   and	   stored	   in	   70%	   (vol/vol)	   ethanol.	   Paraffin-­‐embedded	   tissues	  
were	   sectioned	   and	   stained	   individually	   with	   H&E,	   anti-­‐mouse	   B220,	   anti-­‐mouse	   CD3,	   anti-­‐
mouse	  pan-­‐Ig,	  anti-­‐mouse	  c-­‐myc,	  and	  anti-­‐mouse	  TdT.	  Histologic	  diagnoses	  were	  made	  on	  the	  
basis	  of	  established	  criteria	  (Morse	  et	  al.,	  2002).	  
	  
Southern	   Blotting.	  Genomic	  DNA	  was	   isolated	   from	   tumor	  masses	  or	  normal	   control	   tissues.	  
Southern	   blotting	   was	   performed	   with	   10	   μg	   of	   genomic	   DNA	   digested	   overnight	   with	  
appropriate	  restriction	  enzyme.	  Digested	  DNA	  was	  then	  size-­‐separated	  on	  0.8%	  agarose	  gel	  and	  
	   124 
transferred	   to	   Zeta-­‐Probe	   GT	   (Biorad)	   nylon	   membrane.	   Hybridization	   with	   32P-­‐labeled	   DNA	  
probe	  was	  performed	  in	  50%	  (vol/vol)	  formamide/SScPE	  at	  42°C	  overnight.	  The	  JH4–3	  probe	  was	  
a	   1.6-­‐kb	   HindIII/EcoRI	   fragment	   downstream	   of	   JH4;	   the	   Jκ	   probe	   was	   a	   1-­‐kb	   fragment	  
downstream	  of	  Jκ	  5;	  and	  the	  Cμ	  probe	  was	  a	  869bp	  XbaI/BamHI	  fragment.	  The	  3’	  c-­‐myc	  probe	  
was	  2.5	  kb	  XhoI/BamHI	  fragment.	  
	  
Somatic	  Hypermutation	  Analysis.	  The	  genomic	  region	  encompassing	  JH1	  to	  JH4	  and	  part	  of	  the	  
intron	   downstream	   of	   JH4	   was	   PCR-­‐amplified	   from	   tumor	   DNA	   using	   degenerate	  
oligonucleotides	   corresponding	   to	   the	   different	   VH	   families	   as	   forward	   primers	   and	  
oligonucleotides	   downstream	   of	   JH4	   (5 ′ AGGCTCTGAGATCCCTAGACAG3 ′ 	   or	   5 ′
CCTCTCCAGTTTCGGCTGATCC3′)	   as	   reverse	   primers.	   Proofreading	   polymerase	   (iProof	   High-­‐
Fidelity	   DNA	   Polymerase,	   Biorad)	   was	   used	   for	   amplification	   and	   PCR	   conditions	   were	   as	  
previously	  published	  (Ehlich	  et	  al.,	  1994).	  Amplification	  products	  were	  purified	  from	  agarose	  gel	  
and	   submitted	   to	   sequencing.	   Sequences	   were	   compared	   with	   the	   published	   129/Sv	   and	  
C57/B6	  sequences	  (accession	  nos.	  NT_114985.2	  and	  NT_166318.1,	  respectively).	  	  
	  
Cytogenetic	   Analysis.	   To	   generate	   metaphase,	   freshly	   isolated	   lymphomas	   were	   made	   into	  
single-­‐cell	   suspensions	   and	   cultured	   for	   3-­‐6	   hours	   in	   RPMI	  medium	   containing	   15%	   fetal	   calf	  
serum	  and	  50ng/mL	  Colcemid	  (KaryoMAX	  Colcemid	  Solution;	  GIBCO).	  Metaphase	  spreads	  were	  
prepared	   according	   to	   standard	   protocols	   (Franco	   et	   al.,	   2006).	   Spectral	   karyotyping	   was	  
performed	   with	   a	   mouse	   SKY	   paint	   kit	   (Applied	   Spectral	   Imaging)	   following	   manufacturer’s	  
indications.	  Images	  were	  acquired	  with	  BX61	  Microscope	  (Olympus)	  equipped	  with	  a	  motorized	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automatic	  stage,	  a	  cooled-­‐CCD	  camera,	  and	  an	  interferometer	  (Applied	  Spectral	  Imaging).	  A	  63×	  
objective	   was	   used.	   Analysis	   was	   performed	   with	   the	   HiSKY	   software	   (Applied	   Spectral	  
Imaging).	  At	  least	  15	  metaphases	  per	  each	  sample	  were	  analyzed.	  Two-­‐color	  FISH	  assays	  for	  IgH	  
and	  c-­‐myc	  loci	  were	  performed	  as	  previously	  described	  with	  the	  indicated	  BAC	  probes	  (Franco	  
et	   al.,	   2006).	   Metaphases	   were	   first	   hybridized	   with	   chromosome-­‐specific	   fluorochrome-­‐
conjugated	  paints	  to	  mouse	  chromosome	  12	  and	  15,	  following	  the	  manufacturer’s	  instructions	  
(Applied	   Spectral	   Imaging).	   After	   image	   acquisition	   as	   outlined	   for	   SKY	   experiments,	   selected	  
metaphase	   slides	   were	   treated	   with	   2xSSC	   solution	   for	   20	  minutes	   at	   room	   temperature	   to	  
remove	   painting	   probes.	   Subsequently,	   the	   slides	   were	   dehydrated	   through	   serial	   ethanol	  
washes	   and	   then	   re-­‐hybridize	  with	   fluorochrome-­‐labled	  BAC	  probes.	   To	  prepare	  BAC	  probes,	  
BACs	  were	   labeled	  with	  either	  biotin	   (Biotin-­‐Nick	  Translation	  Mix;	  Roche)	  or	  digoxigenin	   (Dig-­‐
Nick	   Translation	   Mix;	   Roche),	   as	   per	   manufacturer	   instructions.	   200	   ng	   of	   BAC	   DNA	   was	  
precipitated	   with	   mouse	   Cot1	   DNA	   (Invitrogen;	   ratio	   of	   BAC	   DNA	   to	   Cot1	   DNA,	   1:20),	  
resuspended	   in	  15	  µl	  of	  hybridization	  solution	   (50%	   formamide,	  2X	  SSC,	  10%	  dextran	  sulfate,	  
and	  0.15%	  SDS),	  and	  co-­‐denatured	  on	  slides	   for	  4	  min	  at	  73°C.	  Slides	  were	  then	   incubated	   in	  
humidified	  chamber	  at	  37°C	  for	  16	  h,	  washed	  three	  times	  in	  50%	  formamide/2X	  SSC	  for	  5	  min	  
at	  45°C,	  washed	  three	  times	  in	  0.1X	  SSC	  for	  5	  min	  at	  45°C,	  and	  incubated	  with	  avidin-­‐Cy3	  and	  
anti–digoxigenin-­‐FITC	  (Roche;	  1:200	  and	  1:400	  dilution,	  respectively)	  in	  2XSSC/0.05%	  Tween-­‐20	  
for	   1	   h	   at	   37°C.	   After	   three	   washes	   in	   4XSSC/0.05%	   Tween-­‐20,	   slides	   were	   mounted	   in	  
Vectashield	   with	   DAPI	   (Vector	   Laboratories).	   Image	   acquisition	   was	   performed	   as	   outlined	  
above.	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Cloning	   translocation	   junction.	  Genomic	  DNA	   from	   the	   tumor	  was	   individually	  digested	  with	  
various	   restriction	   enzymes	   such	   as	   XbaI,	   SacI,	   and	   PstI	   for	   12	   hours	   and	   then	   purified	  with	  
phenol–chloroform.	   Purified	   DNA	   was	   then	   end-­‐repaired	   with	   a	   combination	   of	   T4	   DNA	  
polymerase,	  DNA	  pol	  I	  Klenow	  fragment,	  and	  T4	  polynucleotide	  kinase	  for	  30	  minutes	  at	  20°C.	  
End-­‐repaired	  DNA	  was	  purified	   and	  A-­‐tailed	  with	  Klenow	  polymerase	  without	  3’	   exonuclease	  
activity.	  A-­‐tailed	  fragments	  were	  then	  ligated	  to	  an	  asymmetric	  adaptor	  at	  a	  molar	  ratio	  of	  20:1	  
for	  one	  hour	  at	  25°C.	  Nested	  PCR	  with	  adaptor-­‐	  and	  locus-­‐specific	  PCR	  primers	  were	  performed	  
on	  ligated	  and	  purified	  DNA	  fragment.	  The	  first	  round	  of	  PCR,	  100-­‐250	  ng	  of	  DNA	  was	  amplified	  
in	  a	  final	  volume	  of	  50	  μl	  using	  a	  forward	  primer	  downstream	  of	  c-­‐myc	   locus	  and	  an	  adaptor-­‐
specific	   reverse	   primer	   (see	   table	   below	   for	   primer	   sequences)	   and	   Phusion	   polymerase	  
(Finnzymes).	  20	  PCR	  cycles	  were	  performed	  in	  the	  following	  conditions:	  98°C	  for	  20	  s,	  65°C	  for	  
30	   s,	   and	   72°C	   for	   4	  minutes.	   The	   second	   round	   of	   PCR	  was	   performed	  with	   another	   set	   of	  
primers	  nested	   from	   the	   first	  c-­‐myc	   and	  adaptor-­‐specific	  primers	  with	   the	   same	  condition	  as	  
described	   above	   but	   with	   30	   PCR	   cycles	   (see	   table	   below	   for	   primer	   sequences).	   After	  
amplification,	  PCR	  products	  were	  run	  on	  1%	  agarose	  gel	  and	  the	  PCR	  band	  was	  cut	  out	  and	  DNA	  
extracted	   from	  the	  gel.	  Purified	  PCR	  product	  was	   sent	   to	   sequencing.	  Sequencing	   reads	   from	  
each	   tumor	   samples	   were	   aligned	   to	   mouse	   reference	   genome	   (Mouse	   July	   2007-­‐NCBI	  
Build37/mm9)	  with	  the	  BLAT	  program	  (Kent,	  2002).	  
	  
Gene	   targeting	   of	   c-­‐myc25xI-­‐SceI	   allele.	   To	   generate	   the	   targeting	   construct,	   the	   I-­‐SceI	   site	  
cassette	  was	   inserted	   into	   the	  pLNTK	   targeting	  vector	  and	   flanked	  with	  a	  4.6-­‐kb	  SphI–SphI	  5’	  
homology	  arm	  encompassing	  c-­‐myc	  exon 1,	  and	  a	  2.6-­‐kb	  SphI–SphI	  3’	  homology	  arm	  containing	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c-­‐myc	  exons	  2	  and	  3.	  The	  targeting	  construct	  was	  electroporated	  into	  TC1	  (129/Sv)	  ES	  cells,	  and	  
screened	  EcoRI-­‐digested	  DNA	  to	  identify	  potentially	  targeted	  ES	  cell	  clones	  by	  Southern	  blotting	  
with	  a	  5’	  probe	  consisting	  of	  the	  1.5-­‐kb	  XbaI–XbaI	  fragment	  upstream	  of	  c-­‐myc	  exon	  1,	  and	  a	  3’	  
probe	  consisting	  of	  the	  1.5-­‐kb	  XhoI–KpnI	  fragment	  downstream	  of	  c-­‐myc	  exon	  3.	  The	  neomycin	  
cassette	   was	   deleted	   from	   targeted	   ES	   clones	   by	   infection	   with	   adenovirus	   expressing	   Cre-­‐
recombinase	  and	  used	   those	   to	   inject	   for	   germline	   transmission	   to	   generate	   c-­‐myc25xI-­‐SceI/WT	  
mice.	  To	  generate	  the	  ROSAI-­‐SceI-­‐GR	  allele,	  the	  previously	  described	  strategy	  (Sasaki	  et	  al.,	  2006)	  
was	   followed	   to	   target	   an	   I-­‐SceI-­‐GR/IRES-­‐tdTomato	   expression	   cassette	   into	   TC1	   (129/Sv)	   ES	  
cells.	   In	  both	  cases,	  the	  Neo	  cassette	  was	  deleted	  from	  targeted	  ES	  clones	  by	  infection	  with	  a	  
Cre-­‐recombinase-­‐expressing	  adenovirus	  before	  generating	  ROSAI-­‐SceI-­‐GR	  mice.	  
	  
B	  cell	  culture	  conditions,	  retroviral	  infection,	  and	  CSR	  assays.	  CD43-­‐	  B	  cells	  were	  isolated	  from	  
spleen	  and	  were	  put	  in	  culture	  at	  a	  density	  of	  1x106/ml	  in	  RPMI	  medium	  containing	  fetal	  bovine	  
serum,	  αCD40	  (1	  μg/ml,	  eBioscience)	  and	  IL-­‐4	  (20	  ng/ml,	  R&D	  Systems).	  Retroviral	  supernatants	  
were	  prepared	  from	  Phoenix	  packaging	  cells	  transfected	  with	  pMX-­‐I-­‐SceI	  vector	  or	  empty	  pMX	  
vector	   as	   control.	   After	   24	   hr	   of	   culture,	   retroviral	   infection	   was	   performed	   by	   adding	   one	  
volume	   of	   viral	   supernatant,	   spinning	   for	   1.5	   hr	   at	   2400	   RPM	   at	   24	   °C	   in	   the	   presence	   of	  
polybrene	  at	   2.5	  μg/ml	   and	   incubating	   cells	  with	   viral	   supernatant	  overnight.	  After	   infection,	  
medium	  was	  changed	  and	  cells	  were	  replated	  at	  0.5x106/ml.	  At	  day	  4	  of	  stimulation,	  infection	  
efficiency	  was	  evaluated	  by	  measuring	   the	  percentage	  of	   cells	   expressing	   the	   retroviral	   IRES-­‐
GFP	  and	  was	  found	  to	  be	  usually	  between	  50%	  and	  85%.	  ROSAI-­‐SceI-­‐GR	  B	  cells	  were	  cultured	   in	  
RPMI	   medium	   as	   above	   but	   with	   15%	   charcoal-­‐stripped	   fetal	   bovine	   serum	   to	   minimize	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nonspecific	   activation	   of	   the	   I-­‐SceI-­‐GR	   fusion	   and	   thus	   obtain	   high	   levels	   of	   cutting	   at	   the	  
appropriate	   time.	  CSR	  was	  evaluated	   in	   the	  case	  of	   retrovirally	   infected	  cells	  by	  staining	  with	  
Cy5-­‐PE-­‐labeled	   anti-­‐mouse	   B220	   (eBiosciences)	   and	   PE-­‐labeled	   anti-­‐mouse	   IgG1	   (BD	  
Biosciences).	  The	  TA-­‐induced	  ROSAI-­‐SceI-­‐GR	  B	  cells	  were	  evaluated	  by	  staining	  with	  Cy5-­‐PE-­‐labeled	  
anti-­‐mouse	  B220	  and	  FITC-­‐labeled	  anti-­‐mouse	  IgG1	  (BD	  Biosciences).	  CSR	  ranged	  between	  15%	  
and	   40%	   for	   retrovirus-­‐infected	   B	   cells	   and	   9%–12%	   for	   TA-­‐induced	   B	   cells,	   due	   to	   lower	  
proliferation	  rates	  in	  charcoal	  stripped	  serum.	  DNA	  was	  prepared	  from	  cells	  at	  day	  4	  of	  culture	  
by	  standard	  methods.	  
	  
Generation	  of	  HTGTS	  libraries	  by	  adaptor-­‐PCR.	  Genomic	  DNA	  from	  c-­‐myc25xI-­‐SceI	  and	  c-­‐myc25xI-­‐
SceI/ROSAI-­‐SceI-­‐GR	  B	  cells	  was	  digested	  overnight	  with	  HaeIII	  and	  HaeIII-­‐generated	  blunt	  ends	  were	  
A-­‐tailed	  with	  Klenow	  polymerase.	  An	  asymmetric	  adaptor	  (composed	  of	  an	  upper	  linker	  and	  a	  
lower	  3’-­‐modified	   linker)	  was	   then	   ligated	  to	   fragmented	  DNA	  at	  a	  molar	   ratio	  of	  20:1	   for	  30	  
min	  at	  25°C.	  To	  remove	  unrearranged	  I-­‐SceI	  cassettes,	  ligation	  reactions	  were	  digested	  either	  
with	   I-­‐SceI,	   or	   with	   both	   EcoRV	   and	   XbaI.	   The	   blocking	   digests	   were	   carried	   out	   for	   8	   hr.	  
Translocation	   junctions	   were	   then	   PCR-­‐amplified	   using	   the	   emulsion	   (em)-­‐PCR	   approach	   as	  
previously	  described	  (Williams	  et	  al.,	  2006).	  In	  the	  first	  round	  of	  PCR,	  1	  μg	  of	  DNA	  was	  amplified	  
in	   a	   final	   volume	   of	   50	   μl,	   using	   a	   biotinylated	   forward	   primer	   (Myc-­‐H;	   see	   table	   below	   for	  
primer	   sequences)	   and	   an	   adaptor-­‐specific	   reverse	   primer	   (AP1)	   and	   Phusion	   polymerase	  
(Finnzymes).	  20	  PCR	  cycles	  were	  performed	  in	  the	  following	  conditions:	  98°C	  for	  10	  s,	  58°C	  for	  
30	  s,	  and	  72°C	  for	  30	  s.	  Multiple	  reactions	  were	  performed	   in	  generating	   large-­‐scale	   libraries.	  
Thereafter,	  biotinylated	  PCR	  products	  were	   isolated	  using	  the	  Dynabeads	  MyOne	  Streptavidin	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C1	  kit	  (Invitrogen)	  and	  an	  additional	  3	  hr	  digestion	  with	  blocking	  enzymes	  was	  performed.	  PCR	  
products	  were	  eluted	  from	  the	  beads	  via	  a	  30	  min	  incubation	  at	  65°C	  in	  95%	  formamide/10	  mM	  
EDTA	  and	  purified.	  The	  purified	  products	  were	  then	  amplified	  in	  a	  second	  round	  with	  em-­‐PCR.	  
30	  μl	  of	  the	  first	  round	  PCR	  product,	  80	  pmol	  each	  of	  primers	  AP2	  and	  Myc-­‐Prelox,	  20	  μl	  ultra-­‐
pure	   BSA	   (Ambion)	   and	   2	   μl	   Taq	   polymerase	   (QIAGEN)	   in	   a	   final	   volume	   of	   200	   μl	   were	  
emulsified	  in	  400	  μl	  of	  an	  oil-­‐surfactant	  mixture.	  The	  emulsion	  mixture	  was	  divided	  into	  50	  μl	  
individual	  aliquots	  and	  PCR	  was	  performed	  using	  the	  following	  conditions:	  30	  cycles	  of	  94°C	  for	  
30	   s,	   60°C	   for	   30	   s,	   and	   72°C	   for	   1	   min.	   Following	   PCR,	   the	   products	   were	   pooled	   and	  
centrifuged	  in	  a	  table-­‐top	  centrifuge	  for	  5	  min	  at	  14,000	  RPM	  to	  separate	  the	  phases	  and	  the	  oil	  
layer	  was	  removed.	  The	  sample	  was	  then	  extracted	  3	  times	  with	  1	  ml	  of	  water-­‐saturated	  diethyl	  
ether	  and	  DNA	  was	  re-­‐purified.	  The	  third,	  non-­‐emulsion,	  round	  of	  PCR	  was	  performed	  with	  the	  
same	   primers	   as	   in	   round	   2,	   but	   with	   the	   addition	   of	   linkers	   and	   barcodes	   for	   MiSeq	  
sequencing.	  After	  amplification,	  the	  pooled	  PCR	  reactions	  were	  size-­‐fractionated	  between	  200	  
and	   800	   base	   pairs	   on	   agarose	   gel.	   PCR	   amplicons	   were	   sequenced	   by	   MiSeq	   (Illumina)	  
platform.	  Raw	  sequences	  were	  analyzed	  and	  mapped	  as	  described	  (Chiarle	  et	  al.,	  2011).	  
	  
	  
	   	  
	   130 
BIBLIOGRAPHY	  
	  
Ahnesorg,	  P.,	  Smith,	  P.	  &	  Jackson,	  S.	  XLF	  interacts	  with	  the	  XRCC4-­‐DNA	  ligase	  IV	  complex	  to	  
promote	  DNA	  nonhomologous	  end-­‐joining.	  Cell	  124,	  301–313	  (2006).	  
Alt,	  F.,	  Zhang,	  Y.,	  Meng,	  F.,	  Guo,	  C.	  &	  Schwer,	  B.	  Mechanisms	  of	  programmed	  DNA	  lesions	  and	  
genomic	  instability	  in	  the	  immune	  system.	  Cell	  152,	  417–429	  (2013).	  
Ambrose,	  M.	  &	  Gatti,	  R.	  Pathogenesis	  of	  ataxia-­‐telangiectasia:	  the	  next	  generation	  of	  ATM	  
functions.	  Blood	  121,	  4036–4045	  (2013).	  
Arnal,	  S.,	  Holub,	  A.,	  Salus,	  S.	  &	  Roth,	  D.	  Non-­‐consensus	  heptamer	  sequences	  destabilize	  the	  
RAG	  post-­‐cleavage	  complex,	  making	  ends	  available	  to	  alternative	  DNA	  repair	  pathways.	  Nucleic	  
Acids	  Res.	  38,	  2944–2954	  (2010).	  
Barlow,	  C.	  et	  al.	  Atm-­‐deficient	  mice:	  a	  paradigm	  of	  ataxia	  telangiectasia.	  Cell	  86,	  159–171	  
(1996).	  
Bassing,	  C.	  &	  Alt,	  F.	  The	  cellular	  response	  to	  general	  and	  programmed	  DNA	  double	  strand	  
breaks.	  DNA	  Repair	  3,	  781–796	  (2004).	  [A]	  
Bassing,	  C.	  &	  Alt,	  F.	  H2AX	  may	  function	  as	  an	  anchor	  to	  hold	  broken	  chromosomal	  DNA	  ends	  in	  
close	  proximity.	  Cell	  Cycle	  3,	  149–153	  (2004).	  [B]	  
Bassing,	  C.	  et	  al.	  Histone	  H2AX:	  a	  dosage-­‐dependent	  suppressor	  of	  oncogenic	  translocations	  
and	  tumors.	  Cell	  114,	  359–370	  (2003).	  
Bassing,	  C.	  et	  al.	  Increased	  ionizing	  radiation	  sensitivity	  and	  genomic	  instability	  in	  the	  absence	  
of	  histone	  H2AX.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  99,	  8173–8178	  (2002).	  
Bassing,	  C.	  et	  al.	  Recombination	  signal	  sequences	  restrict	  chromosomal	  V(D)J	  recombination	  
beyond	  the	  12/23	  rule.	  Nature	  405,	  583–586	  (2000).	  
Bednarski,	  J.	  &	  Sleckman,	  B.	  Integrated	  signaling	  in	  developing	  lymphocytes:	  the	  role	  of	  DNA	  
damage	  responses.	  Cell	  Cycle	  11,	  4129–4134	  (2012).	  
Bender,	  C.	  et	  al.	  Cancer	  predisposition	  and	  hematopoietic	  failure	  in	  Rad50(S/S)	  mice.	  Genes	  
Dev.	  16,	  2237–2251	  (2002).	  
Bernard,	  O.,	  Cory,	  S.,	  Gerondakis,	  S.,	  Webb,	  E.	  &	  Adams,	  J.	  Sequence	  of	  the	  murine	  and	  human	  
cellular	  myc	  oncogenes	  and	  two	  modes	  of	  myc	  transcription	  resulting	  from	  chromosome	  
translocation	  in	  B	  lymphoid	  tumours.	  The	  EMBO	  Journal	  2,	  2375-­‐2383	  (1983).	  
	   131 
Boboila,	  C.	  et	  al.	  Alternative	  end-­‐joining	  catalyzes	  class	  switch	  recombination	  in	  the	  absence	  of	  
both	  Ku70	  and	  DNA	  ligase	  4.	  J.	  Exp.	  Med.	  207,	  417–427	  (2010).	  
Boboila,	  C.,	  Alt,	  F.	  &	  Schwer,	  B.	  Classical	  and	  alternative	  end-­‐joining	  pathways	  for	  repair	  of	  
lymphocyte-­‐specific	  and	  general	  DNA	  double-­‐strand	  breaks.	  Adv.	  Immunol.	  116,	  1–49	  (2012).	  
Bohgaki,	  T.,	  Bohgaki,	  M.	  &	  Hakem,	  R.	  DNA	  double-­‐strand	  break	  signaling	  and	  human	  disorders.	  
Genome	  Integr.	  1,	  15	  (2010).	  	  
Bolland,	  D.	  et	  al.	  Antisense	  intergenic	  transcription	  in	  V(D)J	  recombination.	  Nat.	  Immunol.	  5,	  
630–637	  (2004).	  
Borghesani,	  P.	  et	  al.	  Abnormal	  development	  of	  Purkinje	  cells	  and	  lymphocytes	  in	  Atm	  mutant	  
mice.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  97,	  3336–3341	  (2000).	  
Bossen,	  C.,	  Mansson,	  R.	  &	  Murre,	  C.	  Chromatin	  topology	  and	  the	  regulation	  of	  antigen	  receptor	  
assembly.	  Annu.	  Rev.	  Immunol.	  30,	  337–356	  (2012).	  
Boultwood,	  J.	  Ataxia	  telangiectasia	  gene	  mutations	  in	  leukaemia	  and	  lymphoma.	  J.	  Clin.	  Pathol.	  
54,	  512–516	  (2001).	  
Brady,	  B.,	  Steinel,	  N.	  &	  Bassing,	  C.	  Antigen	  receptor	  allelic	  exclusion:	  an	  update	  and	  reappraisal.	  
J.	  Immunol.	  185,	  3801–3808	  (2010).	  
Bredemeyer,	  A.	  et	  al.	  ATM	  stabilizes	  DNA	  double-­‐strand-­‐break	  complexes	  during	  V(D)J	  
recombination.	  Nature	  442,	  466–470	  (2006).	  
Buck,	  D.	  et	  al.	  Cernunnos,	  a	  novel	  nonhomologous	  end-­‐joining	  factor,	  is	  mutated	  in	  human	  
immunodeficiency	  with	  microcephaly.	  Cell	  124,	  287–299	  (2006).	  
Bunting,	  S.	  &	  Nussenzweig,	  A.	  End-­‐joining,	  translocations	  and	  cancer.	  Nature	  Rev.	  Cancer	  13,	  
443-­‐454	  (2013).	  
Butterworth,	  S.	  &	  Taylor,	  A.	  A	  subpopulation	  of	  t(2;14)(p11;q32)	  cells	  in	  ataxia	  telangiectasia	  B	  
lymphocytes.	  Hum.	  Genet.	  73,	  346–349	  (1986).	  
Callebaut,	  I.	  et	  al.	  Cernunnos	  interacts	  with	  the	  XRCC4	  x	  DNA-­‐ligase	  IV	  complex	  and	  is	  
homologous	  to	  the	  yeast	  nonhomologous	  end-­‐joining	  factor	  Nej1.	  J.	  Biol.	  Chem.	  281,	  13857–
13860	  (2006).	  
Callén,	  E.	  et	  al.	  Chimeric	  IgH-­‐TCRalpha/delta	  translocations	  in	  T	  lymphocytes	  mediated	  by	  RAG.	  
Cell	  Cycle	  8,	  2408–2412	  (2009).	  
	   132 
Callén,	  E.,	  Nussenzweig,	  M.	  &	  Nussenzweig,	  A.	  Breaking	  down	  cell	  cycle	  checkpoints	  and	  DNA	  
repair	  during	  antigen	  receptor	  gene	  assembly.	  Oncogene	  26,	  7759–7764	  (2007).	  	  
Casellas,	  R.,	  Yamane,	  A.,	  Kovalchuk,	  A.	  &	  Potter,	  M.	  Restricting	  activation-­‐induced	  cytidine	  
deaminase	  tumorigenic	  activity	  in	  B	  lymphocytes.	  Immunology	  126,	  316–328	  (2009).	  
Cavalli,	  G.	  &	  Misteli,	  T.	  Functional	  implications	  of	  genome	  topology.	  Nat.	  Struct.	  Mol.	  Biol.	  20,	  
290–299	  (2013).	  
Celeste,	  A.	  et	  al.	  Genomic	  instability	  in	  mice	  lacking	  histone	  H2AX.	  Science	  296,	  922–927	  (2002).	  
Celeste,	  A.	  et	  al.	  H2AX	  haploinsufficiency	  modifies	  genomic	  stability	  and	  tumor	  susceptibility.	  
Cell	  114,	  371–383	  (2003).	  
Chaudhuri,	  J.	  et	  al.	  Evolution	  of	  the	  immunoglobulin	  heavy	  chain	  class	  switch	  recombination	  
mechanism.	  Adv.	  Immunol.	  94,	  157–214	  (2007).	  
Chaudhuri,	  J.,	  Khuong,	  C.	  &	  Alt,	  F.	  Replication	  protein	  A	  interacts	  with	  AID	  to	  promote	  
deamination	  of	  somatic	  hypermutation	  targets.	  Nature	  430,	  992–998	  (2004).	  
Chen,	  J.,	  Cooper,	  D.,	  Férec,	  C.,	  Kehrer-­‐Sawatzki,	  H.	  &	  Patrinos,	  G.	  Genomic	  rearrangements	  in	  
inherited	  disease	  and	  cancer.	  Semin.	  Cancer	  Biol.	  20,	  222–233	  (2010).	  
Chiarle,	  R.	  et	  al.	  Genome-­‐wide	  Translocation	  Sequencing	  Reveals	  Mechanisms	  of	  Chromosome	  
Breaks	  and	  Rearrangements	  in	  B	  Cells.	  Cell	  147,	  107–119	  (2011).	  
Cobb,	  R.,	  Oestreich,	  K.,	  Osipovich,	  O.	  &	  Oltz,	  E.	  Accessibility	  control	  of	  V(D)J	  recombination.	  Adv.	  
Immunol.	  91,	  45–109	  (2006).	  
Corneo,	  B.	  et	  al.	  Rag	  mutations	  reveal	  robust	  alternative	  end	  joining.	  Nature	  449,	  483–486	  
(2007).	  
Coster,	  G.	  &	  Goldberg,	  M.	  The	  cellular	  response	  to	  DNA	  damage:	  a	  focus	  on	  MDC1	  and	  its	  
interacting	  proteins.	  Nucleus	  1,	  166–178	  (2010).	  
Cowell,	  L.,	  Davila,	  M.,	  Kepler,	  T.	  &	  Kelsoe,	  G.	  Identification	  and	  utilization	  of	  arbitrary	  
correlations	  in	  models	  of	  recombination	  signal	  sequences.	  Genome	  Biol.	  3,	  72.1-­‐72.20	  (2002).	  
Crouch,	  E.	  et	  al.	  Regulation	  of	  AID	  expression	  in	  the	  immune	  response.	  J.	  Exp.	  Med.	  204,	  1145–
1156	  (2007).	  
	  
Davey,	  M.	  et	  al.	  Juxtaposition	  of	  the	  T-­‐cell	  receptor	  alpha-­‐chain	  locus	  (14q11)	  and	  a	  region	  
(14q32)	  of	  potential	  importance	  in	  leukemogenesis	  by	  a	  14;14	  translocation	  in	  a	  patient	  with	  T-­‐
	   133 
cell	  chronic	  lymphocytic	  leukemia	  and	  ataxia-­‐telangiectasia.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  85,	  
9287-­‐9291	  (1988).	  
	  
de	  Yébenes,	  V.	  et	  al.	  miR-­‐181b	  negatively	  regulates	  activation-­‐induced	  cytidine	  deaminase	  in	  B	  
cells.	  J.	  Exp.	  Med.	  205,	  2199–2206	  (2008).	  
	  
Derheimer,	  F.	  &	  Kastan,	  M.	  Multiple	  roles	  of	  ATM	  in	  monitoring	  and	  maintaining	  DNA	  integrity.	  
FEBS	  Lett.	  584,	  3675–3681	  (2010).	  
	  
Di	  Noia,	  J.	  &	  Neuberger,	  M.	  Molecular	  mechanisms	  of	  antibody	  somatic	  hypermutation.	  Annu.	  
Rev.	  Biochem.	  76,	  1–22	  (2007).	  
	  
Difilippantonio,	  M.	  et	  al.	  Evidence	  for	  replicative	  repair	  of	  DNA	  double-­‐strand	  breaks	  leading	  to	  
oncogenic	  translocation	  and	  gene	  amplification.	  J.	  Exp.	  Med.	  196,	  469-­‐480	  (2002).	  
	  
Dik,	  W.	  et	  al.	  Different	  chromosomal	  breakpoints	  impact	  the	  level	  of	  LMO2	  expression	  in	  T-­‐ALL.	  
Blood	  110,	  388–392	  (2007).	  
Dixon,	  J.	  et	  al.	  Topological	  domains	  in	  mammalian	  genomes	  identified	  by	  analysis	  of	  chromatin	  
interactions.	  Nature	  485,	  376–380	  (2012).	  
Donehower,	  L.	  et	  al.	  Mice	  deficient	  for	  p53	  are	  developmentally	  normal	  but	  susceptible	  to	  
spontaneous	  tumours.	  Nature	  356,	  215–221	  (1992).	  
Dorsett,	  Y.	  et	  al.	  MicroRNA-­‐155	  suppresses	  activation-­‐induced	  cytidine	  deaminase-­‐mediated	  
Myc-­‐Igh	  translocation.	  Immunity	  28,	  630–638	  (2008).	  
Dudley,	  D.,	  Chaudhuri,	  J.,	  Bassing,	  C.	  &	  Alt,	  F.	  Mechanism	  and	  control	  of	  V(D)J	  recombination	  
versus	  class	  switch	  recombination:	  similarities	  and	  differences.	  Adv.	  Immunol.	  86,	  43–112	  
(2005).	  
Dvorak,	  C.	  &	  Cowan,	  M.	  Radiosensitive	  severe	  combined	  immunodeficiency	  disease.	  Immunol.	  
Allergy	  Clin.	  North	  Am.	  30,	  125–142	  (2010).	  
Ebert,	  A.	  et	  al.	  The	  distal	  V(H)	  gene	  cluster	  of	  the	  Igh	  locus	  contains	  distinct	  regulatory	  elements	  
with	  Pax5	  transcription	  factor-­‐dependent	  activity	  in	  pro-­‐B	  cells.	  Immunity	  34,	  175–187	  (2011).	  
Ehlich,	  A.,	  Martin,	  V.,	  Müller,	  W.	  &	  Rajewsky,	  K.	  Analysis	  of	  the	  B-­‐cell	  progenitor	  compartment	  
at	  the	  level	  of	  single	  cells.	  Curr.	  Biol.	  4,	  573–583	  (1994).	  
Elson,	  A.	  et	  al.	  Pleiotropic	  defects	  in	  ataxia-­‐telangiectasia	  protein-­‐deficient	  mice.	  Proc.	  Natl.	  
Acad.	  Sci.	  U.S.A.	  93,	  13084–13089	  (1996).	  
	   134 
Evans,	  P.	  et	  al.	  Radiation-­‐induced	  delayed	  cell	  death	  in	  a	  hypomorphic	  Artemis	  cell	  line.	  Hum.	  
Mol.	  Genet.	  15,	  1303–1311	  (2006).	  
Feldhahn,	  N.	  et	  al.	  Activation-­‐induced	  cytidine	  deaminase	  acts	  as	  a	  mutator	  in	  BCR-­‐ABL1-­‐
transformed	  acute	  lymphoblastic	  leukemia	  cells.	  J.	  Exp.	  Med.	  204,	  1157–1166	  (2007).	  
Fernandez-­‐Capetillo,	  O.,	  Lee,	  A.,	  Nussenzweig,	  M.	  &	  Nussenzweig,	  A.	  H2AX:	  the	  histone	  
guardian	  of	  the	  genome.	  DNA	  Repair	  3,	  959–967	  (2004).	  
Franco,	  S.,	  Alt,	  F.	  &	  Manis,	  J.	  Pathways	  that	  suppress	  programmed	  DNA	  breaks	  from	  progressing	  
to	  chromosomal	  breaks	  and	  translocations.	  DNA	  Repair	  5,	  1030–1041	  (2006).	  
Frank,	  K.	  et	  al.	  Late	  embryonic	  lethality	  and	  impaired	  V(D)J	  recombination	  in	  mice	  lacking	  DNA	  
ligase	  IV.	  Nature	  396,	  173–177	  (1998).	  
Gao,	  Y.	  et	  al.	  A	  targeted	  DNA-­‐PKcs-­‐null	  mutation	  reveals	  DNA-­‐PK-­‐independent	  functions	  for	  KU	  
in	  V(D)J	  recombination.	  Immunity	  9,	  367–376	  (1998).	  
Gao,	  Y.	  et	  al.	  Interplay	  of	  p53	  and	  DNA-­‐repair	  protein	  XRCC4	  in	  tumorigenesis,	  genomic	  stability	  
and	  development.	  Nature	  404,	  897–900	  (2000).	  
Geisberger,	  R.,	  Rada,	  C.	  &	  Neuberger,	  M.	  The	  stability	  of	  AID	  and	  its	  function	  in	  class-­‐switching	  
are	  critically	  sensitive	  to	  the	  identity	  of	  its	  nuclear-­‐export	  sequence.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  
106,	  6736–6741	  (2009).	  
Gennery,	  A.	  Primary	  immunodeficiency	  syndromes	  associated	  with	  defective	  DNA	  double-­‐
strand	  break	  repair.	  Br.	  Med.	  Bull.	  77-­‐78,	  71–85	  (2006).	  
Giunta,	  S.	  &	  Jackson,	  S.	  Give	  me	  a	  break,	  but	  not	  in	  mitosis:	  the	  mitotic	  DNA	  damage	  response	  
marks	  DNA	  double-­‐strand	  breaks	  with	  early	  signaling	  events.	  Cell	  Cycle	  10,	  1215–1221	  (2011).	  
Goedecke,	  W.,	  Eijpe,	  M.,	  Offenberg,	  H.,	  van	  Aalderen,	  M.	  &	  Heyting,	  C.	  Mre11	  and	  Ku70	  
interact	  in	  somatic	  cells,	  but	  are	  differentially	  expressed	  in	  early	  meiosis.	  Nat.	  Genet.	  23,	  194–
198	  (1999).	  
Gostissa,	  M.	  et	  al.	  Conditional	  inactivation	  of	  p53	  in	  mature	  B	  cells	  promotes	  generation	  of	  
nongerminal	  center-­‐derived	  B-­‐cell	  lymphomas.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  110,	  2934–2939	  
(2013).	  
Gostissa,	  M.	  et	  al.	  Long-­‐range	  oncogenic	  activation	  of	  Igh-­‐c-­‐myc	  translocations	  by	  the	  Igh	  3’	  
regulatory	  region.	  Nature	  462,	  803–807	  (2009).	  
Gostissa,	  M.,	  Alt,	  F.	  &	  Chiarle,	  R.	  Mechanisms	  that	  promote	  and	  suppress	  chromosomal	  
translocations	  in	  lymphocytes.	  Annu.	  Rev.	  Immunol.	  29,	  319–350	  (2011).	  
	   135 
Gottlieb,	  T.	  &	  Jackson,	  S.	  The	  DNA-­‐dependent	  protein	  kinase:	  requirement	  for	  DNA	  ends	  and	  
association	  with	  Ku	  antigen.	  Cell	  72,	  131–142	  (1993).	  
Grabarz,	  A.,	  Barascu,	  A.,	  Guirouilh-­‐Barbat,	  J.	  &	  Lopez,	  B.	  Initiation	  of	  DNA	  double	  strand	  break	  
repair:	  signaling	  and	  single-­‐stranded	  resection	  dictate	  the	  choice	  between	  homologous	  
recombination,	  non-­‐homologous	  end-­‐joining	  and	  alternative	  end-­‐joining.	  Am.	  J.	  Cancer	  Res.	  2,	  
249–268	  (2012).	  
Gu,	  Y.,	  Jin,	  S.,	  Gao,	  Y.,	  Weaver,	  D.	  &	  Alt,	  F.	  Ku70-­‐deficient	  embryonic	  stem	  cells	  have	  increased	  
ionizing	  radiosensitivity,	  defective	  DNA	  end-­‐binding	  activity,	  and	  inability	  to	  support	  V(D)J	  
recombination.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  94,	  8076–8081	  (1997).	  
Guipaud,	  O.	  et	  al.	  B-­‐cell	  chronic	  lymphocytic	  leukaemia:	  a	  polymorphic	  family	  unified	  by	  
genomic	  features.	  Lancet	  Oncol.	  4,	  505–514	  (2003).	  
Guirouilh-­‐Barbat,	  J.	  et	  al.	  Impact	  of	  the	  KU80	  pathway	  on	  NHEJ-­‐induced	  genome	  
rearrangements	  in	  mammalian	  cells.	  Mol.	  Cell	  14,	  611–623	  (2004).	  
Guirouilh-­‐Barbat,	  J.,	  Huck,	  S.	  &	  Lopez,	  B.	  S-­‐phase	  progression	  stimulates	  both	  the	  mutagenic	  
KU-­‐independent	  pathway	  and	  mutagenic	  processing	  of	  KU-­‐dependent	  intermediates,	  for	  
nonhomologous	  end	  joining.	  Oncogene	  27,	  1726–1736	  (2008).	  
Gumy-­‐Pause,	  F.,	  Wacker,	  P.	  &	  Sappino,	  A.	  ATM	  gene	  and	  lymphoid	  malignancies.	  Leukemia	  18,	  
238–242	  (2004).	  
Guo,	  C.	  et	  al.	  CTCF-­‐binding	  elements	  mediate	  control	  of	  V(D)J	  recombination.	  Nature	  477,	  424–
430	  (2011).	  
Gutierrez,	  A.	  et	  al.	  The	  BCL11B	  tumor	  suppressor	  is	  mutated	  across	  the	  major	  molecular	  
subtypes	  of	  T-­‐cell	  acute	  lymphoblastic	  leukemia.	  Blood	  118,	  4169–4173	  (2011).	  
Hecht,	  J.	  &	  Aster,	  J.	  Molecular	  biology	  of	  Burkitt’s	  lymphoma.	  J.	  Clin.	  Oncol.	  18,	  3707–3721	  
(2000).	  
Heintzman,	  N.	  et	  al.	  Distinct	  and	  predictive	  chromatin	  signatures	  of	  transcriptional	  promoters	  
and	  enhancers	  in	  the	  human	  genome.	  Nat.	  Genet.	  39,	  311–318	  (2007).	  
Helmink,	  B.	  &	  Sleckman,	  B.	  The	  response	  to	  and	  repair	  of	  RAG-­‐mediated	  DNA	  double-­‐strand	  
breaks.	  Annu.	  Rev.	  Immunol.	  30,	  175–202	  (2012).	  
Henderson,	  A.	  &	  Calame,	  K.	  Transcriptional	  regulation	  during	  B	  cell	  development.	  Annu.	  Rev.	  
Immunol.	  16,	  163-­‐200	  (1998).	  
	   136 
Hesslein,	  D.	  &	  Schatz,	  D.	  Factors	  and	  forces	  controlling	  V(D)J	  recombination.	  Adv.	  Immunol.	  78,	  
169–232	  (2001).	  
Hewitt,	  S.,	  Chaumeil,	  J.	  &	  Skok,	  J.	  Chromosome	  dynamics	  and	  the	  regulation	  of	  V(D)J	  
recombination.	  Immunol.	  Rev.	  237,	  43–54	  (2010).	  
Hoeijmakers,	  J.	  DNA	  damage,	  aging,	  and	  cancer.	  N.	  Engl.	  J.	  Med.	  361,	  1475–1485	  (2009).	  
Huang,	  C.	  et	  al.	  Defects	  in	  coding	  joint	  formation	  in	  vivo	  in	  developing	  ATM-­‐deficient	  B	  and	  T	  
lymphocytes.	  J.	  Exp.	  Med.	  204,	  1371–1381	  (2007).	  
Jabbour,	  E.	  &	  Kantarjian,	  H.	  Chronic	  myeloid	  leukemia:	  2012	  update	  on	  diagnosis,	  monitoring,	  
and	  management.	  Am.	  J.	  Hematol.	  87,	  1037–1045	  (2012).	  
Jacks,	  T.	  et	  al.	  Tumor	  spectrum	  analysis	  in	  p53-­‐mutant	  mice.	  Curr.	  Biol.	  4,	  1–7	  (1994).	  
Jackson,	  K.,	  Kidd,	  M.,	  Wang,	  Y.	  &	  Collins,	  A.	  The	  shape	  of	  the	  lymphocyte	  receptor	  repertoire:	  
lessons	  from	  the	  B	  cell	  receptor.	  Front.	  Immunol.	  4,	  263	  (2013).	  
Janz,	  S.	  Myc	  translocations	  in	  B	  cell	  and	  plasma	  cell	  neoplasms.	  DNA	  Repair	  5,	  1213–1224	  
(2006).	  
Ji,	  Y.	  et	  al.	  The	  in	  vivo	  pattern	  of	  binding	  of	  RAG1	  and	  RAG2	  to	  antigen	  receptor	  loci.	  Cell	  141,	  
419–431	  (2010).	  
Jones,	  J.	  &	  Simkus,	  C.	  The	  roles	  of	  the	  RAG1	  and	  RAG2	  “non-­‐core”	  regions	  in	  V(D)J	  
recombination	  and	  lymphocyte	  development.	  Arch.	  Immunol.	  Ther.	  Exp.	  (Warsz).	  57,	  105–116	  
(2009).	  
Jung,	  D.	  et	  al.	  Extrachromosomal	  recombination	  substrates	  recapitulate	  beyond	  12/23	  
restricted	  VDJ	  recombination	  in	  nonlymphoid	  cells.	  Immunity	  18,	  65–74	  (2003).	  
Jung,	  D.,	  Giallourakis,	  C.,	  Mostoslavsky,	  R.	  &	  Alt,	  F.	  Mechanism	  and	  control	  of	  V(D)J	  
recombination	  at	  the	  immunoglobulin	  heavy	  chain	  locus.	  Annu.	  Rev.	  Immunol.	  24,	  541–570	  
(2006).	  
Keim,	  C.,	  Kazadi,	  D.,	  Rothschild,	  G.	  &	  Basu,	  U.	  Regulation	  of	  AID,	  the	  B-­‐cell	  genome	  mutator.	  
Genes	  Dev.	  27,	  1–17	  (2013).	  
Kent,	  W.	  BLAT-­‐-­‐the	  BLAST-­‐like	  alignment	  tool.	  Genome	  Res.	  12,	  656–664	  (2002).	  
Kirsch,	  I.,	  Brown,	  J.,	  Lawrence,	  J.,	  Korsmeyer,	  S.	  &	  Morton,	  C.	  Translocations	  that	  highlight	  
chromosomal	  regions	  of	  differentiated	  activity.	  Cancer	  Genet.	  Cytogenet.	  18,	  159–171	  (1985).	  
	   137 
Klein,	  I.	  et	  al.	  Translocation-­‐capture	  sequencing	  reveals	  the	  extent	  and	  nature	  of	  chromosomal	  
rearrangements	  in	  B	  lymphocytes.	  Cell	  147,	  95–106	  (2011).	  
Klein,	  U.	  &	  Dalla-­‐Favera,	  R.	  New	  insights	  into	  the	  pathogenesis	  of	  chronic	  lymphocytic	  leukemia.	  
Semin.	  Cancer	  Biol.	  20,	  377–383	  (2010).	  
Krangel,	  M.	  Mechanics	  of	  T	  cell	  receptor	  gene	  rearrangement.	  Curr.	  Opin.	  Immunol.	  21,	  133–
139	  (2009).	  
Küppers,	  R.	  &	  Dalla-­‐Favera,	  R.	  Mechanisms	  of	  chromosomal	  translocations	  in	  B	  cell	  lymphomas.	  
Oncogene	  20,	  5580–5594	  (2001).	  
Küppers,	  R.	  Mechanisms	  of	  B-­‐cell	  lymphoma	  pathogenesis.	  Nat.	  Rev.	  Cancer	  5,	  251–262	  (2005).	  
Lansford,	  R.,	  Manis,	  J.,	  Sonoda,	  E.,	  Rajewsky,	  K.	  &	  Alt,	  F.	  Ig	  heavy	  chain	  class	  switching	  in	  Rag-­‐
deficient	  mice.	  Int.	  Immunol.	  10,	  325–332	  (1998).	  
Larmonie,	  N.	  et	  al.	  Breakpoint	  sites	  disclose	  the	  role	  of	  the	  V(D)J	  recombination	  machinery	  in	  
the	  formation	  of	  T-­‐cell	  receptor	  (TCR)	  and	  non-­‐TCR	  associated	  aberrations	  in	  T-­‐cell	  acute	  
lymphoblastic	  leukemia.	  Haematologica	  98,	  1173–1184	  (2013).	  
Le	  Noir,	  S.	  et	  al.	  Extensive	  molecular	  mapping	  of	  TCRα/δ-­‐	  and	  TCRβ-­‐involved	  chromosomal	  
translocations	  reveals	  distinct	  mechanisms	  of	  oncogene	  activation	  in	  T-­‐ALL.	  Blood	  120,	  3298–
3309	  (2012).	  
Lewis,	  S.,	  Agard,	  E.,	  Suh,	  S.	  &	  Czyzyk,	  L.	  Cryptic	  signals	  and	  the	  fidelity	  of	  V(D)J	  joining.	  Mol.	  Cell.	  
Biol.	  17,	  3125–3136	  (1997).	  
Li,	  G.	  et	  al.	  Lymphocyte-­‐specific	  compensation	  for	  XLF/cernunnos	  end-­‐joining	  functions	  in	  V(D)J	  
recombination.	  Mol.	  Cell	  31,	  631–640	  (2008).	  
Li,	  Z.	  et	  al.	  The	  XRCC4	  gene	  encodes	  a	  novel	  protein	  involved	  in	  DNA	  double-­‐strand	  break	  repair	  
and	  V(D)J	  recombination.	  Cell	  83,	  1079–1089	  (1995).	  
Liao,	  M.	  et	  al.	  No	  requirement	  for	  V(D)J	  recombination	  in	  p53-­‐deficient	  thymic	  lymphoma.	  Mol	  
Cell	  Biol.	  18,	  3495-­‐3501	  (1998).	  
Lieber,	  M.	  The	  mechanism	  of	  double-­‐strand	  DNA	  break	  repair	  by	  the	  nonhomologous	  DNA	  end-­‐
joining	  pathway.	  Annu.	  Rev.	  Biochem.	  79,	  181–211	  (2010).	  
Lieberman-­‐Aiden,	  E.	  et	  al.	  Comprehensive	  mapping	  of	  long-­‐range	  interactions	  reveals	  folding	  
principles	  of	  the	  human	  genome.	  Science	  326,	  289–293	  (2009).	  
	   138 
Liu,	  M.	  et	  al.	  Two	  levels	  of	  protection	  for	  the	  B	  cell	  genome	  during	  somatic	  hypermutation.	  
Nature	  451,	  841–845	  (2008).	  
Löbrich,	  M.	  &	  Jeggo,	  P.	  Harmonising	  the	  response	  to	  DSBs:	  a	  new	  string	  in	  the	  ATM	  bow.	  DNA	  
Repair	  4,	  749–759	  (2005).	  
Lou,	  Z.	  et	  al.	  MDC1	  maintains	  genomic	  stability	  by	  participating	  in	  the	  amplification	  of	  ATM-­‐
dependent	  DNA	  damage	  signals.	  Mol.	  Cell	  21,	  187–200	  (2006).	  
Luning	  Prak,	  E.,	  Monestier,	  M.	  &	  Eisenberg,	  R.	  B	  cell	  receptor	  editing	  in	  tolerance	  and	  
autoimmunity.	  Ann.	  N.	  Y.	  Acad.	  Sci.	  1217,	  96–121	  (2011).	  
Ma,	  Y.,	  Pannicke,	  U.,	  Schwarz,	  K.	  &	  Lieber,	  M.	  Hairpin	  opening	  and	  overhang	  processing	  by	  an	  
Artemis/DNA-­‐dependent	  protein	  kinase	  complex	  in	  nonhomologous	  end	  joining	  and	  V(D)J	  
recombination.	  Cell	  108,	  781–794	  (2002).	  
Magrath,	  I.	  Epidemiology:	  clues	  to	  the	  pathogenesis	  of	  Burkitt	  lymphoma.	  Br.	  J.	  Haematol.	  156,	  
744–756	  (2012).	  
Mahowald,	  G.	  et	  al.	  Aberrantly	  resolved	  RAG-­‐mediated	  DNA	  breaks	  in	  Atm-­‐deficient	  
lymphocytes	  target	  chromosomal	  breakpoints	  in	  cis.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  106,	  18339–
18344	  (2009).	  
Mailand,	  N.	  et	  al.	  RNF8	  ubiquitylates	  histones	  at	  DNA	  double-­‐strand	  breaks	  and	  promotes	  
assembly	  of	  repair	  proteins.	  Cell	  131,	  887–900	  (2007).	  
Manis,	  J.	  et	  al.	  53BP1	  links	  DNA	  damage-­‐response	  pathways	  to	  immunoglobulin	  heavy	  chain	  
class-­‐switch	  recombination.	  Nat.	  Immunol.	  5,	  481–487	  (2004).	  
Mao,	  C.	  et	  al.	  T	  cell-­‐independent	  somatic	  hypermutation	  in	  murine	  B	  cells	  with	  an	  immature	  
phenotype.	  Immunity	  20,	  133–144	  (2004).	  
Matei,	  I.	  et	  al.	  ATM	  deficiency	  disrupts	  Tcra	  locus	  integrity	  and	  the	  maturation	  of	  CD4+CD8+	  
thymocytes.	  Blood	  109,	  1887–1896	  (2007).	  
Matei,	  I.,	  Guidos,	  C.	  &	  Danska,	  J.	  ATM-­‐dependent	  DNA	  damage	  surveillance	  in	  T-­‐cell	  
development	  and	  leukemogenesis:	  the	  DSB	  connection.	  Immunol.	  Rev.	  209,	  142–158	  (2006).	  
Matheson,	  L.	  &	  Corcoran,	  A.	  Local	  and	  global	  epigenetic	  regulation	  of	  V(D)J	  recombination.	  
Curr.	  Top.	  Microbiol.	  Immunol.	  356,	  65–89	  (2012).	  
Matthews,	  A.	  &	  Oettinger,	  M.	  RAG:	  a	  recombinase	  diversified.	  Nat.	  Immunol.	  10,	  817–821	  
(2009).	  
	   139 
Matthews,	  A.	  et	  al.	  RAG2	  PHD	  finger	  couples	  histone	  H3	  lysine	  4	  trimethylation	  with	  V(D)J	  
recombination.	  Nature	  450,	  1106–1110	  (2007).	  
McDonnell,	  T.	  et	  al.	  bcl-­‐2-­‐immunoglobulin	  transgenic	  mice	  demonstrate	  extended	  B	  cell	  survival	  
and	  follicular	  lymphoproliferation.	  Cell	  57,	  79–88	  (1989).	  
McKinnon,	  P.	  ATM	  and	  the	  molecular	  pathogenesis	  of	  ataxia	  telangiectasia.	  Annu.	  Rev.	  Pathol.	  
7,	  303–321	  (2012).	  
Meaburn,	  K.,	  Misteli,	  T.	  &	  Soutoglou,	  E.	  Spatial	  genome	  organization	  in	  the	  formation	  of	  
chromosomal	  translocations.	  Semin.	  Cancer	  Biol.	  17,	  80–90	  (2007).	  
Meek,	  D.	  Tumour	  suppression	  by	  p53:	  a	  role	  for	  the	  DNA	  damage	  response?	  Nat.	  Rev.	  Cancer	  9,	  
714–723	  (2009).	  
Menanteau,	  M.	  &	  Martinez-­‐Climent,	  J.	  Genomic	  profiling	  of	  mantle	  cell	  lymphoma.	  Methods	  
Mol.	  Biol.	  973,	  147–163	  (2013).	  
Metcalfe,	  J.,	  Heppell-­‐Parton,	  A.,	  McConville,	  C.	  &	  Taylor,	  A.	  Characterization	  of	  a	  B-­‐lymphocyte	  
t(2;14)	  (p11;q32)	  translocation	  from	  an	  ataxia	  telangiectasia	  patient	  conferring	  a	  proliferative	  
advantage	  on	  cells	  in	  vitro.	  Cytogenet.	  Cell	  Genet.	  56,	  91–98	  (1991).	  
Minegishi,	  M.	  et	  al.	  Functional	  and	  molecular	  characteristics	  of	  acute	  lymphoblastic	  leukemia	  
cells	  with	  a	  mature	  T-­‐cell	  phenotype	  from	  a	  patient	  with	  ataxia	  telangiectasia.	  Leukemia	  5,	  88–
89	  (1991).	  
Mitelman,	  F.,	  Johansson,	  B.	  &	  Mertens,	  F.	  The	  impact	  of	  translocations	  and	  gene	  fusions	  on	  
cancer	  causation.	  Nat.	  Rev.	  Cancer	  7,	  233–245	  (2007).	  
Morales,	  J.	  et	  al.	  53BP1	  and	  p53	  synergize	  to	  suppress	  genomic	  instability	  and	  
lymphomagenesis.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  103,	  3310–3315	  (2006).	  
Morse,	  H.	  et	  al.	  Bethesda	  proposals	  for	  classification	  of	  lymphoid	  neoplasms	  in	  mice.	  Blood	  100,	  
246–258	  (2002).	  
Moshous,	  D.	  et	  al.	  Artemis,	  a	  novel	  DNA	  double-­‐strand	  break	  repair/V(D)J	  recombination	  
protein,	  is	  mutated	  in	  human	  severe	  combined	  immune	  deficiency.	  Cell	  105,	  177–186	  (2001).	  
Moshous,	  D.	  et	  al.	  Partial	  T	  and	  B	  lymphocyte	  immunodeficiency	  and	  predisposition	  to	  
lymphoma	  in	  patients	  with	  hypomorphic	  mutations	  in	  Artemis.	  J.	  Clin.	  Invest.	  111,	  381–387	  
(2003).	  
Muramatsu,	  M.	  et	  al.	  Class	  switch	  recombination	  and	  hypermutation	  require	  activation-­‐induced	  
cytidine	  deaminase	  (AID),	  a	  potential	  RNA	  editing	  enzyme.	  Cell	  102,	  553–563	  (2000).	  
	   140 
Neves,	  H.,	  Ramos,	  C.,	  da	  Silva,	  M.,	  Parreira,	  A.	  &	  Parreira,	  L.	  The	  nuclear	  topography	  of	  ABL,	  
BCR,	  PML,	  and	  RARalpha	  genes:	  evidence	  for	  gene	  proximity	  in	  specific	  phases	  of	  the	  cell	  cycle	  
and	  stages	  of	  hematopoietic	  differentiation.	  Blood	  93,	  1197–1207	  (1999).	  
Nishana,	  M.	  &	  Raghavan,	  S.	  Role	  of	  recombination	  activating	  genes	  in	  the	  generation	  of	  antigen	  
receptor	  diversity	  and	  beyond.	  Immunology	  137,	  271–281	  (2012).	  
Nussenzweig,	  A.	  &	  Nussenzweig,	  M.	  Origin	  of	  chromosomal	  translocations	  in	  lymphoid	  cancer.	  
Cell	  141,	  27–38	  (2010).	  
O’Driscoll,	  M.	  &	  Jeggo,	  P.	  The	  role	  of	  double-­‐strand	  break	  repair	  -­‐	  insights	  from	  human	  genetics.	  
Nat.	  Rev.	  Genet.	  7,	  45–54	  (2006).	  
Parada,	  L.,	  McQueen,	  P.	  &	  Misteli,	  T.	  Tissue-­‐specific	  spatial	  organization	  of	  genomes.	  Genome	  
Biol.	  5,	  R44	  (2004).	  
Parada,	  L.,	  McQueen,	  P.,	  Munson,	  P.	  &	  Misteli,	  T.	  Conservation	  of	  relative	  chromosome	  
positioning	  in	  normal	  and	  cancer	  cells.	  Curr.	  Biol.	  12,	  1692–1697	  (2002).	  
Pasqualucci,	  L.	  et	  al.	  Hypermutation	  of	  multiple	  proto-­‐oncogenes	  in	  B-­‐cell	  diffuse	  large-­‐cell	  
lymphomas.	  Nature	  412,	  341–346	  (2001).	  
Pasqualucci,	  L.	  et	  al.	  Molecular	  pathogenesis	  of	  non-­‐Hodgkin’s	  lymphoma:	  the	  role	  of	  Bcl-­‐6.	  
Leuk.	  Lymphoma	  44	  Suppl	  3,	  S5–12	  (2003).	  
Perlman,	  S.,	  Boder,	  E.,	  Sedgewick,	  R.	  &	  Gatti,	  R.	  A.	  Ataxia-­‐telangiectasia.	  Handb.	  Clin.	  Neurol.	  
103,	  307–332	  (2012).	  
Perlot,	  T.	  &	  Alt,	  F.	  Cis-­‐regulatory	  elements	  and	  epigenetic	  changes	  control	  genomic	  
rearrangements	  of	  the	  IgH	  locus.	  Adv.	  Immunol.	  99,	  1–32	  (2008).	  
Phillips,	  J.	  &	  Corces,	  V.	  CTCF:	  master	  weaver	  of	  the	  genome.	  Cell	  137,	  1194–1211	  (2009).	  
Pileri,	  S.	  &	  Falini,	  B.	  Mantle	  cell	  lymphoma.	  Haematologica	  94,	  1488–1492	  (2009).	  
Puebla-­‐Osorio,	  N.	  &	  Zhu,	  C.	  DNA	  damage	  and	  repair	  during	  lymphoid	  development:	  antigen	  
receptor	  diversity,	  genomic	  integrity	  and	  lymphomagenesis.	  Immunol.	  Res.	  41,	  103–122	  (2008).	  
Raghavan,	  S.,	  Swanson,	  P.,	  Wu,	  X.,	  Hsieh,	  C.	  &	  Lieber,	  M.	  A	  non-­‐B-­‐DNA	  structure	  at	  the	  Bcl-­‐2	  
major	  breakpoint	  region	  is	  cleaved	  by	  the	  RAG	  complex.	  Nature	  428,	  88–93	  (2004).	  
Ramiro,	  A.	  et	  al.	  Role	  of	  genomic	  instability	  and	  p53	  in	  AID-­‐induced	  c-­‐myc-­‐Igh	  translocations.	  
Nature	  440,	  105–109	  (2006).	  
	   141 
Ranganath,	  S.	  et	  al.	  Productive	  coupling	  of	  accessible	  Vβ14	  segments	  and	  DJβ	  complexes	  
determines	  the	  frequency	  of	  Vβ14	  rearrangement.	  J.	  Immunol.	  180,	  2339-­‐2346	  (2008).	  
Reina-­‐San-­‐Martin,	  B.,	  Chen,	  J.,	  Nussenzweig,	  A.	  &	  Nussenzweig,	  M.	  Enhanced	  intra-­‐switch	  
region	  recombination	  during	  immunoglobulin	  class	  switch	  recombination	  in	  53BP1-­‐/-­‐	  B	  cells.	  
Eur.	  J.	  Immunol.	  37,	  235–239	  (2007).	  
Reina-­‐San-­‐Martin,	  B.,	  Nussenzweig,	  M.,	  Nussenzweig,	  A.	  &	  Difilippantonio,	  S.	  Genomic	  
instability,	  endoreduplication,	  and	  diminished	  Ig	  class-­‐switch	  recombination	  in	  B	  cells	  lacking	  
Nbs1.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  102,	  1590–1595	  (2005).	  
Robbiani,	  D.	  &	  Nussenzweig,	  M.	  Chromosome	  translocation,	  B	  cell	  lymphoma,	  and	  activation-­‐
induced	  cytidine	  deaminase.	  Annu.	  Rev.	  Pathol.	  8,	  79–103	  (2013).	  
Robbiani,	  D.	  et	  al.	  AID	  is	  required	  for	  the	  chromosomal	  breaks	  in	  c-­‐myc	  that	  lead	  to	  c-­‐myc/IgH	  
translocations.	  Cell	  135,	  1028–1038	  (2008).	  
Robbiani,	  D.	  et	  al.	  AID	  produces	  DNA	  double-­‐strand	  breaks	  in	  non-­‐Ig	  genes	  and	  mature	  B	  cell	  
lymphomas	  with	  reciprocal	  chromosome	  translocations.	  Mol.	  Cell	  36,	  631–641	  (2009).	  
Roddam,	  P.	  et	  al.	  Genetic	  variants	  of	  NHEJ	  DNA	  ligase	  IV	  can	  affect	  the	  risk	  of	  developing	  
multiple	  myeloma,	  a	  tumour	  characterised	  by	  aberrant	  class	  switch	  recombination.	  J.	  Med.	  
Genet.	  39,	  900–905	  (2002).	  
Roix,	  J.,	  McQueen,	  P.,	  Munson,	  P.,	  Parada,	  L.	  &	  Misteli,	  T.	  Spatial	  proximity	  of	  translocation-­‐
prone	  gene	  loci	  in	  human	  lymphomas.	  Nat.	  Genet.	  34,	  287–291	  (2003).	  
Roldán,	  E.	  et	  al.	  Locus	  “decontraction”	  and	  centromeric	  recruitment	  contribute	  to	  allelic	  
exclusion	  of	  the	  immunoglobulin	  heavy-­‐chain	  gene.	  Nat.	  Immunol.	  6,	  31–41	  (2005).	  
Rooney,	  S.	  et	  al.	  Defective	  DNA	  repair	  and	  increased	  genomic	  instability	  in	  Artemis-­‐deficient	  
murine	  cells.	  J.	  Exp.	  Med.	  197,	  553–565	  (2003).	  
Rooney,	  S.	  et	  al.	  Leaky	  Scid	  phenotype	  associated	  with	  defective	  V(D)J	  coding	  end	  processing	  in	  
Artemis-­‐deficient	  mice.	  Mol.	  Cell	  10,	  1379–1390	  (2002).	  
Roos,	  W.	  &	  Kaina,	  B.	  DNA	  damage-­‐induced	  cell	  death:	  from	  specific	  DNA	  lesions	  to	  the	  DNA	  
damage	  response	  and	  apoptosis.	  Cancer	  Lett.	  332,	  237–248	  (2013).	  
Russo,	  G.	  et	  al.	  Molecular	  analysis	  of	  a	  t(14;14)	  translocation	  in	  leukemic	  T-­‐cells	  of	  an	  ataxia	  
telangiectasia	  patient.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  86,	  602–606	  (1989).	  
	   142 
Saintigny,	  Y.,	  Delacôte,	  F.,	  Boucher,	  D.,	  Averbeck,	  D.	  &	  Lopez,	  B.	  XRCC4	  in	  G1	  suppresses	  
homologous	  recombination	  in	  S/G2,	  in	  G1	  checkpoint-­‐defective	  cells.	  Oncogene	  26,	  2769–2780	  
(2007).	  
Saito,	  H.,	  Hayday,	  A.,	  Wiman,	  K.,	  Hayward,	  W.	  &	  Tonegawa,	  S.	  Activation	  of	  the	  c-­‐myc	  gene	  by	  
translocation:	  a	  model	  for	  translational	  control.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  80,	  7476-­‐7480	  
(1983).	  
Sandlund,	  J.	  et	  al.	  A	  subtle	  t(3;8)	  results	  in	  plausible	  juxtaposition	  of	  MYC	  and	  BCL6	  in	  a	  child	  
with	  Burkitt	  lymphoma/leukemia	  and	  ataxia-­‐telangiectasia.	  Cancer	  Genet.	  Cytogenet.	  168,	  69–
72	  (2006).	  
Sasaki,	  Y.	  et	  al.	  Canonical	  NF-­‐kappaB	  activity,	  dispensable	  for	  B	  cell	  development,	  replaces	  
BAFF-­‐receptor	  signals	  and	  promotes	  B	  cell	  proliferation	  upon	  activation.	  Immunity	  24,	  729-­‐739	  
(2006).	  
Schatz,	  D.	  &	  Swanson,	  P.	  V(D)J	  recombination:	  mechanisms	  of	  initiation.	  Annu.	  Rev.	  Genet.	  45,	  
167–202	  (2011).	  
Schatz,	  D.,	  Oettinger,	  M.	  &	  Baltimore,	  D.	  Pillars	  article:	  the	  V(D)J	  recombination	  activating	  gene,	  
RAG-­‐1.	  1989.	  J.	  Immunol.	  180,	  5–18	  (2008).	  
Seifert,	  M.,	  Scholtysik,	  R.	  &	  Küppers,	  R.	  Origin	  and	  pathogenesis	  of	  B	  cell	  lymphomas.	  Methods	  
Mol.	  Biol.	  971,	  1–25	  (2013).	  
Setoodeh,	  R.	  et	  al.	  Double-­‐hit	  mantle	  cell	  lymphoma	  with	  MYC	  gene	  rearrangement	  or	  
amplification:	  a	  report	  of	  four	  cases	  and	  review	  of	  the	  literature.	  Int.	  J.	  Clin.	  Exp.	  Pathol.	  6,	  155–
167	  (2013).	  
Shih,	  H.	  &	  Krangel,	  M.	  Chromatin	  architecture,	  CCCTC-­‐binding	  factor,	  and	  V(D)J	  recombination:	  
managing	  long-­‐distance	  relationships	  at	  antigen	  receptor	  loci.	  J.	  Immunol.	  190,	  4915–4921	  
(2013).	  
Soulas-­‐Sprauel,	  P.	  et	  al.	  V(D)J	  and	  immunoglobulin	  class	  switch	  recombinations:	  a	  paradigm	  to	  
study	  the	  regulation	  of	  DNA	  end-­‐joining.	  Oncogene	  26,	  7780–7791	  (2007).	  
Spicuglia,	  S.,	  Pekowska,	  A.,	  Zacarias-­‐Cabeza,	  J.	  &	  Ferrier,	  P.	  Epigenetic	  control	  of	  Tcrb	  gene	  
rearrangement.	  Semin.	  Immunol.	  22,	  330–336	  (2010).	  
Stankovic,	  T.	  et	  al.	  ATM	  mutations	  in	  sporadic	  lymphoid	  tumours.	  Leuk.	  Lymphoma	  43,	  1563–
1571	  (2002).	  
Stanton,	  L.,	  Watt,	  R.	  &	  Marcu,	  K.	  Translocation,	  breakage	  and	  truncated	  transcripts	  of	  c-­‐myc	  
oncogene	  in	  murine	  plasmacytomas.	  Nature	  303,	  401–406	  (1983).	  
	   143 
Stewart,	  G.	  et	  al.	  The	  DNA	  double-­‐strand	  break	  repair	  gene	  hMRE11	  is	  mutated	  in	  individuals	  
with	  an	  ataxia-­‐telangiectasia-­‐like	  disorder.	  Cell	  99,	  577–587	  (1999).	  
Strasser,	  A.,	  Harris,	  A.,	  Corcoran,	  L.	  &	  Cory,	  S.	  Bcl-­‐2	  expression	  promotes	  B-­‐	  but	  not	  T-­‐lymphoid	  
development	  in	  scid	  mice.	  Nature	  368,	  457–460	  (1994).	  
Subrahmanyam,	  R.	  &	  Sen,	  R.	  Epigenetic	  features	  that	  regulate	  IgH	  locus	  recombination	  and	  
expression.	  Curr.	  Top.	  Microbiol.	  Immunol.	  356,	  39–63	  (2012).	  
Subrahmanyam,	  R.	  &	  Sen,	  R.	  RAGs’	  eye	  view	  of	  the	  immunoglobulin	  heavy	  chain	  gene	  locus.	  
Semin.	  Immunol.	  22,	  337–345	  (2010).	  
Taccioli,	  G.	  et	  al.	  Ku80:	  product	  of	  the	  XRCC5	  gene	  and	  its	  role	  in	  DNA	  repair	  and	  V(D)J	  
recombination.	  Science	  265,	  1442–1445	  (1994).	  
Taylor,	  A.,	  Metcalfe,	  J.,	  Thick,	  J.	  &	  Mak,	  Y.	  Leukemia	  and	  lymphoma	  in	  ataxia	  telangiectasia.	  
Blood	  87,	  423–438	  (1996).	  
Teng,	  G.	  et	  al.	  MicroRNA-­‐155	  is	  a	  negative	  regulator	  of	  activation-­‐induced	  cytidine	  deaminase.	  
Immunity	  28,	  621–629	  (2008).	  
Tillman,	  R.	  E.,	  Wooley,	  A.	  L.,	  Hughes,	  M.,	  Khor,	  B.	  &	  Sleckman,	  B.	  Regulation	  of	  T-­‐cell	  receptor	  
beta-­‐chain	  gene	  assembly	  by	  recombination	  signals:	  the	  beyond	  12/23	  restriction.	  Immunol.	  
Rev.	  200,	  36–43	  (2004).	  
Truffinet,	  V.	  et	  al.	  The	  3’	  IgH	  locus	  control	  region	  is	  sufficient	  to	  deregulate	  a	  c-­‐myc	  transgene	  
and	  promote	  mature	  B	  cell	  malignancies	  with	  a	  predominant	  Burkitt-­‐like	  phenotype.	  J.	  
Immunol.	  179,	  6033–6042	  (2007).	  
Tsai,	  A.	  &	  Lieber,	  M.	  Mechanisms	  of	  chromosomal	  rearrangement	  in	  the	  human	  genome.	  BMC	  
Genomics	  11	  Suppl	  1,	  S1	  (2010).	  
Tsai,	  A.	  et	  al.	  Human	  chromosomal	  translocations	  at	  CpG	  sites	  and	  a	  theoretical	  basis	  for	  their	  
lineage	  and	  stage	  specificity.	  Cell	  135,	  1130–1142	  (2008).	  
Tsai,	  C.,	  Kim,	  S.	  &	  Chu,	  G.	  Cernunnos/XLF	  promotes	  the	  ligation	  of	  mismatched	  and	  noncohesive	  
DNA	  ends.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  104,	  7851–7856	  (2007).	  
Vacchio,	  M.,	  Olaru,	  A.,	  Livak,	  F.	  &	  Hodes,	  R.	  ATM	  deficiency	  impairs	  thymocyte	  maturation	  
because	  of	  defective	  resolution	  of	  T	  cell	  receptor	  alpha	  locus	  coding	  end	  breaks.	  Proc.	  Natl.	  
Acad.	  Sci.	  U.S.A.	  104,	  6323–6328	  (2007).	  
Vanasse,	  G.	  et	  al.	  Genetic	  pathway	  to	  recurrent	  chromosome	  translocations	  in	  murine	  
lymphoma	  involves	  V(D)J	  recombinase.	  J.	  Clin.	  Invest.	  103,	  1669–1675	  (1999).	  
	   144 
Vettermann,	  C.	  &	  Schlissel,	  M.	  Allelic	  exclusion	  of	  immunoglobulin	  genes:	  models	  and	  
mechanisms.	  Immunol.	  Rev.	  237,	  22–42	  (2010).	  
Vitolo,	  U.	  et	  al.	  T	  acute	  lymphoblastic	  leukemia	  in	  ataxia-­‐telangiectasia.	  Report	  of	  a	  case	  
characterized	  by	  monoclonal	  antibodies.	  Haematologica	  69,	  695–700	  (1984).	  
Vousden,	  K.	  &	  Prives,	  C.	  Blinded	  by	  the	  Light:	  The	  Growing	  Complexity	  of	  p53.	  Cell	  137,	  413–431	  
(2009).	  
Vuong,	  B.	  &	  Chaudhuri,	  J.	  Combinatorial	  mechanisms	  regulating	  AID-­‐dependent	  DNA	  
deamination:	  interacting	  proteins	  and	  post-­‐translational	  modifications.	  Semin.	  Immunol.	  24,	  
264–272	  (2012).	  
Wake,	  N.,	  Minowada,	  J.,	  Park,	  B.	  &	  Sandberg,	  A.	  A.	  Chromosomes	  and	  causation	  of	  human	  
cancer	  and	  leukemia.	  XLVIII.	  T-­‐cell	  acute	  leukemia	  in	  ataxia	  telangiectasia.	  Cancer	  Genet.	  
Cytogenet.	  6,	  345–347	  (1982).	  
Wang,	  J.	  &	  Boxer,	  L.	  Regulatory	  elements	  in	  the	  immunoglobulin	  heavy	  chain	  gene	  3’-­‐enhancers	  
induce	  c-­‐myc	  deregulation	  and	  lymphomagenesis	  in	  murine	  B	  cells.	  J.	  Biol.	  Chem.	  280,	  12766–
12773	  (2005).	  
Wang,	  J.	  et	  al.	  Mechanisms	  promoting	  translocations	  in	  editing	  and	  switching	  peripheral	  B	  cells.	  
Nature	  460,	  231–236	  (2009).	  
Wang,	  J.	  et	  al.	  Oncogenic	  transformation	  in	  the	  absence	  of	  Xrcc4	  targets	  peripheral	  B	  cells	  that	  
have	  undergone	  editing	  and	  switching.	  J.	  Exp.	  Med.	  205,	  3079–3090	  (2008).	  
Ward,	  I.	  et	  al.	  53BP1	  cooperates	  with	  p53	  and	  functions	  as	  a	  haploinsufficient	  tumor	  suppressor	  
in	  mice.	  Mol.	  Cell.	  Biol.	  25,	  10079–10086	  (2005).	  
Ward,	  I.	  et	  al.	  53BP1	  is	  required	  for	  class	  switch	  recombination.	  J.	  Cell	  Biol.	  165,	  459–464	  
(2004).	  
Wilda,	  M.	  et	  al.	  Level	  of	  MYC	  overexpression	  in	  pediatric	  Burkitt’s	  lymphoma	  is	  strongly	  
dependent	  on	  genomic	  breakpoint	  location	  within	  the	  MYC	  locus.	  Genes.	  Chromosomes	  Cancer	  
41,	  178–182	  (2004).	  
Williams,	  R.	  et	  al.	  Amplification	  of	  complex	  gene	  libraries	  by	  emulsion	  PCR.	  Nat.	  Methods	  3,	  
545–550	  (2006).	  
Wu,	  C.	  et	  al.	  Dramatically	  increased	  rearrangement	  and	  peripheral	  representation	  of	  Vbeta14	  
driven	  by	  the	  3’Dbeta1	  recombination	  signal	  sequence.	  Immunity	  18,	  75–85	  (2003).	  
	   145 
Xu,	  Y.	  &	  Baltimore,	  D.	  Dual	  roles	  of	  ATM	  in	  the	  cellular	  response	  to	  radiation	  and	  in	  cell	  growth	  
control.	  Genes	  Dev.	  10,	  	  2401-­‐2410	  (1996).	  
Yan,	  C.	  et	  al.	  IgH	  class	  switching	  and	  translocations	  use	  a	  robust	  non-­‐classical	  end-­‐joining	  
pathway.	  Nature	  449,	  478–482	  (2007).	  
Yan,	  J.	  &	  Jetten,	  A.	  RAP80	  and	  RNF8,	  key	  players	  in	  the	  recruitment	  of	  repair	  proteins	  to	  DNA	  
damage	  sites.	  Cancer	  Lett.	  271,	  179–190	  (2008).	  
Yancopoulos,	  G.	  &	  Alt,	  F.	  Developmentally	  controlled	  and	  tissue-­‐specific	  expression	  of	  
unrearranged	  VH	  gene	  segments.	  Cell	  40,	  271–281	  (1985).	  
Zarrin,	  A.	  et	  al.	  Antibody	  class	  switching	  mediated	  by	  yeast	  endonuclease-­‐generated	  DNA	  
breaks.	  Science	  315,	  377–381	  (2007).	  
Zha,	  S.	  et	  al.	  ATM-­‐deficient	  thymic	  lymphoma	  is	  associated	  with	  aberrant	  tcrd	  rearrangement	  
and	  gene	  amplification.	  J.	  Exp.	  Med.	  207,	  1369–1380	  (2010).	  
Zha,	  S.,	  Alt,	  F.,	  Cheng,	  H.,	  Brush,	  J.	  &	  Li,	  G.	  Defective	  DNA	  repair	  and	  increased	  genomic	  
instability	  in	  Cernunnos-­‐XLF-­‐deficient	  murine	  ES	  cells.	  Proc.	  Natl.	  Acad.	  Sci.	  U.S.A.	  104,	  4518–
4523	  (2007).	  
Zhang,	  M.	  &	  Swanson,	  P.	  V(D)J	  recombinase	  binding	  and	  cleavage	  of	  cryptic	  recombination	  
signal	  sequences	  identified	  from	  lymphoid	  malignancies.	  J.	  Biol.	  Chem.	  283,	  6717–6727	  (2008).	  
Zhang,	  Y.	  &	  Rowley,	  J.	  D.	  Chronic	  myeloid	  leukemia:	  current	  perspectives.	  Clin.	  Lab.	  Med.	  31,	  
687–698,	  x	  (2011).	  
Zhang,	  Y.	  et	  al.	  Spatial	  organization	  of	  the	  mouse	  genome	  and	  its	  role	  in	  recurrent	  chromosomal	  
translocations.	  Cell	  148,	  908–921	  (2012).	  
Zhang,	  Y.	  et	  al.	  The	  role	  of	  mechanistic	  factors	  in	  promoting	  chromosomal	  translocations	  found	  
in	  lymphoid	  and	  other	  cancers.	  Adv.	  Immunol.	  106,	  93–133	  (2010).	  
Zhao,	  J.,	  Bacolla,	  A.,	  Wang,	  G.	  &	  Vasquez,	  K.	  Non-­‐B	  DNA	  structure-­‐induced	  genetic	  instability	  
and	  evolution.	  Cell.	  Mol.	  Life	  Sci.	  67,	  43–62	  (2010).	  
Zhu,	  C.	  et	  al.	  Unrepaired	  DNA	  breaks	  in	  p53-­‐deficient	  cells	  lead	  to	  oncogenic	  gene	  amplification	  
subsequent	  to	  translocations.	  Cell	  109,	  811–821	  (2002).	  
Zoete,	  V.,	  Irving,	  M.,	  Ferber,	  M.,	  Cuendet,	  M.	  &	  Michielin,	  O.	  Structure-­‐based,	  rational	  design	  
of T	  cell	  receptors.	  Front.	  Immunol.	  4,	  268	  (2013).	  
